Drug-related deaths reported by Coroners in England, Wales, Guernsey, Jersey and the Isle of Man; Police forces in Scotland; & the Northern Ireland Statistics and Research Agency: annual report January-December 2007 and 17th surveillance report July-December 2007. by Ghodse, Hamid et al.
Drug-related












University of London, UK
ii
np-SAD
International Centre for Drug Policyiii
national programme on Substance
Abuse Deaths
(np-SAD)
Drug-related deaths reported by Coroners in
England, Wales, Northern Ireland, Guernsey,
Jersey and the Isle of Man; Police forces in
Scotland; & the Northern Ireland Statistics and
Research Agency
Annual Report January-December 2007






International Centre for Drug Policyiv
Published by
International Centre for Drug Policy,
St George’s, University of London
Cranmer Terrace, London SW17 0RE
Telephone +44 (0)20 8725 2623 & Fax +44 (0)20 8266 6494
E-mail: npsad@sgul.ac.uk
© 2008 International Centre for Drug Policy
All rights reserved. No part of this publication may be
reproduced, stored in a retrieval system, or transmitted in any
form, without the written permission of the publisher.
ISBN: 978 1 897778 64 7
The views expressed in this report are those of the authors, not necessarily
those of the Department of Health (nor do they reflect Government policy).
np-SAD
International Centre for Drug Policyv
Preface
The Annual Report of drug-related deaths in the United Kingdom and the six-monthly
surveillance report published by the national programme on Substance Abuse Deaths (np-SAD)
is used by universities, the UK Government, national and international agencies as an indicator
of the extent and nature of drug problems and misuse, and makes a contribution towards the
prevention of substance abuse problems.
The Programme could not achieve its goals and objectives without the collaboration and co-
operation of coroners and their officers. It is important to recognise that their collaboration has
been on a voluntary basis and it is the fundamental reason for its success. We would like to
thank them all for their active participation, as well as those who have recently agreed to start
providing information.
I am particularly pleased to report on continuing participation of coroners in Guernsey, Jersey,
the Isle of Man, and Northern Ireland, and of the procurator fiscal for Dumbarton in Scotland.
Again, we are grateful to the Scottish Crime and Drug Enforcement Agency for continuing to
provide information on drug-related deaths reported to the police in Scotland, and to the
Northern Ireland Statistics and Research Agency for information on drug-related poisonings from
the General Mortality Register. Their contributions are important as we aim to maintain a UK-
wide reporting system.
The findings indicate an increase in drug-related deaths during 2007 in the United Kingdom as a
whole, following the increase reported for 2006. This increase is consistent with recently
published figures from the General Mortality Registers for Great Britain on death registrations.
The number of np-SAD cases notified (primarily for England and Wales) also shows an increase
for 2007, This is not good news, and underlines the fact that further vigilance and constant
monitoring of the drug-related fatalities situation is essential for understanding such patterns.
As in previous years, the statistics in this report are intended to inform authorities at the local,
regional and national levels, as well as health professionals and the general public, about the
serious consequences of drug abuse, especially polydrug use. The report also provides a
number of indicators of drug abuse patterns, trends and early warnings on emerging drug
problems so that appropriate and timely action can be taken.
We would like to express our thanks to the Department of Health for renewing its support for this
very important programme. The increased resources made available will enable the Programme
to develop and enhance its role in providing information and advice.
Professor A. Hamid Ghodse
Director
International Centre for Drug Policy
St George’s, University of London
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Key points
Annual Report January - December 2007
 Notifications of 1,539 drug-related deaths occurring in 2007 were received by the
Programme. A total of 107 coroners from 115 jurisdictions in England & Wales, as well as
from Northern Ireland, the Channel Islands and Isle of Man, together with one Procurator
Fiscal from Scotland, provided data. The total number of drug-related deaths (DRDs)
reported in 2007 indicates an increase of 12.7% over the number reported 1,366) in the
previous Annual Report.
 When the figures derived from data provided by the Scottish Crime and Drug Enforcement
Agency and the Northern Ireland Statistics and Research Agency are included, the total
number of drug-related deaths (DRDs) reported in 2007 for the UK is 1,900. This
represents an increase of 8.4% in the number reported by the same sources for 2006
(1,752).
 The demographic profile of fatalities reported to the np-SAD remains consistent with
previous reports. The majority of cases were males (77%), under the age of 45 years
(71%), and White (95%).
 The principal underlying cause(s) of death were: accidental poisoning (63%); intentional
self-poisoning (13%); and poisoning of undetermined intent (12%).
 Opiates/opioids (i.e. heroin/morphine; methadone; other opiates/opioid analgesics), alone
or in combination with other drugs, accounted for the majority (71%) of all np-SAD cases.
 Heroin/morphine alone or in combination with other drugs, accounted for the highest
proportion (48%) of fatalities, a slight increase over the 2006 level of 46%.
 The highest rates of DRDs per 100,000 population aged 16 and over in 2007 were in
Dumbarton (20.6); Brighton & Hove (18.8); Blackpool & the Fylde (14.9); and Peterborough
(10.1). Two of these areas, (Dumbarton and Peterborough) showed a significant increase
over 2006, whilst Brighton & Hove exhibited only a small increase. There was a significant
decline in the DRD rate in Blackpool & the Fylde.
 The following jurisdictions reported significantly lower rates per 100,000 population aged 16
and over than in the previous year: North & West Cumbria (11.4 to 4.5, from 25 to 10
cases); South Manchester (3.5 to 0.9, from 20 to 5 cases); Gateshead & North Tyneside
(5.0 to 0.4, from 14 to one case); Exeter & Greater Devon (4.5 to 2.6, from 22 to 11 cases);
Swansea (6.5 to 0.5, from 12 to 1 case); Plymouth & South West Devon (8.0 to 3.7, from 19
to 9 cases); Blackpool & the Fylde (19.4 to 14.9, from 35 to 27 cases); and Southampton &
New Forest (7.4 to 4.7, from 24 to 16).
 The following jurisdictions reported significantly higher rates per 100,000 population aged
16 & over than in the previous year: Greater Norfolk (2.3 to 7.0, from 14 to 44 cases);
Northern London (2.7 to 5.1, from 29 to 54 cases); West Yorkshire Eastern (4.7 to 7.3, from
40 to 65 cases); Northamptonshire (0.6 to 4.6, from 3 to 25 cases); Preston & Western
Lancashire (2.5 to 6.1, from 14 to 35 cases); Cornwall (3.5 to 8.0, from 15 to 35 cases);
Cheshire (2.4 to 4.7, from 19 to 38 cases); Suffolk (3.0 to 6.1, from 17 to 35 cases); South
Staffordshire (1.0 to 4.3, from 5 to 21 cases); and City of Manchester (2.8 to 5.9, from 10 to
22 cases).
 The following perceptible changes were also observed:
- The proportion of cases involving methadone increased from 17% to 20%; the number of
such cases increased from 264 to 295 cases.
- The proportion of cases involving cocaine increased from 11% to 16%; the number of
such cases increased from 174 to 239 cases.
- The proportion of cases involving hypnotics/sedatives increased from 17% to 21%; the
number of such cases increased from 259 to 309 cases.
- The proportion of cases involving alcohol in combination with other substances increased
from 34% to 38%; the number of such cases increased from 525 to 554 cases.
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I The role of the toxicologist in Coroners’ investigations
Toxicology is the study of drugs and poisons.
It is predominantly a laboratory-based science
with two main requirements. Firstly, analysis
of biological fluids (e.g. post-mortem blood
and urine) to determine the presence,
absence or amount of drugs and alcohol.
Secondly, interpretation of the findings,
primarily in respect to the cause of death as a
diagnostic aid to the Pathologist.
Investigations are performed on behalf of Her
Majesty’s Coroners and are requested in
various circumstances in addition to the
typical situations of suspected drug use,
overdosage or prescription compliance. These
may include instances of fire, hanging,
drowning, falls and road traffic accidents
where the possibility of drug and/or alcohol
involvement is an issue. With a sustained rise
in the number and type of drugs available for
prescription and continuing illicit drug use, the
necessity for toxicological analysis is
becoming increasingly common. This is
coupled with the changing nature of death
investigation in order to rule out the potential
contribution of drugs, particularly in light of the
Shipman Enquiry (2003).
There is no one simple test or assay that can
detect all toxic species. The challenge for
analytical toxicology is to analyse for as many
drugs or poisons as possible using the
specimen types and sample volume available.
This requires the use of numerous
methodologies and techniques to ensure
appropriate and accurate analysis.
Confidence in the result can be achieved by
the use of complementary techniques or
detection methods. For identification, it is
common to compare analytical characteristics
of case data with that of in-house or
commercially available analytical libraries.
Despite advances in technology, identification
can be difficult in some situations, typically
due to the development of newer drugs but
also the absence of any available reference
material for laboratories. The lack of reference
standards can consequently hinder
measurement. In specific cases, and
especially if reference standards are not
available, structural information can be
obtained, particularly using mass-
spectrometry, that may be helpful in
determining the nature of an unknown
substance. The lack of reference standards
can also consequently hinder quantitative
measurements
A primary aim of the toxicologist is to provide
answers to questions that may arise during an
investigation and a good working relationship
with investigators can achieve this. As such,
information is required in order to guide
analysis and to assist in the interpretation of
findings. For example, the circumstances of
death, any evidence of drugs at the scene, the
drug/prescription history of the deceased and
any additional details that may aid in
assessing access to drugs, alcohol, chemicals
or poisons. The involvement of drugs/poisons
is not always obvious and even knowledge of
the deceased’s job or hobbies can be
important. Deaths that have involved
hospitalisation can be particularly complicated
and a comprehensive clinical and prescription
history is used to determine the relevance of
any drugs found.
The concentration of any drug present in
blood or urine is directly related to a number
of factors, in particular; the dose taken, the
route of administration (e.g. by mouth), the
medical status of the individual and the nature
of the drug itself. This can result in low
concentrations even following overdose;
conversely, high concentrations for some
drugs are not always related to excessive use.
Also, in situations where death has occurred
rapidly (e.g. intravenous heroin use), very little
(if any) drug may be present in urine
compared to blood, as there may not have
been sufficient time for the excretion of drugs
or metabolites. As well as influencing
interpretation, these issues also impact on the
methodology used as the analytical
toxicologist has to make sure the technique is
suitable (e.g. sensitive, and linear at the
required sensitivity). Nevertheless,
interpretation of the toxicological findings is
the fundamental role of the toxicologist and
again there are significant challenges and
factors to bear in mind. Particular problems
include: the development of tolerance to drug
effects (e.g. alcohol and opiates), post-
mortem redistribution (whereby the blood
concentration of drug is dependent on the
anatomical site of sample collection),
instability of compounds, post-mortem
production (e.g. alcohol), drug-drug
interactions and pharmacogenomics (differing
genetics can produce fast or slow drug
metabolism). These factors result in an
overlap in drug concentrations found during
therapy and in fatalities; hence it is difficult to
provide a “fatal” range for many drugs.
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Despite this, case experience is invaluable
due to the various drug types, concentrations
and circumstances that can be involved. As
toxicology is still a growing science, and
particularly the area of interpretation of
analytical findings, there is a need for




(ROAR) Forensics, Malvern, Worcestershire
II Introduction
This report continues the series of annual
reports published by the national programme
on Substance Abuse Deaths (np-SAD).
The first part of this publication takes the form
of an annual review of information (including
nil returns) received from coroners in England
& Wales, Northern Ireland, the Isle of Man and
Channel Islands, as well as the procurator
fiscal for Dumbarton, the Scottish Crime and
Drug Enforcement Agency (SCDEA), and the
General Register Office for Northern Ireland
(GRONI) via the Northern Ireland Statistics
and Research Agency, on 1,900 drug-related
deaths that actually occurred in 2007. Since
there are differences in legal and coronial
systems, data collection methods, and
database structures, it is only possible to
examine some aspects of drug-related deaths
at a UK level. The first part then goes on to
examine in detail those deaths reported to the
np-SAD using the Programme’s data collection
form. Since the time lapse between the date of
death and the conclusion of inquest varies
considerably from case to case, there will
undoubtedly be further deaths in 2007 and
deaths from additional coroners that are not
covered by this report. However, these cases
will be analysed in future reports. Information
is presented separately for deaths in Scotland
(Annex AR4) and Northern Ireland (Annex
AR5).
The second part of the report relates to the
surveillance period July to December 2007;
this has not been previously published. These
figures reflect inquests on drug-related deaths
reported to np-SAD during that period and
may include deaths that actually occurred
outside that period. A further 307 inquest
reports were received after publication of the
2007 Annual Report on deaths that occurred
during 2006 (Ghodse et al, 2007). These
cases are also briefly analysed. In order to
provide continuity with previous np-SAD
surveillance reports, changes in the semi-
annual death rates since January 2005 are
also highlighted (see Annex AR3).
There may be higher rates in some areas
compared with previous reporting periods
because of Programme staff visiting
coroners’ offices to collect data themselves,
or because of bilateral checks between the
np-SAD and local confidential inquiries on
case coverage. This has led to more cases
being identified than hitherto, and
subsequently being reported. This is one
way in which the Programme attempts to
monitor the quality and coverage of case
reporting. In many areas that use Mountain
Software1 there are difficulties in readily
identifying relevant cases retrospectively
since the text search facilities are not
presently available for the key fields that
would help selection. Other sources are
available in some coroner’s offices to
identify cases, e.g. diaries and ledgers with
details of individual cases.
Recent studies on mortality in
drug addicts
A number of recent studies on drug abuse-
related mortality have provided examples of
how these studies may play a role in
improving surveillance, informing treatment
provision, and in preventing premature
deaths. Relevant studies, published since
the last annual report, were identified by a
search of databases (including Medline)
and the Internet using combinations of key
words such as “mortality”, “death”, “fatality”,
“drug”, “drug-related”, “poisoning” and
“overdose”. A selection of these studies is
outlined below.
1 Mountain Software provide a bespoke computer
package for coroners comprising management tools,
and the generation of statistical forms and other
reports, including the form used to submit information





Drug poisoning in the US (United States) has
been traditionally seen as an urban problem
but latterly evidence has suggested that at
least one component of the recent increase in
drug poisoning deaths is the rapid increase in
the use of opioid analgesics in rural areas.
Paulozzi and Xi (2008) compared age-
adjusted unintentional and undetermined drug
poisoning mortality rates between 1999 and
2004 from the National Vital Statistics System
in each of six urban-rural categories. They
found that unintentional and undetermined
drug poisoning mortality rates rose by 62%
between 1999 and 2004. Metropolitan county
rates rose by 51%, an increase of 2.7/100,000,
while non-metropolitan county rates rose by
159%, an increase of 4.8/100,000. By 2004,
metropolitan and nonmetropolitan drug
poisoning rates had roughly equalized. In the
narcotic drug category (which included heroin,
cocaine, and opioid analgesics) deaths in the
most urbanised counties increased by 16%
while there was an increase of 248% in the
most rural counties. Heroin rates did not
increase significantly for any urban-rural
category. Cocaine rate increases were largest
in nonmetropolitan counties. Opioid analgesic
rate increases ranged from 52% in large
central metropolitan counties to 371% in non-
metropolitan, noncore counties. The authors
note also that prescription drugs have
replaced heroin and cocaine as the leading
drugs involved in fatal drug overdoses in all
urban-rural categories; and fatal drug
overdoses are no longer a predominantly
urban phenomenon. Intervention strategies will
have to take account of these new patterns.
This shift towards overdoses involving
prescription drugs is borne out by a number of
national and regional studies. Phillips et al
(2008) examined all US death certificates from
1 January 1983 to 31 December 2004 (n =
49,586,156), especially those with fatal
medication errors (FMEs) (n=224,355) for
trends in 4 types of FMEs that vary according
to the relative importance of alcohol/ street
drugs and the relative likelihood of
professional oversight in the consumption of
medications. They found that the overall FME
death rate increased by 360.5% over this
period, far exceeding the increase in death
rates from adverse effects of medications
(33.2%) or from alcohol and/or street drugs
(40.9%). The increase in FMEs varies
markedly by type. Domestic FMEs combined
with alcohol and/or street drugs show the
largest increase (3196%). In contrast, non-
domestic FMEs not involving alcohol and/or
street drugs show the smallest increase
(5%). Domestic FMEs not involving alcohol
and/or street drugs increased by 564%.
Non-domestic FMEs combined with alcohol
and/or street drugs increased by 555%. The
authors conclude, therefore, that domestic
FMEs combined with alcohol and/or street
drugs have become an increasingly
important health problem compared with
other FMEs.
In 2005, poisoning was the second leading
cause of injury death in the United States;
most poisoning deaths are due to
unintentional drug overdoses (Fingerhut,
2008). Narcotic-related deaths have played
the largest role in the increase in all
poisoning deaths from 1999 to 2005,
accounting for 56% of all poisoning deaths
in 2005 (50% in 1999). Absolute numbers
increased 84% over this 7-year period. All
poisoning deaths increased 66% from
19,741 to 32,691 deaths, whereas the
number of such deaths mentioning
methadone increased by 468% to 4,462.
Between 1999 and 2005, poisoning deaths
mentioning methadone increased from 4%
to 14% of all poisoning deaths. More
recently, all poisoning deaths increased by
8% between 2004 and 2005, whereas
those mentioning methadone increased by
16%. Methadone had the largest relative
increase of all narcotic drugs mentioned in
poisoning deaths. However, the absolute
number of such deaths involving
methadone was less than those involving
other opioids or cocaine. Between 73 and
80% of poisoning deaths involving
methadone have been classified as
unintentional;11-13%, of undetermined
intent; 5-7%, suicides; less than 1 percent
as homicides; and about 1 percent were
injuries other than poisoning. Age-specific
rates for methadone death are highest in
35-44 and 45-54 year-old age groups.
Among those aged 55-64 years, the rate in
2005 was nine times the rate in 1999; and
for those in each of the 10-year age groups
covering the span 25-54 years, the rates in
2004 were four to six times the rates in
1999. The largest increase was for young
persons 15-24 years where the rate in 2005
was 11 times that in 1999. In 2005, crude
state death rates for methadone-related
deaths ranged from less than 1 per 100,000
in many of the largest states like California,
New York, Texas, and Pennsylvania to 4 to




Increases in methadone and oxycodone
related deaths have been documented in the
United States in the last couple of years. As a
result, Baker et al (2008) investigated all 1998-
2003 cases in Cuyahoga County, Ohio, in
which post mortem toxicological analyses
revealed the presence of methadone,
hydrocodone, and oxycodone (which were
separated from polydrug intoxications).
Throughout the study, an increase was
observed in the number of positive cases.
Mean and median concentrations in
oxycodone and hydrocodone related deaths
were more than two times greater than those
in non drug-related deaths
The misuse of fentanyl and associated
fatalities has also risen up the agenda in North
America. For example in a Massachusetts
study, Hull et al (2007) reported that, between
September 2005 and November 2006, 5,009
medico-legal investigations associated 107
deaths with licit or illicit fentanyl use, along
with a co-detection of an opiate/opioid or
cocaine/benzoylecgonine, or both. Deaths
associated with illicit fentanyl use occur in
younger people (39.4 vs. 61.5 years) with
higher fentanyl (17.1 ng/ml vs. 4.4 ng/ml) and
lower morphine (76.9 ng/ml vs. 284.2 ng/ml)
post mortem blood concentrations, and more
frequent cocaine co-intoxication (65% vs. 3%),
than deaths associated with illicit fentanyl use.
A wide range of post mortem blood
concentrations of fentanyl was detected (trace
- 280 ng/ml), with a minimum concentration of
7 ng/ml of fentanyl strongly associated with
illicit use of fentanyl in polydrug cases. The
most commonly detected opiates/opioids in
illicit fentanyl users were: morphine (29%),
oxycodone (14.5%), and methadone (14.5%).
Ethanol, cannabinoids, diazepam, citalopram,
and diphenhydramine were each detected in
greater than 10% of the licit fentanyl cases.
Most fentanyl abusers died at their own home
and their deaths were most often classified as
accidental. Mapping of the primary residence
of decedents revealed conspicuous clustering
of illicit fentanyl use cases, as opposed to the
random pattern in licit use cases. Fentanyl
misuse is a public health problem in
Massachusetts.
In May 2006, in response to concern over
reports of increased non-pharmaceutical
fentanyl (NPF) - related deaths, the US Center
for Disease Control (CDC) collaborated with
medical examiners, law enforcement
agencies, and public health departments in six
states and local jurisdictions to establish an ad
hoc surveillance system for NPF-related
deaths (Jones et al, 2008). In each
jurisdiction, reports from participating
medical examiners were reviewed. An NPF-
related death was defined as one in which
(a) fentanyl caused or contributed to the
death, (b) evidence was found of the
involvement of pharmaceutical fentanyl
products, and (c) toxicology testing
confirmed fentanyl in the body, in unused
drugs of the decedent, or in a specimen
from a person with whom the decedent
shared drugs. Public health departments
and law enforcement agencies collaborated
with participating medical examiners,
initially identifying NPF-related deaths that
occurred during April 2005–May 2006 and
adding new NPF-related deaths as they
were identified. In September 2006, the
Drug Enforcement Agency (DEA) took over
the surveillance system, using the same
case definition; data collection ended in
May 2007. Between 4 April 2005 and 28
March 2007, the CDC/DEA surveillance
system identified 1,013 NPF-related deaths.
The monthly incidence of NPF deaths
peaked in June 2006 at 150 cases and
decreased to one death in both February
and March 2007. Among the 984 decedents
whose sex and age were known, 577
(58.6%) were aged 35–54 years, and 788
(80.1%) were male. Among the 984
decedents whose race/ethnicity were
known, 545 (55.4%) were White, 392
(39.8%) were Black, and 41 (4.2%) were
Hispanic. The pattern of NPF overdoses
was probably related to illicit drug
distribution networks. For example, the NPF
used in Chicago and Detroit is believed to
have come from clandestine production at a
site in Mexico. However, active surveillance
in other areas with high rates of heroin use
(e.g., New York City) did not find NPF-
related deaths.
Woodall et al (2008) identified seven cases
from Toronto, Canada, over a 3-year period
where fentanyl, either alone or in
combination with other factors, contributed
to death following the oral abuse of
Duragesic patches. The decedents
comprised three females and four males
with ages ranging from 20 to 51 years.
Post-mortem blood fentanyl concentrations
ranged from 7 to 97ng/ml. Two deaths were
classified as fentanyl overdose, three cases
were classified as a fentanyl and ethanol
overdose, one death was considered to be
mixed drug intoxication and the remaining
death was described as a combination of
fentanyl-related and medical causes.
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Shah et al (2008) analysed medical examiner
data for all unintentional drug overdose deaths
in New Mexico during 1990-2005. It was found
that the overall unintentional drug overdose
death rate in the state increased from 5.6 per
100,000 in 1990 to 15.5 per 100,000 in 2005.
Heroin caused the highest number of deaths
during the study period, with a notable rate of
increase in prescription opioid overdose death
during 1998-2005. The most common
categories causing death were: heroin alone
and heroin/alcohol among Hispanic males;
heroin/alcohol among American Indian males;
and prescription opioids alone among white
males and all female subpopulations. The
authors concluded that intervention aimed at
preventing drug overdose death should be
targeted according to use patterns among at-
risk subpopulations.
During a 4-year period, Chugh et al (2008)
prospectively evaluated all patients who
consecutively had sudden cardiac death and
underwent investigation by the medical
examiner in the metropolitan area of Portland,
Oregon. A total of 22 sudden cardiac death
cases with therapeutic levels of methadone
(mean 0.48+/-0.22 mg/L; range 0.1-0.9 mg/L)
were identified (mean age 37.0+/-10 years,
68% were male) and compared with 106
consecutive sudden cardiac death cases
without evidence of methadone (mean age
42+/-13 years, 69% were male). The most
common indication for methadone use was
pain control (n=12, 55%). Among cases
receiving methadone therapy, sudden death-
associated cardiac abnormalities were
identified in only 23% (n=5), with no clear
cause of sudden cardiac death in the
remaining 77% (n=17). Among non-
methadone cases, sudden death-associated
cardiac abnormalities were identified in 60%
(n=64, P=.002). The authors conclude that the
significantly lower prevalence of cardiac
disease in the case group implicates
methadone, even at therapeutic levels, as a
likely cause of sudden death.
Smyth et al (2007) examined premature
mortality in terms of years of potential life lost
(YPLL) among a cohort of long-term heroin
addicts. They followed a cohort of 581 male
heroin addicts in California for more than 33
years. In the latest follow-up conducted in
1996/97, 282 subjects (48.5%) were confirmed
as deceased by death certificates. They found
that, on average, addicts in this cohort lost
18.3 years (SD=10.7) of potential life before
age 65. Of the total YPLL for the cohort,
22.3% of the years lost was due to heroin
overdose, 14.0% due to chronic liver
disease, and 10.2% to accidents. The total
YPLL and YPLL by death cause in this
addict cohort were significantly higher than
that of US population. They concluded that
the YPLL among addicts was much higher
than that in the national population; within
the cohort, premature mortality was higher
among Whites and Hispanics compared to
African-American addicts.
Vlahov et al (2008) studied 2089 injecting
drug users (IDUs) aged 18-35 years
between 1997 and 1999 in 5 US cities.
Median age was 24 years; 62% were male,
with a mean duration of injecting of 3 years.
Using the National Death Index, they
identified 68 deaths over a follow-up period
through December 2002 with a mortality
rate of 7.1/1000 person years. The adjusted
standardized mortality ratios (SMR; with
national data as the reference) for IDUs
was 3.7 for 1997; this increased to 9.8 by
1998, and then continuously declined to 2.5
by 2002. According to the authors, these
data confirm considerable excess mortality
among recent onset injection drug users
compared to non-IDU peers in the general
population and indicate the need for
improved quality and accessibility to drug
abuse treatment and overdose prevention.
Miller et al (2007) investigated patterns of
premature mortality, prior to age 30 years,
among young IDUs. Since 1996, 572 young
(< or = 29 years) IDUs had been enrolled in
the Vancouver Injection Drug Users Study
(VIDUS). Semi-annually, participants
completed an interviewer-administered
questionnaire and underwent serologic
testing for HIV and hepatitis C (HCV).
Twenty-two participants died prior to age 30
years during the follow-up period giving an
overall crude mortality rate of 1,368 per
100,000 person-years. Young women IDUs
were 54 times (95%CI; 29.6-90.8) and
young men IDUs were 13 times (95%CI;
5.5, 25.3) more likely to die prematurely
when compared to the Canadian non-IDU
population of the same age. Factors
associated with mortality included HIV
infection and sex work.
Walley et al (2008) assessed the impact of
recent heavy alcohol use, heroin/cocaine
use, and homelessness on short-term
mortality in HIV-infected persons. They
analyzed survival in a longitudinal cohort of
595 HIV-infected persons with alcohol
problems at 6-month intervals in 1996-
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2005. Death within six months of their last
assessment occurred in 31 subjects (5.2%).
Heroin or cocaine use [hazard ratio (HR), 2.43;
95% confidence interval (CI), 1.12-5.30)] and
homelessness (HR, 2.92; 95% CI, 1.32-6.44)
were associated with increased mortality, after
controlling for other effects.
Naso et al (2008) provided a retrospective
evaluation of drugs detected in a paediatric
(i.e. less than 19 years of age) post-mortem
population between the years 1998 and 2002
(n = 730). Forty-two percent of deaths were
deemed to be natural, 27% accident, 13%
undetermined, 5% suicide, and 2% homicide.
Of the 640 cases subjected to comprehensive
testing, 38% were positive for at least one
compound. Resuscitative/treatment drugs
were detected most frequently (56% of
positive results), followed by illicit drugs (26%),
and ethanol (11%). In this population, the
authors recommended that illicit drugs and
ethanol should be targeted for testing,
especially when limited specimens are
available for analysis.
European research has shown that Substance
Use Disorders (SUDs) emerging in
adolescence are known to predict early
mortality (Kjelsberg 2000). Clark et al (2008)
examined this in the US context by looking at
870 adolescents (aged 12-18 years) from
clinical programmes (n= 510) and community
sources (n= 360) followed up for an average of
8 years. Subjects recruited from clinical and
community settings were similar on gender,
age, and ethnic group composition. There
were 21 deaths amongst these subjects, with
an average age at death of 22.8 years. In 12
cases for which the information could be
collected, the causes of death were motor
vehicle accidents (5), homicide (4), suicide (1),
drug overdose (1), or other accident (1). In
Cox regression models examining the main
effects of individual independent variables,
survival time was significantly predicted by
gender and ethnic group. Survival time was
significantly predicted by SUDs, hazardous
use, and selling drugs, but was not predicted
by suicide attempts. Among African American
males with SUDs, 23% died by age 25; an
odds ratio of 10.3 compared to White males.
Australasian studies
In Australia, Gibson et al (2008) examined the
predictors of mortality in a randomized study of
methadone vs. buprenorphine maintenance
treatment. They carried out a 10-year
longitudinal follow-up of mortality among
participants in a previous randomized trial
of methadone versus buprenorphine
maintenance treatment. The sample
consisted of a total of 405 heroin-
dependent (DSM-IV) participants aged 18
years and above who participated in the
original study. They identified an overall
mortality rate of 8.8 deaths per 1000
person-years (py) of follow-up. The rate for
those out of treatment was 14.3 compared
to 0.7/1000 py for those retained in
pharmacotherapy. Increased exposure to
episodes of opioid treatment reduced the
risk of mortality; there was no differential
mortality among methadone versus
buprenorphine participants. Older
participants randomized to buprenorphine
treatment had significantly improved
survival than younger ones on methadone
programmes. The risk of premature
mortality in those of aboriginal or Torres
Strait Islander origin was 5 times that of
other ethnic groups. The authors concluded
that increased exposure to opioid
maintenance treatment reduces the risk of
death in opioid-dependent people.
Stoove et al (2008) aimed to provide
Australian data comparable to those
reported internationally on the rate of
mortality among IDUs. They retrospectively
examined mortality among participants
(n=220) from the first Australian cohort
study of IDUs. The overall mortality rate
among those followed up was 0.8 per 100
py (95% CI, 0.6-1.2 per 100 py). Mortality
was higher among males, most common
among those in their early thirties and drug-
related mortality occurred typically after
substantial injecting careers. Extensive
experience of incarceration (≥ 3 times) was
associated with increased risk of mortality.
Rates of mortality among Australian IDUs
were considered to be lower than those
reported internationally,
The blood toxicology of coronial cases in
Sydney, Australia, involving a total of 705
cases of death due to opioid toxicity and 28
morphine positive homicide cases between
1 January 1998 and 31 December 2002
were compared by Darke et al (2007).
There was no significant difference
between the median morphine
concentrations of the overdose and
homicide groups (0.50 versus 0.45 mg/l).
The overdose group was more likely to
have blood alcohol (OR 3.21) present, but
less likely to have methadone (OR 0.26)
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and cannabis (OR 0.04). There was a
significant negative correlation between blood
morphine and alcohol concentrations among
the overdose group (rho = -0.32), but not
among the homicide group (rho = -0.03).
Independent predictors of a higher blood
morphine concentration were a lower alcohol
concentration and a higher methadone
concentration. This study suggests that
morphine concentrations per se are not
diagnostic of overdose; the importance of co-
ingestion of alcohol has to be taken into
account in such events.
Another Australian study of coronial cases
examines the demographic characteristics,
circumstances of death, toxicological results
and major organ pathology of
methylamphetamine-related deaths in that
country (Kaye et al, 2008). A total of 371
cases in which methylamphetamine was listed
as a cause of death were identified from the
National Coronial Information System (NCIS).
The mean age of decedents was 33 years
(range 15-61 years); 77% were male and 41%
were unemployed. Route of administration
was predominantly by injection (89%). Drugs
other than methylamphetamine were detected
in 89% of cases, mostly benzodiazepines
(41%) and morphine (36%). The median blood
methylamphetamine concentration was 0.2
mg/l (range 0.02–15.0 mg/l). Deaths were
overwhelmingly accidental, with 14%
determined to be suicides, and occurred in a
private home (71%). Cardiovascular
pathology, typically coronary artery
atherosclerosis, was detected in 54% of
decedents. Cerebrovascular pathology,
typically cerebral haemorrhage and hypoxia,
was present in 20% of cases. The authors
concluded that users need to be informed of
the potential harms of methylamphetamine
use, particularly those associated with the
cardiotoxicity of methamphetamine and the
use of methylamphetamine in conjunction with
other drugs.
Darke et al (2008) analyzed 485 consecutive
homicide cases autopsied at the New South
Wales Department of Forensic Medicine
(1996-2005). Substances were detected in
62.6% of cases, and illicit drugs in 32.8%.
Alcohol, cannabis, opioids, and stimulants
were most commonly detected. Cases where
death resulted from a physical altercation were
more likely to have had alcohol and cannabis
present. Illicit drugs were prominent amongst
firearms deaths. The proportion of alcohol
positive cases increased from 25% on Monday
to 49% for Saturdays/Sundays. Alcohol was
more common in incidents in the 00:01-
06:00 h and 18:00-24:00 h periods. They
concluded that psychoactive substances
appear to substantially increase the risk of
death by homicide.
European studies
Jönsson et al (2007) explored data on drug
abusers subjected to a forensic autopsy in
Sweden during 2002-2003. They examined
10,273 deceased individuals during the
study period, 7% (743/10,273) of whom
were classified as drug abusers. Illicit drugs
were detected in 70% of cases. On
average, about four substances per case
(legal or illegal) were detected post mortem.
The most common substances were
ethanol and morphine. In total, 50%
(372/743) died of poisoning, while 22%
(161/743) died of natural causes. Death
was considered to be directly or indirectly
due to drug abuse in 47% (346/743) of
cases, whereas evidence of drug abuse
was an incidental finding in 21% (153/743)
or based on case history alone in 33%
(244/743) of cases.
Knudsen et al (2008) documented all 259
cases of GHB poisonings in Gothenburg,
Sweden, treated at the local University
Hospital during 1995-2004. Furthermore
they identified, between 1996 and 2004,
743 seizures of GHB; 236 seizures of 1,4-
butanediol, and 343 seizures of GBL.
During 2004 only, there were 6 deaths with
heroin, 7 with GHB, 32 with amphetamine,
6 with cocaine, and 1 with methadone. Of
the 7 GHB fatalities, 5 were attributed to
overdose, the others to suicide and trauma.
The mean age of decedents was 22 years
(range 16-27 years).
Bjornaas et al (2008) studied mortality rate
and causes of death among all 185
hospitalised opioid addicts treated for self-
poisoning or admitted for voluntary
detoxification in Oslo, Norway, between
1980 and 1981. All deaths that had
occurred by the end of 2000 were identified
from the Central Population Register.
During a period of 20 years, 70 opioid
addicts died (37.8%), with a standardized
mortality ratio (SMR) equal to 23.6 (95% CI,
18.7-29.9). The SMR remained high during
the whole period, ranging from 32.4 in the
first five-year period, to 13.4 in the last five-
year period. There were no significant
differences in SMR between self-poisonings
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and those admitted for voluntarily
detoxification. The registered causes of death
included accidents (11.4%), suicide (7.1%),
cancer (4.3%), cardiovascular disease (2.9%),
and violent deaths (2.9%). The authors
concluded that the risk of death among opioid
addicts was significantly higher for all causes
of death compared with the general
population.
Ødegård et al (2007) identified causes of
death among Norwegian drug abusers and
investigated the risk factors for fatal overdose
and other causes of death. They analysed a
cohort of 501 drug abusers admitted to
treatment at the State Clinic for Drug Addicts,
120 km south of Oslo, in the period 1981-
1991. Crude incidence rates for all deaths and
overdose deaths did not appear to vary with
age. At every age the risk of death was higher
with a long-term history of drug abuse, and
more so for fatal overdose than for death by
other causes. Overdose accounted for 47% of
all deaths (88% of drug-related mortality),
followed by suicide (11%, AIDS (10%), and
liver diseases (5%). The annual mortality was
estimated at 2.5%, and the SMR was 23%.
Clausen et al (2008) conducted a prospective
cross-registry study with up to 7 years follow-
up of all opiate dependents in Norway who
applied for Opioid Maintenance Treatment
(OMT) (n = 3789). They were cross-linked with
data from the death registry from Statistics
Norway. Date and cause of death were
crossed with dates for initiation and
termination of OMT, and subjects' age and
gender. A baseline was established from the
waiting list mortality rate. Intention-to-treat was
investigated by analysing mortality among the
entire population that started OMT. The
researchers found that mortality in treatment
was reduced by half (Relative risk: R = 0.5))
compared with pre-treatment. In the "intention-
to-treat" perspective, the mortality risk was
reduced to an RR of 0.6 compared with pre-
treatment. The patients who left the treatment
programme showed a higher mortality rate,
particularly males.
An unusual epidemic of poisonings due to the
powerful opioid designer drug 3-methylfentanyl
(TMF) was revealed among Estonian drug
users in 2005-2006 (Ojanperä et al, 2008).
The number of TMF-related fatal accidental
poisonings identified was 46 and 71 for 2005
and 2006, respectively. The proportion of male
victims was 91.5% and the mean age at death
of all victims was 26 years. TMF was used
predominantly by intravenous injection.
Concomitant use of other drugs involved
alcohol, amphetamines, benzodiazepines,
and cannabis, and very rarely other opioids.
Cruts et al (2008) aimed at developing a
method to estimate the total mortality
among problem drug users. The results
from a cohort study among methadone
patients in Amsterdam were projected on
the whole population of problem drug users
in that country. In a first unadjusted
estimation, the estimated total number of
deaths among problem drug users in The
Netherlands in 2001 was 606. After
adjustment for age, the estimated mortality
decreased to 573 deaths, and after
adjustment for HIV infection, this estimate
again decreased to 479 deaths. From the
ultimately estimated mortality, 11% was
considered to be not related to drugs, 23%
was attributed directly to drugs, and 66%
was attributed indirectly to drugs.
A prospective study of 161 victims of falls
from height was undertaken by French
researchers in Lyon (Fanton et al 2007).
The aim was to determine the benefit of
systematic qualitative and quantitative
toxicological analysis in examining such
fatalities. The primary cause of death was
suicide (85%), followed by accidents (7%)
and homicide (1%). Cause of death was
undetermined in the remaining cases. In the
suicide cases, there was evidence of
psychotropic medicines in 57% of the
observations, with a much higher proportion
of benzodiazepines and antidepressants in
women than in men. Quantitative
toxicological analysis showed overdose on
medication in 16 suicide victims, with toxic
levels in 11 of these. Systematic qualitative
and quantitative toxicological analysis made
a significant contribution to the verdict of
suicide by revealing either an unknown
psychiatric treatment or a toxic level.
Bauer et al (2008) investigated mortality in
a cohort of 269 opioid-dependent German
patients enrolled in synthetic opioid
maintenance therapy during 1998-1999.
Structured interviews (Euro-ASI), urinalysis
at time of interview as well as autopsy
findings from deceased patients were
analyzed. After six mailings, information
from 147 (55%) patients was obtained and
85 patients (32%) were interviewed. Of
these 77% (n = 65) were still enrolled in
maintenance therapy, 19% (n = 16) were
drug-free and 5% (n = 4) had relapsed.
There were 29 fatalities; 38% died of
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intoxication with illicit substances, 35% related
to AIDS and 28% to somatic complications.
The SMR was 29. According to the authors,
the study confirmed the high mortality rate in
this patient group and supported the
importance of maintenance therapy.
The quality of street heroin seized in Vienna,
Austria, in 1999 was examined by Risser et al
(2007) to establish whether there was a
relationship between the purity of street heroin
and heroin-related emergencies and deaths.
Street heroin confiscated by the Viennese
police, run-sheets of drug-related
emergencies, and post mortem reports of
drug-related deaths in Vienna in 1999 were
analyzed. During the study period, 387 heroin-
related emergencies and 75 deaths were
registered in Vienna. The decedents consisted
of 20 females and 55 males; females were
significantly younger than males (26 vs. 31
years). In 16 cases, only morphine could be
detected, and these deaths were classified as
pure heroin-related deaths. In the remaining
59 cases, morphine, in addition to other CNS
depressant drugs and/or alcohol, was detected
(polydrug heroin-related deaths). Thirty per
cent of male heroin victims had additionally
consumed alcohol, in contrast to 35% of
female heroin users. There were no
statistically significant associations between:
blood alcohol concentration and morphine
concentration in the medulla oblongata; the
morphine concentration in the medulla
oblongata blood for females and males; and
morphine concentration in the medulla
oblongata for polydrug heroin-related deaths
and pure heroin-related deaths. Time-series
analysis revealed no statistically significant
relationship between the rate of heroin-related
incidents and the diacetylmorphine
concentration of street heroin. Compared with
reports from other countries, Viennese street
heroin, with a median diacetylmorphine
content of 6.5%, was generally of low quality.
The widely held belief that the number of
heroin-related deaths could be explained
simply through fluctuations in the purity of
street heroin could not be substantiated, even
though the results of this study do not rule out
an association between the purity of heroin
and heroin-related deaths/ emergencies.
In Italy, Davoli et al (2007) evaluated the
impact of a range of treatments for opiate
dependence on overdose mortality. They
carried out a prospective cohort study of
10,454 heroin users entering treatment 1998-
2001 followed-up for 10,208 person-years in
treatment and 2,914 person-years out of
treatment. They observed 41 overdose
deaths, 10 whilst in treatment and 31 out of
treatment, generating annual mortality rates
of 0.1% and 1.1% and SMRs of 3.9 [95%
confidence interval (CI) 2.8-5.4] and 21.4
(16.7-27.4), respectively. Retention in any
treatment was protective against overdose
mortality (HR 0.09 95% CI 0.04-0.19)
compared to the risk of mortality out of
treatment, independent of treatment type
and potential confounders. The risk of a
fatal overdose was 2.3% in the month
immediately after treatment and 0.77% in
the subsequent period; compared to the
risk of overdose during treatment the HR
was 26.6 (95% CI 11.6-61.1) in the month
immediately following treatment and 7.3
(3.3-16.2) in the subsequent period. They
concluded that a range of treatments for
heroin dependence reduced overdose
mortality risk. However, they pointed out as
well that considerable excess mortality risk
in the month following treatment indicates
the need for greater health education of
drug users and implementation of relapse
and overdose death prevention
programmes.
Ferri et al (2007) described the overall and
cause-specific mortality among heroin
users attending Public Treatment Centres
in Italy. The study involved a cohort of
10,376 patients (8881 men and 1495
women) enrolled over a period of 18
months between September 1998 and
September 2000 and followed-up through
March 2001 (VEdeTTE study). They
identified 190 deaths which occurred during
the study period: 70 deaths were due to
overdose (37%), and 38 to AIDS (20%).
The direct standardized overall mortality
rate per 1000 person-years was 12.0 (CI
95% 5.4-18.6). The findings also revealed
that overdose is the leading cause of death
in heroin users (mortality rate 2.6/1000 p-y
(95% CI 0.8-4.5) among males and
4.0/1000 p-y (95% CI 0.9-7.2) among
females. The population attributable fraction
highlighted that 14% (95% CI 10.9-18.5) of
deaths in people aged 30-34 in Italy in 2000
could be attributed to heroin addiction. The
authors concluded that mortality observed
in their cohort was lower than that observed
in previous studies, mainly due to reduction
of AIDS and overdose mortality. However,
their findings confirmed excess mortality




Pavarin. (2008) examined mortality rates in a
cohort of 347 cocaine addicts enrolled in
treatment programmes at the SerTs (Drug
Addiction Services) of Bologna's metropolitan
area from 1989 to 31 December 2004. A total
of 7 male deaths: one caused by AIDS, one by
drug overdose, three by vascular diseases,
two by injuries and poisonings. The mortality
rate was 4.98 per 1000 person-years in both
sexes, 5.38 for males. The survival chance
after 12 years from the first contact with the
SerTs was 89%. The death risk goes down
after two years from the first enrolment and
drops remarkably only after two years from the
last contact with the drug treatment service.
Excess mortality for all causes among males
in comparison with the general population was
five-fold (SMR 4.75). The highest SMR was
related to vascular diseases (15), followed by
overdose (10) and suicide (7).
In a 17-year cohort study (1987-2004) of
Spanish injecting drug users (IDUs), Ferreros
et al (2008) examined changes in cause-
specific mortality before and after 1997
according to human immunodeficiency virus
(HIV) serological status. A total of 7186 IDUs
contributed 80677.218 person-years to the
study. The overall mortality rate was 19.7 per
1000 person-years (95% CI, 18.8-20.7). This
rate decreased from 22.9 per 1000 (95% CI,
21.4-24.7) before 1997 to 17.4 per 1000 (95%
CI, 16.3-18.6) after 1997 [relative risk (RR)
0.83; 95% confidence interval (CI), 0.75-0.92].
HIV-negative individuals showed a similar
pattern for drug overdose, suicide and
accident mortality. Both groups showed an
increase in proportional mortality in liver-
related causes, cardiovascular diseases and
cancer.
A mortality crisis followed the break-up of the
Soviet Union in 1992, but there has been
relatively little analysis of death rates among
young people, many of which appear related
to alcohol and other drug (AOD) use. Death
rates range from exceedingly high in some
countries of the Commonwealth of
Independent Sates (CIS), for example Russia,
to very low in others (e.g. Armenia). This
divergence increased considerably over the
1990s. Redmond and Spooner (2008)
examined reasons for the divergence in youth
deaths. An ecological study of country-level
data was used to explore the relationships
between risk factors, AOD use and youth
deaths across time and between countries.
Qualitative research literature was used to
supplement the statistical data. AOD abuse
risk factors were divided into 'proximal causes'
(e.g. AOD availability) and 'distal causes'
(e.g. social cohesion, welfare, culture).
Proximal risk factors appeared to explain
some of the AOD use and death data, but
they did not explain all of the country
differences. Analysis of distal risk factors
suggested that family and community
strengths are important factors in the trends
in AOD abuse and youth mortality. They
concluded that policy response to AOD
abuse and mortality among young people
needs to attend to both proximal and distal
factors.
In Ireland, a report by the National Suicide
Research Foundation (2008) presented the
results of a study analysing data routinely
collected in 2002 by means of Form 104.
This form was introduced in 1968 ‘to
supplement the information on the
Coroner’s Certificate for the better statistical
classification of cause of death’. The form
was expanded in 1998 to facilitate a more
detailed recording of the circumstances
surrounding unexpected deaths, and now
contains a number of mandatory fields:
socio-demographic information, medical
history, psychosocial factors, circumstances
of death and contributing factors. One of
these forms was completed for 1,718 (95%)
of all the deaths in 2002 that led to an
inquest. There was a high level of
completeness for socio-demographic
information (75% and above) but low levels
for medical history and contributing factors
(35% and below). In 88% of cases, Garda
(police) opinion as to the cause of death (as
recorded on the form) agreed with that of
the Central Statistical Office. The majority
of unreturned forms related to deaths
registered in Dublin. This may have led to
inaccurate recording of the external causes
of deaths in the area. Furthermore, the
authors suggest that cases of suicide in
Dublin were commonly misclassified as
being of ‘undetermined intent’, which may
partially explain the lower suicide rate found
in Dublin compared to other areas of the
country. The most important findings were:
(a) in general, a higher proportion of male
deaths than female deaths were alcohol
dependent; (b) 15% of suicide deaths were
alcohol dependent, compared to one-fifth of
deaths by accident, homicide or
undetermined cause; (c) one-third of
undetermined deaths were drug dependent,
compared to 13% of accidental deaths; (d)
of the homicide deaths, one-quarter of the
men were drug dependent, compared to
none of the women; (e) of the suicide
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deaths, 34% of women were drug dependent,
compared to 16% of men, and a higher
percentage of women than men were
dependent on prescription medication. The
authors made a number of recommendations,
including the development of a new system to
record medical and psycho-social information
on deaths that lead to an inquest.
The results of two studies by the European
Alliance Against Depression looking at gender
differences in methods of suicide (using ICD10
codes X60-X84) have recently been published.
The first looked at the proportions of 7 leading
suicide methods used in 16 European
countries between 2000 and 2004/5 (Värnik et
al, 2008a). Hanging was the most common
suicide method among both males (54.3%)
and females (35.6%). For males poisoning by
drugs (8.6%) was the third most common
method whereas for females (24.7%) it was
the second most prevalent method, but the
leading cause in five countries (England,
Finland, Ireland, Scotland and Switzerland).
The second study took a closer look at those
aged 15-24 years in 15 countries (Värnik et al,
2008b). Hanging was still the most frequent
method used for both genders. Poisoning by
drugs was the joint-fifth most common method
for males but the joint-second for females,
both at an average rate of 0.6 per 100,000
population. Suicide rates by drug poisoning for
males in England and Scotland were 0.5 and
2.6 respectively; the corresponding rates for
females were 0.5 and 2.7.
In a recent editorial, Morgan et al (2008)
emphasized that surveillance of deaths related
to drug misuse in Europe is important for
measuring the impact of intervention and for
planning future harm reduction strategies, but
it cannot answer more fundamental questions,
such as understanding what are the main
drivers of drug overdose trends. According to
these authors, the number of overdose deaths
is related to the interplay between changes in
the size of the drug-using population and to
their overdose mortality risk, with the latter
related to other factors such as the proportion
of IDU in treatment or changes in drug
administration. By 2004/05 the drug-related
mortality rate in England and Wales (using the
Drug Strategy definition) was one of the
highest in Europe. However, case definition
and data extraction from mortality statistics
varies between countries despite there being a
common European definition. In none of the
other selected European countries did the
overdose mortality rate double during the
1990s. Instead the evidence suggests that
mortality rates declined in Spain and Italy
and were stable in Germany. In addition,
the other selected countries all achieved
substantially greater reductions in drug-
related deaths than England and Wales
between 1999 and 2004/05, with Germany
and Italy exceeding a 20% decrease and
Spain (six cities) reducing the drug-related
mortality rate by 17%. The increase in
overdose deaths during the 1990s in
England and Wales was driven largely by
increases in the prevalence of heroin use.
The authors suggest that the reduction in
overdose deaths from 2001 may have been
the result of the rate of increase in
treatment superseding any increase in the
prevalence of drug misuse, thereby
reducing the overall risk of overdose death.
However, in the United Kingdom since 1993
there has been no investment in large-scale
longitudinal studies that could test this
hypothesis and monitor trends in overall
risk of overdose. Mortality patterns can be
changing substantially and quickly and
large-scale cohort studies are needed in
different European countries, including the
UK, to provide comparable information
about overdose risk. Interpreting mortality
statistics and trends in drug use is complex,
and unlikely to lead to any firm conclusions
without information on overdose risk. The
authors argue that a better understanding
of the mechanisms that underlie overdose
mortality statistics is required.
British studies
Smith and Crome (2007) report that the
annual reports for drug abuse deaths in the
North Staffordshire area are, as a whole,
about average for the country. Certain
patterns appear to emerge: men die more
commonly than women from drug-related
problems. The figures for the period 2001–
2005 indicate an average of just over eight
deaths per annum in the under-30 age
group, with a peak of 13 in 2002 and only
six in 2005. The striking thing about the
findings is that deaths from drug abuse,
which invariably involve heroin in all age
groups, typically and increasingly take
place in the older age groups. Only six of
the 23 drug abuse related deaths in 2005
were of persons under 30 years old, and
just two under 25. While the average
number of drug-related deaths is just over
eight per annum in the under-30 age group,
the average number of deaths per annum in
the same age group over the same period
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from road collisions in the North Staffordshire
area alone was 15: one is statistically much
more likely to die in a car than as a result of
drug abuse, though drugs, and alcohol, may
help achieve that end. It is difficult to be too
precise about how many deaths each year are
due to the effects of alcohol. Because chronic
alcoholism, liver cirrhosis and so on are
regarded as natural causes and do not have to
be reported to the coroner, many such deaths
will go straight to the Registrar of Deaths and
bypass the coroner’s office altogether. During
2005 all deaths reported to the North
Staffordshire coroner having a clear link with
alcohol, whether as a part of a drug-related
death, a fall downstairs whilst drunk, a road
traffic accident, or just plain simple liver
cirrhosis, were identified as part of a study. In
the current climate, even such research as this
will undoubtedly under-record these deaths.
However, despite the fact that the majority of
alcohol-related deaths are now regarded as
deaths from natural causes, many such deaths
are still referred to the coroner (possibly a
hangover from the previous system) and
alcohol was a feature in a very substantial
number of deaths. The overall total number of
alcohol-related deaths in 2005 was 117,
including 73 non-inquest cases.
Secondary analysis of the DORIS cohort study
(1033 Scottish drug users recruited in 2001-2
and followed up at 33 months) found that 38
deaths occurred in the cohort, giving a
standardised mortality ratio of 1244 (Bloor et
al, 2008). Only 22 of the 38 deaths in drug
users were classified as drug related deaths.
From estimates of the size of the problem drug
using populations in both England and
Scotland, the contribution of deaths in drug
users to national death rates was estimated:
the attributable risk fraction for Scotland is
17.3% and that for England is 11.1%.
Excluding estimated numbers of deaths in drug
users brings down the age-standardised
mortality at ages 15-54 years from 196 to 162
per 100,000 in Scotland and from 138 to 122
per 100,000 in England; 32.0% of the excess
mortality in Scotland is due to drug use. The
researchers conclude that the standardised
mortality ratio for Scottish drug users is 12
times as high as for the general population.
The higher prevalence of problem drug use in
Scotland than in England accounts for a third
of Scotland’s excess mortality over England.
Successful public health efforts to reduce the
prevalence of problem drug use in Scotland or
deaths in Scottish drug users would have a
dramatic impact on overall mortality in
Scotland.
The Fife Drug Deaths Monitoring and
Prevention Group investigated drug deaths
in Fife in 2005-7 (Baldacchino et al, 2008).
The number of deaths was higher in 2006
(19) and 2007 (20) than in 2005 (15), and
was below the Scottish average. Most
deaths in Fife occur in large towns, but at
no higher rates than in rural communities.
The majority (83%) of individuals’ home
town and town of death matched; the rest
died within 10 miles of their home towns.
Drug-related deaths are more likely to occur
in socially deprived areas and areas with
other drug-related problems. The mean age
of decedents was 31 years (range 17-48).
Multiple morbidities were present in the
youngest and oldest individuals: the
youngest tending to have psychological
conditions; the oldest had physical health
problems. Most deaths occur during the
spring time; this may be linked with victims’
release from prison. Most such deaths
occur at the weekend; but this is unlikely to
be linked with prison release patterns.
Victims were most likely to live alone and in
council accommodation at the time of their
death. Heroin/morphine (80%), diazepam
(43%) and alcohol (35%) were the 3 main
substances of misuse detected in cases of
drug deaths in Fife. Benzodiazepines as a
class, are the substances most commonly
implicated (89%). Psychostimulants (e.g.
MDMA) were involved in 10% of deaths;
however there is a recent emergence
(2007) of deaths involving cocaine. These
findings are consistent with Scotland-wide
research but not reflected in UK national
research where heroin/morphine, alcohol
and other opioids are the most frequently
detected substances of misuse. The
majority of cases were positive for two or
more combinations of drugs in toxicology
reports: heroin/morphine appeared in 7/10
combinations, benzodiazepines featured in
5/10, and alcohol in 3/10. Benzodiazepines
and heroin/morphine combined were the
most frequently misused substances (41%
of cases), followed by alcohol and morphine
(19%), as well as a few overdoses on
heroin alone. One-fifth (22%) were
receiving pharmacological treatments; most
were prescribed methadone (18%). Of
these decedents 16% were still on a
methadone programme when they died.
Studies previously reported in the np-SAD
annual reports have not revealed any
significant changes in deaths attributable to
co-proxamol. Legislative changes in 2005
led to a phased withdrawal of co-proxamol
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from the UK market. Sandilands and Bateman
(2008) undertook a retrospective,
observational study of mortality relating to
poisoning by single agents in Scotland for the
period 2000-2006. Mortality data were
obtained from the General Register Office
Scotland, and primary care prescribing data
from the Information and Statistics Division of
the Scottish Executive Health Department. A
significant reduction in the proportion of
poisoning deaths due to co-proxamol was
observed following the changes in legislation
[mean 2000-2004, 37 deaths (21.8% of total
poisoning deaths); 2006, 10 (7.8%); P <
0.0001]. The most significant reduction was
seen in male out-of-hospital deaths [mean
2000-2004, 17 (21.8%); 2006, two (2.9%)].
This was associated with a decline in
prescriptions by 60% within 6 months of
legislation. The authors argue that legislation
has resulted in a major reduction in the
number of deaths associated with co-proxamol
poisoning in Scotland, with no compensatory
increase in mortality from poisonings from
other common analgesics. They extrapolate
that a minimum of 300 lives across the UK
have been saved by the withdrawal of co-
proxamol.
The Centre for Suicide Prevention based at
the University of Manchester has recently
published its findings for Scotland on suicide
and homicide by people with mental illness
(CSP, 2008). Amongst the range of issues
explored are the roles of alcohol and drug
misuse in such deaths. The study covers
1,373 patient suicides in the period April 1997
to December 2005. There was a history of
alcohol misuse in 785 (131 deaths p.a.) and a
history of drug misuse in 522 (87 deaths p.a.).
Dual diagnosis was found in a quarter of
patient suicides – 343 in total (57 deaths p.a.).
Forty-one of the 58 patient homicides had a
history of alcohol misuse, and 45 cases had a
history of drug misuse. About a quarter (13)
had been identified as having a dual
diagnosis. Among all perpetrators, whether
patients or not, alcohol and drug dependence
were the most common diagnoses. In both
suicide and homicide, most were not under the
care of addiction services. The report
concludes that alcohol and drugs are the most
pressing mental health problems in Scotland.
The seventh report on confidential enquiries
into maternal deaths in the United Kingdom
recently reported on deaths between 2003 and
2005 (Lewis, 2007). Maternal deaths are
extremely rare in the United Kingdom; only
295 women who died from causes directly or
indirectly related to their pregnancy, out of
more than two million mothers who gave
birth in the United Kingdom (UK) during this
period. Eleven per cent of those who died
of any cause had problems with drugs or
alcohol; 60% of these were known to drug
services. Fifty-seven women out of the 98
women whose deaths were attributable to
psychiatric causes had problems with
substance abuse: 45 were misusing drugs
and 12 were alcohol dependent. One death
resulted from volatile substance abuse. The
majority of those who were drug dependent
were using heroin, but most were also
using methadone, amphetamines, cocaine,
benzodiazepines and some alcohol as well.
A small number died from suicide, the rest
died from an accidental overdose of their
drug of abuse, physical consequences of
their abuse or related medical conditions.
Some died from domestic abuse. Many of
the subjects were socially excluded; most
being homeless or living in very inadequate
conditions. The report concludes that
substance misuse makes a significant
contribution to maternal mortality in general,
and especially to psychiatric causes.
Farrell and Marsden (2008) investigated
drug-related deaths among newly released
prisoners in England and Wales. They took
into account a national sample of 48,771
male and female sentenced prisoners
released during 1998-2000 with all
recorded deaths included up to November
2003. They recorded 442 deaths, of which
261 (59%) were drug-related. In the year
following index release, the drug-related
mortality rate was 5.2 per 1000 among men
and 5.9 per 1000 among women. All-cause
mortality in the first and second weeks
following release for men was 37 and 26
deaths per 1000 per annum, respectively
(95% of which were drug-related). There
were 47 and 38 deaths per 1000 per
annum, respectively, among women, all of
which were drug-related. In the first year
after prison release, there were 342 male
deaths (45.8 were expected in the general
population) and there were 100 female
deaths (8.3 expected in the general
population). Drug-related deaths were
attributed mainly to substance use
disorders and drug overdose. Coronial
records cited the involvement of opioids in
95% of deaths, benzodiazepines in 20%,
cocaine in 14% and tricyclic
antidepressants in 10%. The authors
concluded that newly released prisoners
are at acute risk of drug-related death and
np-SAD
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that appropriate prevention measures should
be implemented. (See also Farrell and
Marsden (2005).)
Hickman et al (2008) recently discussed the
evidence in support of the hypothesis that
alcohol increases the risk of a heroin/opiate
overdose through a pharmacological
interaction. A few facts are already well
established, including: opiate overdose deaths
rarely involve a single drug; alcohol is the most
common drug involved; there is a negative
association between alcohol and morphine
concentration at post mortem; and post-
mortem levels of morphine are often below the
levels expected of highly tolerant individuals.
Although the existing evidence, according to
the authors, is consistent with the hypothesis
that heroin users who drink alcohol may
require less heroin to overdose than those
who do not drink (all other factors being
equal), other causal (and non-causal)
pathways could not be ruled out. In fact, they
suggested that alcohol could be associated
negatively with tolerance, or confounded by
other factors.
Flanagan (2008) reports (using data that were
partially revised by ONS in 2007) that deaths
from fatal poisoning (accidents, suicides and
open verdicts) in England and Wales have
declined steadily (from 3,952 in 1979 to 2,565
in 2004). There was also a small annual
reduction in suicides in males and in females
over this period. In 2004, self-poisoning
accounted for 25% of suicides and open
verdicts in males (n = 862) and 45% in
females (n = 540). Poisoning death rates per
million prescriptions were about 10 times
higher for tricyclic anti-depressants (TCAs)
than for selective serotonin reuptake inhibitors
(SSRIs) in England and Wales between 1993
and 2004. However, despite increased
prescribing of SSRIs and related compounds
in recent years, there has been a fall of 10% in
the annual number of antidepressant-related
poisoning deaths, in line with the reduction in
suicides (all methods) over this period.
Citalopram appears to have higher overdose
toxicity than other SSRIs. Of newer non-SSRI
antidepressants, the overdose toxicity of
venlafaxine, although lower than that of TCAs,
appears to be higher than that of SSRIs, with
seizures, serotonin syndrome,
rhabdomyolysis, renal failure and hepatic
failure having been reported. Poisoning deaths
involving antipsychotics either alone, or with
other drugs and/or alcohol were much fewer
than those involving anti-depressants (713 and
5,602 deaths, respectively, in England and
Wales, 1993-2004). Following the
restriction on thioridazine prescription
(2000), thioridazine-associated fatal
poisoning fell to zero by 2002. However,
this pattern was balanced by an increase in
deaths associated with atypical
antipsychotics, most notably clozapine,
olanzapine and quetiapine. Antipsychotic-
related poisoning deaths were higher in
2004 than at any time since 1993.
Wong et al (2008) hypothesised that
organomegaly is associated with chronic
substance use, and may represent a
prognostic indicator. The weights of hearts,
livers and spleens from 280 deceased
chronic alcoholics (CA) and 33 deceased
chronic drug users (CD) were compared to
those of 291 deceased controls (e.g. non-
substance users who died of traumatic
injuries) investigated by the Division of
Pathology at the University of Edinburgh.
Alcohol misuse was associated with
cardiomegaly (27% vs. 19%, male CA vs.
control) and hepatomegaly (38% vs. 15%).
In CA, occurrence of hepatomegaly was
associated with death at a younger age
(female mean age 47+/-9.4, p<0.009, male
mean age 50+/-11.6, p<0.007). The study
identified the potential role of hepatomegaly
as a determinant of poorer outcome in
chronic alcohol misusers.




recently become drugs of abuse in the UK.
These substances have stimulant effects
comparable to amphetamines but with a
lower potency and differential global
scheduling status. They have been sold as
a supposed legal alternative to ecstasy. A
few non-fatal and fatal cases where BZP
has been detected and typically involving
other drugs have been published
internationally. However, toxicity involving
BZP alone has also been reported. No case
data currently exist for 3-TFMPP. Elliott and
Smith (2008) used ultraviolet (UV) and
liquid chromatography-mass spectrometry
data to distinguish the structures of
positional isomers of TFMPP and CPP, and
confirm the presence of BZP and 3-TFMPP
in three UK fatalities (road traffic deaths
and a fatal fall), with two cases involving
both drugs. These are the first reported
cases of 3-TFMPP in post-mortem fluid. In
all cases, other drugs and/or ethanol were
found. BZP was found at concentrations of
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0.71, <0.50, and 1.39 mg/L while 3-TFMPP
was found at concentrations of 0.05 and 0.15
mg/L in post-mortem blood. Concentrations
were also measured in urine. Although BZP
and 3-TFMPP were not the direct cause of
death, the toxicological findings presented in
this paper may assist the interpretation of
future cases involving these drugs. (The
presence of these substances in np-SAD
cases are discussed in the commentary
below.)
III Drug-related deaths in the United Kingdom
1. Demography
Notifications of 1,539 drug-related deaths
occurring in 2007 were received by the np-
SAD. Responses (including nil returns) were
received from a total of 107 out of 115
coroners' jurisdictions in England and Wales.
This is a coverage rate of about 93%. In
addition, the coroners in Northern Ireland,
Guernsey, Jersey and the Isle of Man
contributed data analysed in this Annual
Report, as well as one Procurator Fiscal in
Scotland.
Furthermore, the SCDEA and the NISRA
provided data reported to them for deaths in
the period under examination. These deaths
do not represent the full number of drug-
related deaths in the UK since not all deaths
are reported to the SCDEA (see next
paragraph), and further inquests remain to be
completed in England, Wales and Northern
Ireland on deaths that occurred in 2007.
Deaths reported to the SCDEA by Scottish
police forces are those which meet the
definition used by the Association of Chief
Police Officers (Scotland) – “where there is
prima facie evidence of a fatal overdose of
controlled drugs. Such evidence would be
recent drug misuse, for example controlled
drugs and/or a hypodermic syringe found in
close proximity to the body and/or the person
is known to the police as a drug misuser
although not necessarily a notified addict.”
Thus, most suicides in Scotland will be
excluded.
Table 1, together with Figures 1-3, takes into
account the data from the np-SAD as well as
the SCDEA and the NISRA. Therefore the
total number of drug-related deaths in the UK
from the above sources is 1,900 in 2007,
compared to 1,752 cases from the same
sources in the equivalent period in 2006. This
represents an increase of 8.4%. However, this
increase is in part due to several more
coroners’ areas reporting to the Programme, a
much improved flow of information from
Northern Ireland, as well as to an actual
increase in the number of cases notified.
A comparison of the areas which reported to
np-SAD in both years shows that the number
of cases increased by 9.6% (from 1,363 to
1,494 deaths). Furthermore the average
number of cases notified per area increased
from 13.1 for 2006 to 14.4 for 2007.
The majority (79%) of cases were male (Table
1). This proportion varied from 71% in
Northern Ireland to 89% in Scotland.
Location of death was reported in all but 340
cases (17.8%) – mostly in Scotland. Where
place of death was reported, about 69% died
at a defined residential address (i.e. the
deceased’s home address or other private
residential address), 19% died in hospital and
12% died elsewhere (e.g. in a public place).
The proportion dying at a defined residential
address ranged from 68% for np-SAD cases
to 89% in Scotland and 79% in Northern
Ireland. The corresponding proportions for
deaths in hospital ranged from 20% for np-
SAD cases to 10% in Scotland and 4% in
Northern Ireland.
The mean age at death was 38.7 years for all
sources combined. However, there were
differences between the individual datasets:
np-SAD 39.6 years; SCDEA 33.3 years; and
NISRA 43.0 years. There were also
differences in the mean ages broken down by
gender. Whereas the overall average age for
males was 38.6 years compared to 44.3 for
females (a difference of 6 years), the mean
age for males in Scotland (33.4 years) was
only slightly higher than that for females (32.6
years). However, in Northern Ireland the gap
was considerably greater; the mean age for
males was 40.6 years compared to 48.9 years
for females. Similar patterns are exhibited by
the median age and semi-interquartile ranges.
The above differences reflect distinctions in
the nature and purpose of the data sources,
the types of cases covered, and the volumes
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of cases dealt with by them. These variations
also illustrate the limitations on making
comparisons between them. Additional
information for each of these registers is given
below.
Table 1: Demographic variables for drug-related deaths, UK, 2007
























Variable Category Number (%)
Total 1,900 (100.0)
Gender Male 1,503 (79.1)
Female 397 (20.9)






Over 64 71 (3.7)
Location of death Defined residential address 1,076 (56.7)
Hospital 299 (15.7)
Other 185 (9.7)
Not known 340 (17.9)
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IV Profile of np-SAD cases
1. Demography
Notifications of 1,539 drug-related deaths
occurring in 2007 were received by the np-
SAD that met the Programme’s case criteria.
Responses (including nil returns) were
received from a total of 107 out of 115
coroners' jurisdictions in England and Wales.
This is a coverage rate of about 93%. In
addition, the coroners in Northern Ireland,
Guernsey, Jersey and the Isle of Man
contributed data analysed in this Annual
Report, as well as one Procurator Fiscal in
Scotland.
The majority (77%) of cases were male (Table
2). The median age at death was 37.9 years
(semi-interquartile range = 8.4) (Figures 4-6).
The majority (71%) of cases were under 45
years. Where ethnicity was known, the
majority were White (94.7%); the rest were
Black (2.4%), Asian (1.3%), and Other (1.6%).
Just under half (49%) were unemployed.
There were similar proportions living alone
(45%) or with others (43%), but 5% were of no
fixed abode.
Table 2: Demographic variables for drug-related deaths, np-SAD cases, 2007
2. Drug-related death rates (Annex AR2)
The jurisdictions in England and Wales
reporting the highest annual drug-related
death rates per 100,000 population aged 16
years and over in 2007 were as follows:
Brighton & Hove (18.8); Blackpool & the Fylde
(14.9); and Peterborough (10.1). Dumbarton
had a rate of 20.6.
3. Location of death
Location of death was reported in all but three
cases. About 69% died at a defined
residential address (i.e. the deceased’s home
address or other private residential address),
19% died in hospital and 12% died elsewhere
(e.g. in a public place).
Variable Category Number (%)
Total 1,539 (100.0)
Gender Male 1,189 (77.3)
Female 350 (22.7)






Not known 102 (6.6)
Living arrangements Alone 887 (44.8)
With others 657 (42.8)
No fixed abode 70 (4.5)
Other 51 (3.3)
Not known 72 (4.7)
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4. Underlying cause(s) of death (Annex
AR1)
To enable comparison with various national
and international datasets all causes of death
have been coded according to the
International Classification of Diseases (ICD-
10). This is an international standard for the
classification of diseases and health-related
problems published by the World Health
Organisation (1992). The proportions of ICD-
10 categories of underlying cause(s) of death
were as follows:
 Accidental poisoning (X40-X47): 62.7%
 Intentional self-poisoning (X60-X67):
13.2%
 Poisonings of undetermined intent (Y10-
Y15): 11.8%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 12.3%
5. Manner of death
The ‘intentionality‘ of deaths based on the
coroner’s verdict and/or or other additional
information employing ICD-10 codes is
inappropriate for informing interested parties
as to whether certain categories of drug-
related deaths can be prevented.
Whilst the ‘cause’ of death (as given in the
preceding section) is concerned with the
disease or injury responsible for the lethal
sequence of events, the ‘manner’ of death
explains how the cause of death arose, i.e. a
natural or violent death. In accordance with
best international practice, the following
categories for ‘manner of death’ have been
adopted: natural, accidental, suicidal,
homicidal, undetermined, and unclassified/not
specified.
Verdicts of ‘dependence on drugs’ or ‘non-
dependent abuse of drugs’ are regarded as
‘accidental’. The ‘manner of death’ is derived
from information such as the verdict or
‘finding’, history of drug misuse or
dependence, post mortem drugs, and other
information; and is based on the interpretation
of the death by np-SAD and clinical
presentation/profile of the individual case.







 Unclassified/not specified: 0.8%
6. Substances implicated in death
6.1 All substances
Psychoactive drugs were not directly
implicated in 5% of cases (n = 77). Of the
remaining 1,462 cases, the principal
substances implicated were heroin/morphine
(48%), alcohol in combination with other
substances (38%), other opiates/opioid
analgesics (25%), anti-depressants (21%),
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hypnotics/sedatives (21%); methadone (20%),
and cocaine (16%).
Figure 7 takes into account data where one of
the following drugs was known to be
implicated: alcohol, anti-depressants, cocaine,
ecstasy-type drugs, heroin/morphine,
hypnotics/sedatives, methadone, or other
opiates/opioid analgesics.
6.2 Single substances
The following substances, as the sole
implicated drug, accounted for 483 (33%)
deaths: heroin/morphine (14%), other
opiates/opioid analgesics (4%), anti-
depressants (4%), methadone (4%), cocaine
(3%), hypnotic/sedatives (1.4%), ecstasy-type
drugs (0.7%), anti-psychotics (0.6%),
amphetamines (0.5%), and cannabis (0.2%).
Table 3: Psychoactive substances implicated in death, np-SAD cases, 2007
Drug category Number (%) of cases
where no other
substance was implicated
Number (%) of cases
where drug was
implicated
Total 1,462 (100.0) 1,462 (100.0)
Alcohol - 554 (37.9)
Amphetamines 8 (0.5) 55 (3.8)
Anti-depressants 58 (4.0) 308 (21.1)
Anti-epileptics 4 (0.3) 36 (2.5)
Anti-psychotics 9 (0.6) 55 (3.8)
Cannabis 3 (0.2) 55 (3.8)
Cocaine 40 (2.7) 239 (16.3)
Ecstasy-type drugs 10 (0.7) 45 (3.1)
GHB 2 (0.1) 7 (0.5)
Heroin/morphine 202 (13.8) 708 (48.4)
Hypnotic/sedatives 20 (1.4) 309 (21.1)
Methadone 63 (4.3) 295 (20.2)
Other opiates/opioid analgesics 63 (4.3) 365 (25.0)
Notes: Column totals may sum to more than 100% since more than one substance may be implicated in a death. Not
all cases had drugs directly implicated in death; these are excluded from this table.
7. Prescribed psychoactive drugs (Table
4)
Altogether, 811 np-SAD cases were reported
to be receiving prescribed psychoactive drugs
at the time of their death. Within this group,
prescribed drugs of the following therapeutic
drug classes were reported: anti-depressants
(46%); hypnotic/sedatives (40%); other
opiate/opioid analgesics (21%); anti-
psychotics (21%) and methadone (16%).
‘Polypharmacy’, i.e. multiple prescriptions of
psychoactive drugs, occurred in 66% of these
cases.
np-SAD
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1. Prescribed psychoactive drugs
Of the 811 cases prescribed psychoactive
drugs at the time of their death, 55% had
those same drugs, alone or in combination
with other drugs, implicated in their death
(Table 4). This proportion ranged from 26%
for anti-psychotics to 82% for
heroin/morphine.
The following paragraphs take a closer look at
the relationship between deaths and the
involvement of prescribed medication. This
approach is to be distinguished from that in
Table 4, which only looks at those on
prescribed medication.
1.1 Methadone
Methadone, alone and in combination with
other drugs, was implicated in 295 cases. Of
these, 71% may have obtained methadone
from illicit sources, compared to 29% who
were known to be receiving prescribed
methadone prior to their death (Percentage
Ratio: PR = 2.4, 95% CI = 2.0 - 2.9).
Methadone alone was implicated in 63 cases.
Of these, 73% may have obtained the drug
from illicit sources, compared to 27% who
were known to be receiving prescribed
methadone, compared to (PR = 2.7, 95% CI =
1.8 - 4.2).
Overall, it appears that methadone-related
deaths are more likely to arise from illicit than
licit methadone.
1.2 Anti-depressants
Anti-depressants, alone and in combination
with other drugs, were implicated in 308
cases. Of these, 74% were known to be
receiving prescribed anti-depressants at the
time of their death, compared to 26% who
may have used drugs prescribed for others
(PR = 2.9, 95% CI = 2.4 - 3.5).
Anti-depressants alone were implicated in 58
cases. Of these, 71% were known to be
receiving prescribed anti-depressants,
compared to 29% who may have used drugs
prescribed for others (PR = 2.4, 95% CI = 1.6
- 3.7).
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Those receiving prescribed anti-depressants
were significantly more likely to have that
class of drug implicated in their death, either
in combination or as the sole drug, compared
to those who had apparently used drugs
prescribed to others.
Table 4: Prescribed psychoactive medication, np-SAD cases, 2007
Drug category
Number (%) of cases on
prescribed
psychoactive medication
Number (%) of cases
where same drug was
implicated in death
Total 811 (100.0)
Amphetamines 2 (0.2) 1 (50.0)
Anti-depressants 374 (46.1) 199 (53.2)
Anti-epileptics 77 (9.5) 21 (27.3)
Anti-psychotics 173 (21.3) 45 (26.0)
Heroin/morphine 28 (3.5) 23 (82.1)
Hypnotic/sedatives 328 (40.4) 128 (39.0)
Methadone 128 (15.8) 86 (67.2)
Other opiates/opioid analgesics 168 (20.7) 104 (61.9)
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual
and more than one substance may be implicated in a death.
1.3 Other opiates/opioid analgesics
Other opiates/opioid analgesics (e.g.
dihydrocodeine, dextropropoxyphene) alone
and in combination with other drugs, were
implicated in 365 cases. Of these, 72% may
have obtained the drug by other means,
compared to the 28% who were known to be
receiving prescribed opiate/opioid analgesics
prior to their death (PR = 2.5, 95% CI = 2.1 -
3.0).
Other opiate/opioid analgesics alone were
implicated in 63 cases. Of these, the drugs
were apparently obtained by other means in
63% of cases, compared to being prescribed
in 37% of cases (PR = 1.7, 95% CI = 1.2 -
2.5).
1.4 Hypnotics/sedatives
Hypnotic/sedatives, alone and in combination
with other drugs, were implicated in 309
cases. Of these, 68% may have obtained
them illicitly, compared to the 32% who were
known to be receiving a prescription for this
class of drug (PR = 2.2, 95% CI = 1.8 - 2.6).
Twenty cases had hypnotic/sedatives alone
implicated in their death, of whom 14 (70%)
had received the drug on prescription,
compared to 6 (30%) who may have obtained
it illicitly (PR = 2.3, 95% CI = 1.1 - 4.8).
In summary, there was a tendency that those
prescribed hypnotics/ sedatives were more
likely to have that class of drug implicated in
fatality if only one substance was implicated.
2. Gender and underlying cause(s) of
death
Males were significantly more likely than
females to die of accidental poisoning (66%
vs. 50%) (PR = 1.3, 95% CI = 1.2 - 1.5).
Females, by contrast, were significantly more
likely than males to die of intentional self-
poisoning (22% vs. 11%) (PR = 2.0, 95% CI =
1.6 - 2.6), and poisoning of undetermined
intent (19% vs. 10%) (PR = 2.0, 95% CI = 1.5
- 2.6).
3. Gender and manner of death
A similar pattern was revealed in respect of
manner of death. Males were more likely than
females to die an accidental death (73% vs.
58%) (PR = 1.3, 95% CI = 1.1 - 1.4).
Conversely, females were more likely than
males to die of suicide (24% vs. 14%) (PR =
1.7, 95% CI = 1.4 - 2.2), or a death where the
manner was undetermined (15% vs. 10%)
(PR = 1.6, 95% CI = 1.2 - 2.1).
4. Age and underlying cause(s) of death
Those aged less than 45 years were more
likely than older cases to die of accidental
poisoning (80% vs. 45%) (PR = 1.8, 95% CI =
1.6 - 2.0). Those aged 45 years or over, by
contrast, were more likely than younger cases
to die of intentional self-poisoning (28% vs.
7%) (PR = 3.8, 95% CI = 2.9 - 4.9), and
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poisoning of undetermined intent (15% vs.
11%) (PR = 1.4, 95% CI = 1.1 - 1.9).
5. Age and manner of death
Cases aged less than 45 years were more
likely than older cases to die accidentally
(76% vs. 53%) (PR = 1.4, 95% CI = 1.3 - 1.6).
Conversely, those aged 45 years or over were
more likely than younger cases to die
intentionally (30% vs. 11%) (PR = 2.8, 95% CI
= 2.2 - 3.4), or in a manner that was
undetermined (14% vs. 10%) (PR = 1.4, 95%
CI = 1.0 - 1.9).
Table 5: Age and psychoactive drug implicated in death, np-SAD cases, 2007
Age-group (years) Number (%)
where drug
was implicated
Drug category (alone or in combination)
most frequently implicated in each age
group
All ages 1,462 (100.0) Heroin/morphine (48.4%)
Under 15 1 (0.1) Anti-depressants & hypnotics/sedatives (1)
15–24 166 (11.4) Heroin/morphine (44.0%)
25-34 415 (28.4) Heroin/morphine (61.9%)
35-44 459 (31.4) Heroin/morphine (54.7%)
45-54 253 (17.3) Heroin/morphine (38.7%)
55-64 109 (7.5) Anti-depressants (41.3%)
65 & over 59 (4.0) Other opiates/opioid analgesics (45.8%)
6. Age and drug implicated in death
In cases aged 15-44 years, heroin/morphine
(56%) was the most frequently mentioned drug
contributing to fatality. In those aged 45 years
and over, other opiates/opioid analgesics
(36%) were mentioned most often (Table 5).
7. Gender and drug implicated in death
The pattern of drug-specific fatality is
somewhat different in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (54%); alcohol-
in-combination (40%); other opiates/opioid
analgesics (23%); methadone (20%),
hypnotic/sedatives (20%); cocaine (17%); and
anti-depressants (16%).
Furthermore, there is a higher proportion of
cases of drug-specific fatality among males
compared to females in respect of cannabis,
ecstasy-type drugs and GHB.
Among female cases, the most frequently
mentioned drugs were: anti-depressants
(38%); other opiates/opioid analgesics (33%);
alcohol-in-combination (32%); heroin/morphine
(29%); hypnotic/sedatives (26%); methadone
(21%); and cocaine (13%).
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VI Drug abuse/dependence
Cases reported to np-SAD with a history of
drug abuse/dependence (n = 794) were
compared to those without such a history (n =
414) on the following variables: demography,
location of death, underlying cause(s) and
manner of death. Three hundred and thirty-
one np-SAD cases (22%) were reported as
“not known” with respect to history of drug
abuse/dependence. These cases were
excluded from further analysis.
1. Demography
In comparison with non drug abusers (NDAs:
65%), drug abusers/dependents (DAs: 82%)
were more likely to be male (PR = 1.3, 95% CI
= 1.2 - 1.4) and less than 45 years of age,
81% compared to 52% (PR = 1.6, 95% CI =
1.4 - 1.7). The median age at death for DAs
was 36.2 years (semi-interquartile range =
6.6), while that for NDAs was 44.3 years
(semi-interquartile range = 11.1) (Mann-
Whitney U = 110,425 p< 0.0005).
2. Location of death
There was no significant difference between
DAs (72%) and NDAs (67%) with respect to
the location of their death. In both groups the
majority died at home or in a defined
residential address. Hospital deaths
accounted for a lower proportion of DA deaths
(19%) than those amongst NDAs (21%). A
higher proportion of DAs (9%) died in
temporary accommodation or in public places
than NDAs (5%) (PR = 1.8, CI = 1.1 - 3.0).
3. Underlying cause(s) of death
DAs were more likely than NDAs to die of
accidental poisoning (76% vs. 42%) (PR =
1.8, 95% CI = 1.6 - 2.1; – Figure 8). NDAs, by
contrast, were more likely than DAs to die of
intentional self-poisoning (31% vs. 4%) (PR =
7.6, 95% CI = 5.3 - 11.0), and poisoning of
undetermined intent (19% vs. 7%) (PR = 2.7,
95% CI = 2.0 - 3.8).
4. Manner of death
A similar pattern is exhibited with regard to
manner of death. DAs were more likely than
NDAs to die an accidental death (82% vs.
48%) (PR = 1.7, 95% CI = 1.5 - 2.1).
Conversely, NDAs were more likely than DAs
to die of suicide (33% vs. 7%) (PR = 4.8, 95%
CI = 3.6 - 6.4), or a death where the manner
was undetermined (17% vs. 7%) (PR = 2.5,
95% CI = 1.8 - 3.5).
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VII np-SAD drug-related deaths in 2006 reported in
2007/8
Profile of cases
A further 307 inquest reports were received
from coroners in 2007/8 on deaths occurring
in 2006, giving an updated total number of
deaths in 2006 of 1,673. Demographic details
and a summary of principal drugs implicated
in death are presented below. The distribution
of deaths according to coroners’ jurisdictions
is summarised in Annex AR2.
1. Demography
The majority of cases were male (77%). The
median age at death was 35.1 years (semi-
interquartile range – 7.9), with 79% being
under the age of 45 years. Where ethnicity
was known, 94.3% were White, 2.2% Black,
2.2% Asian, and 1.3% Other. Approximately
43% of cases were unemployed and 41% of
cases were living with others at the time of
their death (Table 6). Where history of drug
abuse or dependence was known, 74% had
such a history.
Table 6: Demographic variables, additional 2006 np-SAD cases
Variable Category Number (%) of np-SAD
cases in 2006 reported in
2007/8
Total 307 (100.0)
Gender Male 237 (77.2)
Female 70 (24.8)






Not known 36 (11.7)
Living Arrangements Alone 109 (35.5)
With others 126 (41.0)
No fixed abode 10 (3.3)
Other 19 (6.2)
Not known 43 (14.0)
2. Location of death
The majority of cases (67%) died at a defined
residential address (e.g. the deceased’s home
address or other private residential address),
19% died in hospital and 14% died elsewhere
(e.g. in a public place).
3. Underlying cause(s) of death
The proportions of ICD-10 categories of
underlying cause of death were as follows:
 Accidental poisoning (X40-X47): 56.7%
 Intentional self-poisoning (X60-X67):
13.4%
 Poisoning of undetermined intent (Y10-
Y14): 13.0%
 Other and unknown causes: 16.9%
4. Manner of death
The cause of death is considered to have






 Unclassified/not specified: 0.3%
5. Substances implicated in death
The principal psychoactive substances
implicated were: heroin/morphine (46%),
alcohol in combination with other drugs (41%),
other opiates/opioid analgesics (25%),
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hypnotics/sedatives (24%), anti-depressants
(22%), methadone (17%) and cocaine 13%.
Heroin/morphine as the sole implicated drug
accounted for 15% of deaths, anti-depressants
4%, cocaine 4% and methadone 4% of
deaths. The breakdown of psychoactive
substances implicated in death is given in
Table 7.
Table 7: Psychoactive substances implicated in death, additional 2006 np-SAD cases
Drug category Number (%) of cases where
no other substance
implicated
Number (%) of cases where
drug implicated
Total 284 (100.0) 284 (100.0)
Alcohol - 117 (41.2)
Amphetamines 2 (0.7) 6 (2.1)
Anti-depressants 12 (4.2) 63 (22.2)
Anti-epileptics 1 (0.4) 3 (1.1)
Anti-psychotics 0 (1.0) 12 (4.2)
Cannabis 1 (0.4) 8 (2.8)
Cocaine 12 (4.2) 38 (13.4)
Ecstasy-type drugs 2 (0.7) 11 (3.9)
GHB 0 (0.0) 0 (0.0)
Heroin/morphine 43 (15.1) 130 (45.8)
Hypnotics/sedatives 4 (1.4) 69 (24.3)
Methadone 10 (3.5) 47 (16.5)
Other opiates/opioid
analgesics
7 (2.5) 71 (25.0)
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
VIII Changes between 2006 and 2007
The following section compares deaths in
2007 with those that occurred in 2006
(including updated data). The sources of
information are the same for both years, i.e.
cases reported using the np-SAD data
collection form. Figures for 2007 (and 2006, to
a lesser extent) can be expected to increase
as further inquests are completed and the
results notified to the Programme. The figures
for 2007, therefore, cannot be compared
directly with those in previous np-SAD
publications.
1. Demographic characteristics
The figure reported on here for deaths in 2007
is 1,539, a decrease of about 8% from the
previous year (1,673). As more data are
received for 2007 this gap will narrow. The
demographic profile of cases remained stable
in 2007 with no significant changes in age,
gender, ethnicity, and employment status
distributions. However, there was a small
increase in the median age at death, from 37
to 38 years, with a consequent reduction
(from 72% to 71%) in the proportion aged
under 45 years. There was an increase in the
proportion living alone (from 41% to 45%). A
small decline was observed in the proportion
of deaths occurring in hospital (from 22% to
19%), and in the proportion of cases with a
history of drug abuse or addiction (from 67%
to 66%).
2. Underlying cause(s) of death
The proportion of accidental deaths increased
from 60% in 2006 to 63% in 2007. By
contrast, poisonings of undetermined intent
decreased from 15.8% to 11.8%; whilst
intentional self-poisoning deaths remained
unchanged at 13.2%.
3. Manner of death
The patterns observed for underlying cause(s)
of death were echoed for the manner of
death. The proportion of accidental deaths
increased from 65.8% in 2006 to 69.3% in
2007 (PR = 1.1, 95% CI = 1.0 - 1.1), as did
suicides – from 15.2% to 16.2%. Conversely,
the proportion of undetermined deaths
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decreased from 15.4% to 11.2% (PR = 1.4,
95% CI = 1.1 - 1.6). Natural deaths (2.5% -
2.5%), homicides (0.1% - 0.1%), and deaths
unclassified/not specified (1.1% - 0.9%)
remained stable.
4. Substances implicated in death
4.1 Multiple substances
Data on implicated drugs were available for
1,462 deaths occurring in 2007 (1,550 in
2006). Heroin/morphine remained the most
frequently mentioned drug in 2007, having
been implicated in 48% of deaths, slightly
higher than in the previous year. There were
increases both in the number and proportion
of mentions of methadone, hypnotics/
sedatives, other opiates/ opioid analgesics,
cocaine, cannabis, and for alcohol-in-
combination (Table 8).
4.2 Single substance
There were significant changes between 2006
and 2007 in the proportions accounted for by
individual drugs in fatalities related to a single
substance, especially falls for heroin/morphine,
methadone, and anti-depressants (Table 9).
Table 8: Changes in proportions of psychoactive substances implicated in multiple












33.9 37.9 1.1 1.0 - 1.2 + 4.0
Amphetamines 3.4 3.8 1.1 0.8 - 1.6 + 0.4
Anti-depressants 18.3 21.1 1.1 1.0 - 1.3 + 2.8
Anti-epileptics 1.9 2.5 1.3 0.8 - 2.1 + 0.6
Anti-psychotics 4.5 3.8 1.2 0.8 - 1.7 - 0.7
Cannabis 2.1 3.8 1.8 1.2 - 2.7 + 1.7
Cocaine 11.2 16.3 1.5 1.2 - 1.7 + 5.1
Ecstasy-type drugs 3.4 3.1 1.1 0.8 - 1.6 - 0.3
GHB 0.5 0.5 1.1 0.4 - 2.8 -
Heroin/morphine 45.9 48.4 1.1 1.0 - 1.1 + 2.5
Hypnotic/sedatives 16.7 21.1 1.3 1.1 - 1.5 + 4.4
Methadone 17.0 20.2 1.2 1.0 - 1.4 + 3.2
Other opiates/ opioid
analgesics
22.6 25.0 1.1 1.0 - 1.3 + 2.4
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
Table 9: Changes in proportions of psychoactive substances implicated in single










Amphetamines 1.0 0.5 1.9 0.8 - 4.4 - 0.5
Anti-depressants 5.2 4.0 1.4 1.0 - 1.9 - 1.2
Anti-epileptics 0.6 0.3 2.1 0.7 - 6.9 - 0.3
Anti-psychotics 1.3 0.6 2.1 1.0 - 4.6 - 0.7
Cannabis 0.2 0.2 1.1 0.2 - 5.2 -
Cocaine 2.7 2.7 1.0 0.7 - 1.5 -
Ecstasy-type drugs 1.2 0.7 1.7 0.8 - 3.7 - 0.5
GHB 0.1 0.2 3.2 0.3 - 30.5 + 0.1
Heroin/morphine 17.9 13.8 1.3 1.1 - 1.5 - 4.1
Hypnotic/sedatives 1.3 1.4 1.1 0.6 - 2.0 + 0.1
Methadone 5.4 4.3 1.3 0.9 - 1.7 - 1.01
Other opiates/
opioid analgesics
5.0 4.3 1.2 0.8 - 1.6 - 0.7
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5 Deaths per 100,000 population
5.1 Changes in jurisdictions with highest
rates in 2006
The following jurisdictions reported annual
drug-related death rates of 10/100,000 or
higher in 2006: Blackpool & the Fylde (19.4);
Brighton & Hove (17.8); Jersey (12.3);
Dumbarton (11.3); and Newcastle-upon-Tyne
(10.1). Of these five areas, Dumbarton
showed a significant increase and Brighton &
Hove a slight increase, whilst the other areas
showed significant declines.
5.2 Changes in jurisdictions with lowest rates
in 2006
The following jurisdictions reported annual
drug-related death rates of less than 1 per
100,000 population in 2006: Cardiff & Vale of
Glamorgan (0.00); City of London (0.00);
Guernsey (0.00); Herefordshire (0.00); Isles of
Scilly (0.00); North Lincolnshire & Grimsby
(0.00); South Shropshire (0.00); Stamford
(0.00); Wiltshire (0.2); Inner West London
(0.3); South & West Cambridgeshire (0.3);
North Yorkshire Eastern (0.5);
Northamptonshire (0.6); Nottinghamshire
(0.7); Darlington & South Durham (0.9); and
Powys (0.9). Of these, the City of London,
Isles of Scilly, South Shropshire, and Wiltshire
remained unchanged. Powys was the only
area to show a decline. The rest showed
some increases, the most evident being:
Boston & Spalding (+759%);
Northamptonshire (+667%); South & West
Cambridgeshire (+667%). North Lincolnshire
& Grimsby (+310%); Inner West London
(+300%); Herefordshire (+200%); and
Guernsey (+190%).
5.3 Jurisdictions with highest rates in 2007
The following jurisdictions reported annual
drug-related death rates higher than
10/100,000 in 2007: Dumbarton (20.6);
Brighton & Hove (18.8); Blackpool & the Fylde
(14.9); and Peterborough (10.1). Of these four
areas, two (Dumbarton and Peterborough)
showed a significant increase over 2006,
whilst Brighton & Hove exhibited only a small
increase. There was a significant decline in
Blackpool & the Fylde.
5.4 Jurisdictions with lowest rates in 2007
The following jurisdictions reported annual
drug-related death rates of less than
1/100,000 in 2007: Wiltshire (0.2); Gateshead
& South Tyneside (0.4); North Yorkshire
Eastern (0.4); Swansea (0.5); Wolverhampton
(0.5); Essex & Thurrock (0.6); Gloucestershire
(0.6); Knowsley, St Helens & Sefton (0.6);
Warwickshire (0.7); Cardiff & Vale of
Glamorgan (0.8); Black Country (0.9); South
Manchester (0.9); and Stamford (0.9). The
following areas reported that there had been
no relevant cases: Ceredigion; City of London;
Isles of Scilly; Powys; and South Shropshire.
IX Commentary
General patterns
This is the ninth annual report produced by
the national programme on Substance Abuse
Deaths. This annual report is different from
the semi-annual surveillance reports in that it
reports on deaths that actually occurred in
2007, even where inquests (or other
investigations) were completed in 2008. The
report provides useful information that
continues to assist policy makers, such as the
Department of Health and the Devolved
Administrations, to assess the impact of
service provision and other interventions.
The demographic profile of np-SAD cases
remains consistent with last year’s report. The
majority of cases were males (77%), under
the age of 45 years (71%), and White (95%).
Where the information was available, at least
66% of the sample was drug abuser/
dependent, as defined by the Programme.
This review is different to those in previous
years in respect of its geographical coverage.
As indicated earlier, information on individual
Scottish cases is more comprehensive. This
year, as in 2006, the Northern Ireland
Statistics and Research Agency (NISRA)
have provided data on drug-related poisoning
deaths, registered by the General Register
Office for Northern Ireland, up to the end of
2007.
Annex AR4 provides information on the rates
per 100,000 population (aged 16 and over) for
np-SAD cases in 2007 broken down by DAAT
area of usual residence and by place of death.
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Dumbarton recorded the highest annual death
rate (20.6/100,000 population) in 2007.
Brighton & Hove (18.8) and Blackpool & the
Fylde (14.9) recorded the second and third
highest annual death rates in 2007,
respectively. Peterborough (10.1) also had a
relatively high rate.
Ceredigion (0.0), the City of London (0.0), the
Isles of Scilly (0.0), Powys (0.0), and South
Shropshire (0.0) recorded the lowest death
rates in 2007.
On the whole, the present annual report has
seen a 13% increase in the number of DRDs
reported to the np-SAD compared to the
number reported in last year’s report.2
Although the compliance rate (93%) of
coroners is higher than last year, the
observed rise is likely to be real rather than a
reflection of improved reporting rates by some
coroners. This is borne out by the fact that the
average number of cases per area increased
in 2007. Further support for this being a real
increase can be derived from the fact that the
number of drug poisoning and drug misuse
deaths registered in England and Wales also
rose between 2006 and 2007 by 2.7% and
2.2% respectively (ONS, 2008). There was
also a substantial increase reported in
Scotland using a number of different
definitions (GROS, 2008).
The proportion of deaths due to poisoning of
undetermined intent declined by 4 percentage
points in 2007. Most deaths (63%) were due
to accidental poisoning. Over recent years
there has been a trend towards more
substances, including alcohol, being
implicated in deaths. However, in the last year
there appears to have been a major shift in
this direction - with a corresponding decline in
mono-valent deaths. Whereas in 2006 the
proportion of deaths accounted for by one
substance was 44% in 2006 this had fallen to
33% by 2007. The proportion of fatalities
related to alcohol-in-combination increased
from 34% to 38% over this period.
Fatalities related to the consumption of most
illicit drugs have shown an increase. There
was an increase in the proportion of deaths
involving opiates and synthetic opioids in
2 The number of deaths in England that occurred in 2007
and was reported to the Programme which meets the
criteria used for monitoring the Government’s drug
strategy number 1,206. This is about 14% higher than the
corresponding number for 2006 (1,059).
2007, following a decrease for deaths
involving heroin/morphine in 2006.
Methadone
A recurrent theme in the np-SAD annual
reports has been deaths due to methadone.
The number of such fatalities continues to rise
(from 159 in 2004 to 295 in 2007), as has the
proportion of all deaths in which it is
implicated (from 12.4% to 20.2% over the
same period). Although the number of deaths
in which methadone was the sole drug
mentioned reported to the Programme
declined in 2007, the figures still remain
significantly high for a substance which is
primarily used in substitution treatment.
Diversion continues to be an important feature
of methadone deaths, in that in up to 70% of
such cases methadone prescribed for one
individual has been consumed by another
person.
The UK experience is not unique, there has
been an increasing number of deaths in North
America involving the misuse of prescribed
opioids, particularly methadone, oxycodone
and to a lesser extent fentanyl (Hull et al,
2007; Baker et al, 2008; Fingerhut, 2008;
Jones et al, 2008). These findings underline
the paradox that whilst the wider provision of
and accessibility to opioid maintenance
treatment reduces the risk of death, such
drugs are dangerous when used
inappropriately, especially with other
substances.
Opiate and opioid-dependent populations
have very elevated mortality rates (Ferri et al,
2007; Jönsson et al, 2007; Smyth et al, 07;
Bauer et al, 2008; Bloor et al, 2008; Pavarin,
2008). The risk of dying is reduced
substantially for those who are retained in
treatment (Clausen et al, 2008; Gibson et al,
2008). However, the risk increases again for
those leaving treatment prematurely, and for
those completing detoxification treatment or
prison sentence, especially during the first
month (Davoli et al, 2007; Farrell and
Marsden, 2008). The increased chance of
dying in the period immediately following
treatment highlights the need for continual
health education of drug users and the
implementation of targeted relapse and
overdose death prevention programmes,
where these are not already in place (Davoli
et al, 2007; Shah et al, 2008).
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Opioid analgesics
Sandilands and Bateman (2008) found that if
the reduction in Scottish poisoning deaths
associated with co-proxamol was extrapolated
to the whole of the UK at least 300 lives have
been saved following the phased withdrawal
of co-proxamol over the three-year period
January 2005 to December 2007 (Duff, 2005).
This reduction is also evident in np-SAD data:
from 2003 to 2007 the proportion of cases
involving co-proxamol or dextropropoxyphene
fell from 11.3% to 2.0% of all cases where a
psychoactive substance was implicated in
death. During the same period the proportion
accounted for by tramadol rose from 2.3% to
3.8%. This supports our previous suggestion
that tramadol is emerging as a replacement
for co-proxamol.
Other prescribed medications
There appears to have been a small decrease
in deaths directly caused by anti-psychotics,
but increases in most of the traditionally
prescribed psychoactive medications, e.g.
anti-depressants, hypnotics/sedatives, and
other opiates/opioid analgesics. The results
for anti-psychotics and anti-depressants are in
line with the findings reported by Flanagan
(2008).
Cocaine
The fatal consequences of widespread
consumption of cocaine in the UK continue to
become more evident (see below for a more
detailed discussion). Whilst the number of
cases involving cocaine notified to np-SAD
was 128 in 2004, it had nearly doubled to 239
in 2007. Over the period, the proportion of
cases involving cocaine increased from 10%
to 16%, including one unusual case where
death occurred following consumption of
cocaine powder mixed with water.
Amphetamines
The proportion of deaths in which
amphetamines and cannabis were implicated
rose, whereas that for ecstasy-type drugs fell.
The number of deaths in which amphetamine
was implicated has risen in each of the last
three years, standing at 55 in 2007 (22 in
2004). Last year we noted that there was a
possibility that such an increase may echo
growing concern about the increasing use of
methylamphetamine (‘crystal meth’) in the UK.
To date, there were 6 cases in both 2006 and
2007 where this drug was reported in the post
mortem toxicology to the Programme. In one
of the 2007 cases, death was due to mixed
drug poisoning including methylamphetamine.
In other cases it seems likely that the
presence of the substance was associated
with the use of ecstasy. Given the presence of
methylamphetamine amongst some drug-
using populations in the UK (Bolding et al,
2006; Wood et al, 2008), these consumers
need to be informed of the potential harms
caused by consuming the drug especially with
other substances (Kaye et al, 2008).
Piperazines
The np-SAD is aware of at least 12 deaths in
England and Wales (there have been none in
Scotland or Northern Ireland) up to the end of
2007 where piperazines have been found
post-mortem; one of these has yet to go to
inquest. Details for three of the cases are
given in the literature review above (Elliot and
Smith, 2008). For the 11 cases occurring in
2006-7 reported to np-SAD, benzylpiperazine
(BZP) and 3-trifluoromethylphenylpiperazine
monohydrochloride (TFMPP) were found in 6
cases; BZP in 4 cases, and
chlorophenylpiperazine (CPP) in 1 case. In
two cases piperazines (BZP; BZP and
TFMPP) were mentioned – along with other
substances - specifically as the cause of
death. In a further case CPP was included in
the substances where the death was
described as multiple mixed drug intoxication.
Populations at risk of premature death
The np-SAD surveillance programme,
together with the literature reviewed above,
has identified a number of populations with a
higher risk of dying prematurely. These
populations include:
 Those with mental illness who may
commit suicide or homicide;
 Pregnant females, especially those with
psychiatric problems;
 Polysubstance users, particularly those
using alcohol and/or cocaine.
 Those finishing/leaving treatment or
prison in the period immediately following
their release
 Those who have recently commenced
injecting drug use
 Young female injecting drug users,
especially those with HIV or those
engaged in sex work
 Those with long injecting careers
 Those who are homeless or ‘roofless’
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Conclusions
A number of the studies reviewed above have
demonstrated that opioid maintenance
treatment can play a role in reducing the rates
of excess mortality among opioid-using
populations compared to the general
populace. However, there are reports of
greater involvement of prescription drugs,
especially opioids, in overdose fatalities.
The findings of the research outlined above
suggest that the likelihood of death for a
number of other at-risk populations could be
lessened through being in a suitable treatment
programme. There is a need to make sure
that interventions are aimed at these
populations.
Some of these issues also emerge from the
data collected by np-SAD, and highlight the
important role of surveillance in monitoring the
ever-changing evolution of the drugs
phenomenon. Continued vigilance is needed
in respect of the role of prescribed and ‘Over
the Counter’ medications in fatalities, e.g. the
increased use of tramadol. If considered
appropriate, further regulation or legislation
may be required.
The surveillance role of the Programme in
identifying new problems can be illustrated by
reference to the fact that the misuse of
fentanyl was reported in last year’s annual
report. The emergence of toxicological reports
mentioning methylamphetamine and
piperazines have been discussed in this
year’s commentary. By identifying changes in
drug use and associated mortality elsewhere,
the Programme is able to look out for and
monitor developments in the UK.
Mortality patterns can change substantially
and rapidly and large-scale cohort studies are
needed in the UK to provide information about
overdose and other causes of death that drug
users face. There has been no investment in
large-scale longitudinal studies that can help
interpret mortality statistics since the closure
of the Home Office Addicts Index over a
decade ago. This need is also evident in other
European countries (Morgan et al, 2008).
X A closer look – nature, extent and pattern of cocaine-
related mortality
Introduction
Cocaine is one of the most commonly used
illicit substances in England and Wales with a
lifetime prevalence rate of 2.6 % among those
aged 16-59 years (Murphy & Roe, 2007). In
EU member states and Norway, the
corresponding rate in those aged 15-64 years
is about 4% (EMCDDA, 2007). In the UK,
cocaine and crack are classified as Class A
drugs under the Misuse of Drugs Act 1971.
Cocaine (benzoylmethyl ecgonine) is obtained
from the coca plant (Erythroxylon coca) which
is widely grown in western South America
(principally Bolivia, Colombia and Peru).
Traditional use of the coca plant has been
associated with Andean Indians who chew
coca leaves for its stimulant properties. The
two most common forms of cocaine in the UK
are cocaine hydrochloride (HCl) and crack.
Cocaine HCl is the powder form, often
administered nasally, orally and by injection.
Another form of cocaine is the ‘free-base’
produced by dissolving cocaine HCl in water
and ammonia followed by ether. This mixture
results in two layers – purer cocaine as the
upper layer. Cocaine is extracted by
evaporating the solvent, leaving the lower
layer which is the ‘free-base’.
‘Crack’ is a form of cocaine free-base
manufactured through a less inflammable
method. Cocaine HCl solution is mixed with
sodium bicarbonate and the solution heated.
The insoluble base floats on the solution
(Warner, 1993). The dry form of the insoluble
base is termed ‘crack’. The most common
form of crack administration is by smoking.
This mode of delivery is very efficient,
producing euphoria within 10 seconds,
compared to 20 seconds in injectable cocaine
HCl and about 5 minutes through nasal
administration (Lipton et al, 2000). Rapid
absorption of smoked crack and relatively low
street price compared to cocaine HCl has
made this drug very appealing to young
people. For instance, in England and Wales,
lifetime prevalence of crack use (1.4%) in
those aged 16-24 years is higher than that for
the entire population (1%) studied (Murphy
and Roe, 2007). A survey of clubbers in the
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UK between 1999-2003 gives lifetime
prevalence rates of cocaine use of 73-80%
and 13-16% for crack use (McCambridge et al
(2005). The respondents reported current use
prevalence of 28 to 41% for cocaine and 1.2
to 2.4% for crack.
There is an upward trend in the number of
cocaine-related deaths in the UK; the most
recent figures for mentions of cocaine
(including crack) on death certificates in Great
Britain show these to be at record levels
(GROS, 20908; ONS, 2008). Over a 15-year
period, Schifano and Corkery (2008) reported
nearly a 40-fold increase in the number of
deaths in the UK where cocaine/crack was
mentioned; from five in 1990 to 188 in 2004.
During the same period, the price of street
cocaine fell significantly from £87/g of powder
in 1990 to £52/g in 2004 while that of 0.2g of
crack declined from £25 to £19. Inevitably, the
number of problematic cocaine users
presenting to treatment in England increased
four-fold during this period.
Surprisingly, there was no statistically
significant correlation between the number of
cocaine-related deaths and average purity of
police and custom seizures. In contrast,
increase in the number of crack-related
deaths had a statistically significant negative
correlation with the average purity of police
seizures, suggesting that the increase in the
number of cocaine-related fatalities was more
likely due to indirect causes, e.g.,
polysubstance toxicity, effects of adulterants,
underlying psychopathology, etc. In summary,
it would seem that price, availability and, to a
lesser extent, purity have significantly




The pharmacodynamic properties of cocaine
are multifaceted; for a good overview see
EMCDDA (2007). Cocaine produces euphoria
by increasing synaptic levels of dopamine in
mesolimbic brain regions (Kuhar et al, 1991).
This property has established cocaine as a
drug with high abuse liability. In the medium
and long term, this action leads to
psychological dependence and in extreme
cases to the development of seizures.
Cocaine’s potential for producing seizures is
also associated with its action as a serotonin
re-uptake inhibitor, where serotonin
accumulation induces intense central nervous
system (CNS) stimulation (Lipton et al, 2000).
Cocaine is also known to inhibit presynaptic
noradrenalin and dopamine re-uptake, as well
as the action of monoamine oxidase at
synapses. This action results in enduring
sympathetic activation that manifests as
increased vasoconstriction, increased cardiac
contractility, increased vasospasm,
hypertension, hyperthermia, hypoglycaemia
and mydriasis (White and Lambe, 2003).
Cocaine’s ability to increase platelet
adherence and promote coagulation
contributes to its infarct potential (He et al,
1994). Taken together, cocaine toxicity can
result in a complex symptomatology that
affects major internal organs and systems of
the body.
Often, cocaine use is closely associated with
the use of other substances, mainly alcohol,
opioids, cannabis and other stimulants. Also,
many cocaine users are cigarette smokers.
Co-ingestion of substances often results in
additive or synergistic effects. For instance,
combined administration of cocaine and
tobacco can accentuate the harmful effects of
cocaine on myocardial supply-demand
balance, resulting in cardiovascular
complications (Afonso et al, 2007; Moliterno et
al, 1994). Also, cocaine interacts with alcohol
in the liver to form coca-ethylene. This
compound, considered to be more hazardous
than cocaine, is known to block the re-uptake
of dopamine and contribute to heightened
cardiovascular complications commonly
associated with cocaine use (Afonso et al,
2007). Studies of co-ingestion of cocaine and
heroin (“speedball”) have revealed increases
in cardiovascular and subjective effects that
were below the threshold of an additive model
of drug interaction (Foltin and Fischman,
1992). Rather, the continued use of speedball
among illicit drug users is considered to be
largely motivated by the need to reduce the
‘crash’ from cocaine intoxication (Guzam and
Ettenberg, 2004). However, this does not
make speedball toxicity less hazardous than
distinct cocaine or heroin toxicity.
Potential fatalities arising from direct
toxicity
The cumulative effects of cocaine, even in
small doses, can result in complications
(Karch, 2002). Therefore, the minimum and
lethal doses of cocaine are unspecified,
indicating an idiosyncratic pattern of
complications and eventual fatality. System–
specific complications of cocaine ingestion
and toxicity are summarised below. Death can
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occur from a single complication or from a
combination of complications.
CNS: The most commonly reported
complications in this category include
headache, stroke, transient neurological
deficits, subarachnoid haemorrhage, seizures,
toxic encephalopathy and coma. Also,
sequelae of chronic cocaine use can include
dystonia, tardive dyskinesia, chorea, and
akathisia (Glauser & Queen, 2007; Boghdadi
& Henning, 1997; Benowitz, 1998)
Cardiovascular system: Common
complications in this category include
hypertension, arrhythmias, myocarditis,
myocardial ischemia and infarction, and shock
(Benowitz, 1998; Knuepfer, 2003; White and
Lambe, 2003).
Respiratory system: The following respiratory
complications have been reported –
pulmonary oedema, pulmonary haemorrhage,
pulmonary infarct, pneumomediastinum,
respiratory arrest, and pneumothorax
(Benowitz, 1998; White & Lambe, 2003).
Smoking of crack or free-base cocaine is
known to result in thermal epiglottitis (Mayo-
Smith and Spinale, 1997), and in severe acute
exacerbation of asthma (Rubin and
Neugarten, 1990; Rome et al, 2000). Crack
smokers can also suffer from ‘crack lung’, a
complication characterised by fever, chest
pain, dyspnoea, hypoxemia, persistent diffuse
alveolar infiltrates and respiratory failure
(Forrester et al, 1990; Glauser and Queen,
2007).
Renal system: The main renal complications
are acute renal failure, rhabdomyolysis and
renal infarction (Glauser and Queen, 2007).
Renovascular atherogenic damage has been
reported in cases of cocaine-related death
(Dipaolo et al, 1997).
Gastro-intestinal system: Common
complications in this category include
ischaemic gastritis, ulceration, infarction and
hepatotoxicity (White and Lambe, 2003).
Smoking of crack or free-base cocaine can
also induce intestinal perforations (Muniz and
Evans, 2001).
Indirect association with fatalities
The lifestyle associated with cocaine/crack
use is a risk factor for premature mortality
among cocaine users. The risks involved in
funding cocaine/crack habits through illegal
means, such as prostitution, burglary, violent
offending drug trafficking, and gang
involvement can be life threatening,
accounting for a large proportion of cocaine-
related homicides. Tardiff et al (2002)
observed in a New York study that cocaine
was implicated in the majority of drug-related
homicides where the types of drugs implicated
were known. Also, homicide committed by
drug dealers is known to account for at least
30% of deaths among cocaine abusers
(Tardiff et al, 1989, 1994, 1995).
Cocaine has been implicated in fatal road
traffic accidents (RTAs). In a review of studies
of fatal injuries from RTAs, Macdonald et al
(2003) reported that the proportion of fatally
injured drivers testing positive for cocaine
ranged between 0.3% and 10%. In many of
these studies other drug metabolites were
detected at post-mortem, suggesting the
deleterious effects of combined use of
cocaine and other substances on driving.
Cocaine intoxication is known to sometimes
lead to dysfunction in cerebral serotonergic
neurotransmission that can manifest as
excessive aggression and heightened suicidal
tendency. Not surprisingly, the National
Violent Death Reporting System in the US has
observed that approximately 10% of
toxicology tests of suicide victims in 13 states
were positive for cocaine (Karch et al, 2006).
Similarly, suicide accounts for about 5-10% of
cocaine–related deaths (Tardiff et al, 1989;
Darke et al, 2005).
Cocaine fatality is increasingly associated with
body packing and body stuffing. ‘Body
packing’ can be described as the act of
swallowing or inserting into a body cavity,
multiple small packages, such as condoms,
containing illicit drugs for the purpose of
smuggling across national borders or into
prisons (Bulstrode et al, 2002). Those who
engage in body packing are commonly
referred to as ‘mules’. ‘Body stuffing’ refers to
the act of swallowing poorly wrapped
packages of illicit drugs with a view to
concealing them from law enforcement
agents, usually during a drug raid (Havis et al,
2005; Norfolk, 2007).
The first fatality from body packing was
reported by Suarez et al (1977). There has
since been a significant increase in the
detection of this practice (Klein et al, 2000;
Koehler et al, 2005). This problem is also an
issue in the UK (Ghodse et al, 2006:26; HM
Revenue & Customs, 2007:37-8). One of the
main risks of fatality related to body packing is
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the rupture of the small packages in the
gastro-intestinal (GI) tract which in turn results
in cocaine overdose. In one of such cases,
cocaine levels in cardiac blood post-mortem
were relatively high (4.67mg/L) (Koehler et al,
2005). Cocaine toxicity occurs more rapidly in
body stuffing due to poor or no packaging.
np-SAD data
Cocaine was found at post mortem or
implicated in 350 deaths that occurred in 2007
that were notified to the np-SAD. Cocaine was
implicated in 239 cases.
Where cocaine was implicated in combination
with other psychoactive substances in deaths,
the main substances involved were:
heroin/morphine (92%); alcohol (59%);
methadone (35%); hypnotics/sedatives (35%);
other opiates (typically metabolites of heroin)/
opioid analgesics (35%); anti-depressants
(21%); ecstasy-type drugs (13%);
amphetamines (9%); and cannabis (8%).
Crack was implicated in at least 4% of these
cases, and coca-ethylene in 3%. The most
common combinations with cocaine were:
benzodiazepines and heroin/other opiates +
(24.6%); heroin only (14.1%); alcohol
(including coca-ethylene) (12.6%); heroin and
alcohol (0.5%); benzodiazepines and
heroin/other opiates and alcohol (8.0%); other
drugs and opiates (8.0%); other opiates and
alcohol (7.0%); and heroin and other opiates
excluding alcohol (7.0%). About four-fifths
(81%) of these cases related to males. The
majority (88%) were aged less than 45 years
when they died; with a median age of 35
years (range 18-60 years). Just under half
(46%) lived with others and 41% lived alone.
Nearly half (47%) were unemployed; 40%
were employed. Most (61%) died at a
residential address and 25% in hospital.
Cocaine was solely implicated in 40 cases
(16.7% of cases where it was involved); of
these, 33 (83%) were males. All but five cases
were aged less than 45 years when they died;
median age 33 years (range 17-59 years).
Fourteen of the monovalent cases lived alone;
22 with others. Most (23 cases) were
employed; 7 were unemployed. Twenty-three
died at a residential address and 14 in
hospital.
The underlying cause(s) of death were as
follows: accidental poisoning (25); intentional
poisoning (1); poisoning of undetermined
intent (1); intentional hanging (4); hanging,
intent undetermined; drug abuse (3); cardio-
respiratory arrest (1); cardiomegaly (1);
embolism and thrombosis of specified veins
(1); hypertension (1); and intentional
obstruction (1). The specific mechanisms of
death given were: acute pulmonary oedema;
cardiac arrhythmias; cardiac dysfunction;
cardiac failure; cardio-respiratory arrest/failure
(2); cerebrovascular event; cocaine
associated cardiomegaly; compression of the
neck; dissecting aortic aneurysm; hypoxic
brain injury; hanging/suspension (2); intestinal
obstruction; myocardial ischaemia,
inflammation and fibrosis; poisoning, effects
of, intoxication, toxicity, overdose of cocaine
(21); and sudden death associated with
cocaine use.
Concluding remarks
Cocaine is a dangerous drug that has
deleterious effects on the body internal
organs. The fact that the complications arising
from cocaine ingestion are not dose-specific
underscores the hazard in the use of this drug
even in small doses. It is likely that the extent
of cocaine-related deaths is underestimated
given that the majority of cocaine fatalities are
due to direct toxicity which may be mistaken
for natural causes. It is therefore essential that
doctors and emergency workers remain
vigilant when dealing with medical
complications and emergencies that are
commonly associated with cocaine ingestion..
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Non-opioid analgesics, antipyretics and anti-
rheumatics
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism
and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified
Other drugs acting on the autonomic nervous
system


























Non-opioid analgesics, antipyretics and anti-
rheumatics
Anti-epileptic, sedative-hypnotic, Anti-parkinsonism
and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified
Other drugs acting on the autonomic nervous
system
























































Mental & behavioural disorders due to psychoactive
substance use
Chronic alcoholism
Harmful use - opioids
Dependence - opioids
Intoxication - cocaine
Harmful use - cocaine
Intoxication - volatile substances
Harmful use – multiple other
Dependence – multiple/other




















































Phlebitis & thrombophlebitis of deep vessel of lower
extremity
Embolism/thrombosis of other specified veins
Other hypotension
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Diseases of the respiratory system
Pneumonia due to Klebsiella pneumoniae
Bronchopneumonia
Adult respiratory distress syndrome













Diseases of the liver
Other & unspecified intestinal obstruction
Alcoholic liver disease
































Multiple injuries of head
Head injuries unspecified
Decapitation/traumatic amputation at neck level
Injuries of the thorax
Injury of spleen
Pedestrian injured in collision with 2/3 wheeled
motor vehicle
Driver injured in collision with heavy transport work
Driver injured in collision with fixed/stationary object
Car driver injured in non-collision accident




























Aspiration of gastric contents/foreign body in
respiratory tract
Asphyxiation from effects of carbon monoxide
Asphyxiation

















Whilst in bath tub
Whilst in natural water
























































Metabolic acidosis, exc. diabetic acidosis
Epileptic seizure related to alcohol & drugs
Epileptic seizures
Brain damage, anoxic or hypoxic
Groin abscess
Poisoning, other non-steroidal anti-inflammatory
Poisoning, synthetic opioid analgesic
Hypothermia
Inhalation of smoke and fumes
Assault by drugs
Unspecified fall
Contact with knife, sword or dagger (stab wound)
R99 12 0.8 Unascertained
Where possible, causes of death have been grouped together in terms of the mechanisms of death. At present, although all
causes of death on the death certificate (together with other information if available) are taken into consideration in classifying
underlying cause of death, the principal cause of death is used here by np-SAD to allocate the ICD-10 code. In order to achieve
a greater level of consistency, a hierarchical system was introduced for classifying the underlying cause of death using ICD-10
criteria for deaths involving multiple substances. Deaths that involve a combination of narcotics and other psychoactive drugs are
coded as narcotic deaths. Where possible a code which specifies intentionality is used.
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Annex AR2: np-SAD cases in 2007 by coroner’s
jurisdiction (16 years and over) and
deaths in 2006 reported in 2007/8













Queen's Household 0 0.00 0
ENGLAND
AVON 12 1.38 6
BEDFORDSHIRE 16 3.38 1
BERKSHIRE 1 0.15 0
BUCKINGHAMSHIRE
Buckinghamshire 16 4.10 1
Milton Keynes 7 3.90 0
CAMBRIDGESHIRE
North & East Cambridgeshire 4 2.86 0
Peterborough 13 10.06 2
South & West Cambridgeshire 8 2.30 1
CHESHIRE 38 4.67 11
CORNWALL
Cornwall 35 7.99 11
Isles of Scilly 0 0.00 0
CUMBRIA
North & West Cumbria 10 4.52 4
South & East Cumbria 4 2.11 0
DERBYSHIRE
Derby & South Derbyshire 22 4.56 2
North Derbyshire 14 4.26 0
DEVON
Exeter & Greater Devon 11 2.58 2
Plymouth & South West Devon 9 3.73 19
Torbay & South Devon 6 3.02 0
DORSET
Bournemouth, Poole & Eastern
Dorset
39 9.76 0
Western Dorset 4 2.11 0
DURHAM
Darlington & South Durham 4 1.79 2
North Durham 3 1.10 6
EAST SUSSEX
Brighton & Hove 40 18.84 0
East Sussex 15 3.60 2
ESSEX
Essex & Thurrock 7 0.64 5
Southend & South East Essex 16 5.91 0
GLOUCESTERSHIRE 3 0.63 0
GREATER MANCHESTER
Manchester 22 5.89 9
North Manchester 13 2.71 2
South Manchester 5 0.88 0
West Manchester 15 2.37 0
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Central Hampshire 6 2.15 0
North East Hampshire 7 2.22 0
Portsmouth & South East Hampshire 17 3.71 4
Southampton & New Forest 16 4.73 1
HEREFORDSHIRE 3 2.04 0
HERTFORDSHIRE 18 2.11 0
HUMBERSIDE
East Riding & Hull 22 4.55 0
ISLE OF WIGHT 6 5.17 0
KENT
Central & South East Kent 10 3.76 3
Mid Kent & Medway 8 1.93 0
North East Kent - - -
North West Kent - - -
LANCASHIRE
Blackburn, Hyndburn & Ribble Valley 19 8.70 0
Blackpool & the Fylde 27 14.94 1
East Lancashire 13 6.68 2
Preston & West Lancashire 35 6.05 1
LEICESTERSHIRE
Leicester City & South Leicestershire - - 11
Rutland & North Leicestershire 7 1.91 0
LINCOLNSHIRE
Boston & Spalding 9 7.73 1
North Lincolnshire & Grimsby 8 3.12 1
Spilsby & Louth 11 8.47 0
Stamford 1 0.94 0
West Lincolnshire 13 5.95 1
LONDON
City of London 0 0.00 0
Eastern London 10 1.14 16
Inner North London 40 5.82 2
Inner South London 51 6.12 0
Inner West London 9 1.19 0
Northern London 54 5.10 3
Southern London 19 2.27 0
Western London 51 4.89 18
MERSEYSIDE
Knowsley, St Helens & Sefton 3 0.61 0
Liverpool 24 6.70 0
Wirral 15 5.98 4
NORFOLK
Greater Norfolk 44 7.01 5
Great Yarmouth 1 1.29 0
NORTHAMPTONSHIRE 25 4.60 18
NORTHUMBERLAND
North Northumberland 4 4.20 2
South Northumberland - - -
NORTH YORKSHIRE
North Yorkshire Eastern 2 0.97 1
North Yorkshire Western 2 0.70 0
York - - -
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NOTTINGHAMSHIRE 11 1.26 0
OXFORDSHIRE 10 1.84 1
SHROPSHIRE
Mid & North Shropshire 2 1.25 0
South Shropshire 0 0.00 0
The Wrekin 4 3.12 0
SOMERSET
Eastern Somerset 7 3.23 0
Western Somerset 5 2.39 0
SOUTH YORKSHIRE
South Yorkshire East 15 3.42 1
South Yorkshire West 27 4.37 1
STAFFORDSHIRE
South Staffordshire 21 4.25 1
Stoke-on-Trent & North Staffordshire 11 2.93 8
SUFFOLK 35 6.07 0
SURREY 20 2.25 2
TEESSIDE
Hartlepool 3 4.10 8
Teesside 25 6.64 12
TYNE & WEAR
Gateshead & South Tyneside 1 0.36 0
Newcastle-upon-Tyne 10 4.44 1
North Tyneside - - -
Sunderland 4 1.74 8
WARWICKSHIRE 3 0.70 0
WEST MIDLANDS
Birmingham 30 3.15 4
Black Country 6 0.89 2
Coventry 9 3.65 0
Wolverhampton 1 0.53 5
WEST SUSSEX 34 5.37 0
West YORKSHIRE
West Yorkshire Eastern 65 7.32 5
West Yorkshire Western 43 4.98 3
WILTSHIRE 1 0.19 2
WORCESTERSHIRE 6 1.32 0
WALES
Bridgend & Glamorgan Valleys 12 3.51 4
Cardiff & the Vale of Glamorgan 3 0.83 2
Carmarthenshire 2 1.37 0
Central North Wales - - -
Ceredigion 0 0.00 0
Gwent 16 3.55 1
Neath & Port Talbot 7 6.24 1
North East Wales - - -
North West Wales 5 3.26 0
Pembrokeshire 6 6.28 0
Powys 0 0.00 0
Swansea 1 0.53 0
NORTHERN IRELAND
Northern Ireland 23 1.67 30
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GUERNSEY 1 1.87 0
JERSEY 7 9.39 1
ISLE OF MAN 4 6.03 0
SCOTLAND
Dumbarton 20 20.56 0
Please note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no
reports were submitted for the specific period from that jurisdiction or area. In subsequent reports these rates may
increase as more inquests on deaths in 2007 are held and/or notified to the np-SAD. These rates should therefore be
regarded as minimum rates.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 23 of the coroners' jurisdictions in
England and Wales as well as the area covered by the Procurators Fiscal region in Dumbarton, are not co-
terminous with these boundaries and cover parts of such areas (see Appendix 1). Where administrative areas are
split between jurisdictions, the estimated population has been divided into two or three as applicable. However, this
means that the population of some coroners' jurisdictions may be either over- or under-estimated. It is necessary to
make such assumptions until more accurate figures can be obtained or calculated.
(2) Notified after the publication of the np-SAD Annual Report, 2007.
(3) The amalgamations of the following coroner’s jurisdictions during the period covered by this report mean that rates
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire
(1 April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in
Cumbria, the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to form
two new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Annex AR3: Changes in annual death rate per 100,000
population for np-SAD cases (16 years old
and over), and annual percentage of all







































Queen's Household 0 0.00 0.00 0 0.00 0.00
ENGLAND
AVON 19 2.30 2.72 12 1.38 2.07
BEDFORDSHIRE 24 5.22 12.83 16 3.38 8.00
BERKSHIRE - - - 1 0.15 0.43
BUCKINGHAMSHIRE
Buckinghamshire 13 3.40 8.50 16 4.10 10.32
Milton Keynes 7 4.09 7.07 7 3.90 5.34
CAMBRIDGESHIRE
North & East Cambridgeshire 3 2.24 4.11 4 2.86 7.69
Peterborough 9 7.15 8.91 13 10.06 12.75
South & West
Cambridgeshire
1 0.29 0.45 8 2.30 3.65
CHESHIRE 19 2.37 3.25 38 4.67 6.32
CORNWALL
Cornwall 15 3.52 4.13 35 7.99 9.26
Isles of Scilly 0 0.00 0.00 0 0.00 0.00
CUMBRIA
North & West Cumbria 25 11.35 - 10 4.52 7.14
South & East Cumbria 6 3.18 - 4 2.11 2.30
DERBYSHIRE
Derby & South Derbyshire 15 3.19 6.94 22 4.56 8.76
North Derbyshire 17 5.26 5.92 14 4.26 4.96
DEVON
Exeter & Greater Devon 22 4.54 5.99 11 2.58 3.63
Plymouth & South West
Devon
19 7.98 4.90 9 3.73 3.45




30 7.56 18.99 39 9.76 24.53
Western Dorset 7 3.78 9.21 4 2.11 4.88
DURHAM
Darlington & South Durham 2 0.90 1.59 4 1.79 4.17
North Durham 4 1.50 1.64 3 1.10 1.54
EAST SUSSEX
Brighton & Hove 38 17.81 19.00 40 18.84 20.00
East Sussex 20 4.92 6.62 15 3.60 5.36
ESSEX
Essex & Thurrock 17 1.60 3.53 7 0.64 1.50
Southend & South East
Essex
11 4.18 12.36 16 5.91 14.29
GLOUCESTERSHIRE 11 2.36 3.36 3 0.63 0.92
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Manchester 10 2.80 1.78 22 5.89 4.89
North Manchester 10 2.09 2.99 13 2.71 3.92
South Manchester 20 3.51 3.58 5 0.88 1.11
West Manchester 14 2.21 3.00 15 2.37 2.82
HAMPSHIRE
Central Hampshire 5 1.82 2.44 6 2.15 3.24
North East Hampshire 8 2.58 7.27 7 2.22 6.31
Portsmouth & South East
Hampshire
15 3.38 4.70 17 3.71 6.20
Southampton & New Forest 24 7.37 12.44 16 4.73 8.94
HEREFORDSHIRE 0 0.00 0.00 3 2.04 3.57
HERTFORDSHIRE 19 2.27 5.38 18 2.11 4.90
HUMBERSIDE
East Riding & Hull 13 2.77 4.98 22 4.55 10.33
ISLE OF WIGHT 8 6.90 10.96 6 5.17 6.12
KENT
Central & South East Kent 14 5.36 8.00 10 3.76 6.76
Mid Kent & Medway 11 2.69 4.76 8 1.93 3.74
North East Kent - - - - - -




12 5.58 5.56 19 8.70 8.19
Blackpool & the Fylde 35 19.39 24.31 27 14.94 18.75
East Lancashire 16 8.36 10.26 13 6.68 8.39
Preston & West Lancashire 14 2.47 3.37 35 6.05 8.10
LEICESTERSHIRE
Leicester City & South
Leicestershire
11 2.65 1.70 - - -
Rutland & North
Leicestershire
8 2.25 3.98 7 1.91 6.36
LINCOLNSHIRE
Boston & Spalding 1 0.87 1.61 9 7.73 13.85
North Lincolnshire & Grimsby 0 0.00 0.00 8 3.12 7.08
Spilsby & Louth 2 1.58 3.23 11 8.47 22.45
Stamford 0 0.00 0.00 1 0.94 3.23
West Lincolnshire 13 6.14 9.56 13 5.95 12.75
LONDON
City of London 0 0.00 0.00 0 0.00 0.00
Eastern London 16 1.83 3.86 10 1.14 2.92
Inner North London 46 6.86 8.97 40 5.82 7.46
Inner South London 53 6.57 10.15 51 6.12 10.18
Inner West London 2 0.26 0.47 9 1.19 2.19
Northern London 29 2.74 6.18 54 5.10 13.67
Southern London 14 1.68 4.26 19 2.27 6.53
Western London 64 6.14 9.70 51 4.89 12.81
MERSEYSIDE
Knowsley, St Helens &
Sefton
9 1.85 3.61 3 0.61 1.33
Liverpool 29 7.92 6.08 24 6.70 4.99
Wirral 9 3.57 2.83 15 5.98 5.23
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Greater Norfolk 14 2.28 4.29 44 7.01 12.02
Great Yarmouth - - - 1 1.29 2.44
NORTHAMPTONSHIRE 3 0.58 1.11 25 4.60 10.68
NORTHUMBERLAND
North Northumberland 9 9.48 6.12 4 4.20 2.96
South Northumberland - - - - - -
NORTH YORKSHIRE
North Yorkshire Eastern 1 0.50 0.95 2 0.97 1.50
North Yorkshire Western 3 1.09 2.50 2 0.70 1.75
York - - - - - -
NOTTINGHAMSHIRE 6 0.71 1.37 11 1.26 2.68
OXFORDSHIRE 7 1.38 1.78 10 1.84 2.76
SHROPSHIRE
Mid & North Shropshire 6 3.81 6.52 2 1.25 2.02
South Shropshire 0 0.00 0.00 0 0.00 0.00
The Wrekin 4 3.14 4.49 4 3.12 5.88
SOMERSET
Eastern Somerset 4 1.88 3.88 7 3.23 6.54
Western Somerset 7 3.40 5.00 5 2.39 3.68
SOUTH YORKSHIRE
South Yorkshire East 18 4.14 5.17 15 3.42 4.78
South Yorkshire West 37 6.13 8.37 27 4.37 6.03
STAFFORDSHIRE
South Staffordshire 5 1.03 1.39 21 4.25 7.14
Stoke-on-Trent & North
Staffordshire
7 1.88 1.47 11 2.93 2.51
SUFFOLK 17 3.03 6.51 35 6.07 12.68
SURREY 23 2.65 6.35 20 2.25 5.65
TEESSIDE
Hartlepool 1 1.40 1.37 3 4.10 5.26
Teesside 20 5.41 5.80 25 6.64 8.12
TYNE & WEAR
Gateshead & South Tyneside 14 5.01 7.73 1 0.36 0.62
Newcastle-upon-Tyne 23 10.07 6.46 10 4.44 3.65
North Tyneside 1 0.64 0.48 - - 0.00
Sunderland 8 3.49 2.31 4 1.74 1.41
WARWICKSHIRE 12 2.76 5.33 3 0.70 1.40
WEST MIDLANDS
Birmingham 41 4.37 4.14 30 3.15 3.11
Black Country 15 2.23 4.39 6 0.89 1.97
Coventry 9 3.69 4.57 9 3.65 4.41
Wolverhampton 2 1.04 1.22 1 0.53 0.97
WEST SUSSEX 25 4.02 8.22 34 5.37 11.60
West YORKSHIRE
West Yorkshire Eastern 40 4.73 7.65 65 7.32 13.05
West Yorkshire Western 36 4.28 8.00 43 4.98 10.64
WILTSHIRE 1 0.20 0.37 1 0.19 0.36
WORCESTERSHIRE 12 2.66 4.56 6 1.32 2.27
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8 2.39 3.11 12 3.51 3.64
Cardiff & the Vale of
Glamorgan
0 0.00 0.00 3 0.83 0.56
Carmarthenshire 3 2.07 3.37 2 1.37 2.63
Central North Wales - - - - - -
Ceredigion 2 3.05 5.88 0 0.00 0.00
Gwent 8 1.81 5.10 16 3.55 11.76
Neath & Port Talbot 5 4.54 7.04 7 6.24 12.07
North East Wales - - - - - -
North West Wales 12 7.89 9.09 5 3.26 3.79
Pembrokeshire 2 2.11 3.39 6 6.28 8.96
Powys 1 0.93 1.43 0 0.00 0.00
Swansea 12 6.48 8.05 1 0.53 0.64
NORTHERN IRELAND
Northern Ireland) 2 0.15 0.97 23 1.67 -
THE ISLANDS
GUERNSEY 0 0.00 0.00 1 1.87 11.11
JERSEY 9 12.29 25.00 7 9.39 16.67
ISLE OF MAN 1 1.53 2.13 4 6.03 20.00
SCOTLAND
Dumbarton 11 11.34 - 20 20.56 -
Please note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no
reports were submitted for the specific period from that jurisdiction or area prior to or shortly after the preparation of the
previous annual report. In subsequent reports these rates may increase as more inquests on deaths in 2007 are held
and/or notified to the np-SAD. These rates should therefore be regarded as minimum rates.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 23 of the coroners' jurisdictions in
England and Wales are not co-terminous with these boundaries, as well as the area covered by the Procurators
Fiscal region in Dumbarton, and cover parts of such areas (see Appendix 1). Where administrative areas are split
between jurisdictions, the estimated population has been divided into two or three as applicable. However, this
means that the population of some coroners' jurisdictions may be either over- or under-estimated. It is necessary
to make such assumptions until more accurate figures can be obtained or calculated.
(2) Inquests held on all ages.
(3) The amalgamations of the following coroner’s jurisdictions during the period covered by this report mean that rates
for the new areas have been calculated retrospectively based on published figures: High Peak and Scarsdale were
merged to form North Derbyshire (1 February 2006); Gloucester and Cheltenham merged to form Gloucestershire
(1 April 2006). In Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in
Cumbria, the three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to
form two new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Annex AR4: np-SAD cases in 2007 by Drug and Alcohol
Action Team area (16 years and over)
Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
ENGLAND
NORTH EAST
County Durham 4 0.96 4 0.96
Darlington 3 3.72 3 3.72
Gateshead 1 0.64 1 0.64
Hartlepool 4 5.47 3 4.10
Middlesbrough 8 7.24 9 8.14
Newcastle-upon-Tyne 10 4.44 10 4.44
North Tyneside* - - - -
Northumberland 4 1.56 4 1.56
Redcar and Cleveland 6 5.30 6 5.30
South Tyneside 0 0.00 0 0.00
Stockton on Tees 10 6.54 10 6.54
Sunderland 4 1.74 4 1.74
NORTH WEST
Blackburn with Darwen 12 11.25 16 15.01
Blackpool 20 17.18 22 18.90
Bolton 9 4.34 7 3.37
Bury 3 2.05 3 2.05
Cheshire 24 4.27 27 4.81
Cumbria 15 3.65 14 3.41
Halton 5 5.26 4 4.21
Knowsley 1 0.83 0 0.00
Lancashire 60 6.32 55 5.79
Liverpool 20 5.58 24 6.70
Manchester 21 5.62 22 5.89
Oldham 4 2.34 4 2.34
Rochdale 7 4.31 6 3.70
Salford 2 1.12 2 1.12
Sefton 5 2.21 3 1.33
St Helens 0 0.00 0 0.00
Stockport 1 0.44 1 0.44
Tameside 3 1.74 3 1.74
Trafford 2 1.17 1 0.59
Warrington 8 5.09 7 4.45
Wigan 5 2.02 6 2.43
Wirral 15 5.98 15 5.98
YORKSHIRE AND HUMBER
Barnsley 7 3.85 8 4.40
Bradford 21 5.45 25 6.49
Calderdale 3 1.87 1 0.62
Doncaster 13 5.54 14 5.96
East Riding of Yorkshire 4 1.45 6 2.18
Kingston-upon-Hull 14 6.71 16 7.67
Kirklees 18 5.65 19 5.97
Leeds 39 6.23 37 5.91
North East Lincolnshire 0 0.00 0 0.00
North Lincolnshire 6 4.65 6 4.65
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
North Yorkshire 3 0.61 4 0.82
Rotherham 5 2.45 5 2.45
Sheffield 18 4.13 18 4.13
Wakefield 26 9.95 26 9.95
York - - - -
EAST MIDLANDS
Derby 14 7.32 15 7.84
Derbyshire 25 4.04 21 3.39
Leicester* 0 0.00 0 0.00
Leicestershire 6 1.15 6 1.15
Lincolnshire 36 6.31 33 5.78
Northamptonshire 23 4.23 25 4.60
Nottingham 3 1.26 4 1.68
Nottinghamshire 8 1.27 7 1.11
Rutland 0 0.00 0 0.00
WEST MIDLANDS
Birmingham 28 3.56 31 3.94
Coventry 8 3.24 9 3.65
Dudley 2 0.81 2 0.81
Herefordshire 3 2.04 3 2.04
Sandwell 3 1.32 1 0.44
Shropshire 2 0.84 2 0.84
Solihull 1 0.61 1 0.61
Staffordshire 25 3.70 22 3.26
Stoke-on-Trent 9 4.65 9 4.65
Telford and Wrekin 4 3.12 4 3.12
Walsall 3 1.49 3 1.49
Warwickshire 4 0.93 4 0.93
Wolverhampton 1 0.53 1 0.53
Worcestershire 5 1.10 4 0.88
EAST
Bedfordshire 7 2.15 6 1.84
Cambridgeshire 14 2.87 12 2.46
Essex 11 0.99 8 0.72
Hertfordshire 18 2.11 18 2.11
Luton 8 5.44 10 6.81
Norfolk 45 6.45 45 6.45
Peterborough 11 8.51 13 10.06
Southend-on-Sea 11 8.40 14 10.70
Suffolk 33 5.72 34 5.89
Thurrock 1 0.85 0 0.00
LONDON
Inner London
Camden 13 6.64 17 8.69
City of London 0 0.00 0 0.00
Hackney 13 7.96 13 7.96
Hammersmith and Fulham 15 10.38 14 9.69
Haringey 14 7.74 10 5.53
Islington 12 7.63 14 8.91
Kensington and Chelsea 1 0.66 1 0.66
Lambeth 15 6.68 17 7.57
Lewisham 11 5.31 9 4.34
Newham 2 1.05 1 0.53
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Southwark 10 4.44 14 6.22
Tower Hamlets 14 8.19 18 10.53
Wandsworth 0 0.00 1 0.42
Westminster 7 3.44 9 4.43
Outer London
Barking and Dagenham 2 1.58 2 1.58
Barnet 9 3.43 7 2.67
Bexley 2 1.13 1 0.56
Brent 5 2.28 6 2.74
Bromley 5 2.07 5 2.07
Croydon 8 2.97 10 3.72
Ealing 8 3.23 6 2.42
Enfield 7 3.11 9 4.00
Greenwich 8 4.54 11 6.24
Harrow 2 1.16 2 1.16
Havering 2 1.08 1 0.54
Hillingdon 10 5.02 9 4.52
Hounslow 8 4.51 9 5.08
Kingston-upon-Thames 4 3.10 6 4.64
Merton 2 1.23 0 0.00
Redbridge 2 1.00 2 1.00
Richmond-upon-Thames 4 2.76 3 2.07
Sutton 2 1.34 2 1.34
Waltham Forest* 2 1.14 4 2.29
SOUTH EAST
Bracknell Forest* - - - -
Brighton and Hove 39 18.37 39 18.37
Buckinghamshire 14 3.59 16 4.10
East Sussex 15 3.60 15 3.60
Hampshire 32 3.09 31 3.00
Isle of Wight 6 5.17 6 5.17
Kent* 15 1.34 16 1.42
Medway towns 3 1.50 2 1.00
Milton Keynes 7 3.90 7 3.90
Oxfordshire 9 1.75 10 1.94
Portsmouth 6 3.66 5 3.05
Reading* - - - -
Slough* - - 1 1.06
Southampton 10 5.18 11 5.70
Surrey 22 2.48 20 2.25
West Berkshire* 1 0.84 - -
West Sussex 39 6.16 34 5.37
Windsor and Maidenhead* - - - -
Wokingham* 2 1.60 - -
SOUTH WEST
Bath and North East Somerset 2 1.35 3 2.03
Bournemouth 26 18.91 30 21.82
Bristol 8 2.31 8 2.31
Cornwall & Isles of Scilly 32 7.27 34 7.73
Devon 12 1.92 12 1.92
Dorset 10 2.96 4 1.19
Gloucestershire 3 0.63 3 0.63
North Somerset 2 1.19 2 1.19
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Drug and Alcohol Action Team National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Plymouth 12 5.81 10 4.84
Poole 5 4.40 7 6.16
Somerset 12 8.00 13 3.05
South Gloucestershire 0 0.00 0 0.00
Swindon 1 0.66 0 0.00
Torbay 5 4.48 5 4.48
Wiltshire 1 0.28 1 0.28
WALES
Bro Taf 13 2.19 12 2.02
Dyfed Powys 6 1.44 5 1.20
Gwent 15 3.33 15 3.33
Iechyd Morgannwg 11 2.69 11 2.69
North Wales 8 1.44 6 1.08
NORTHERN IRELAND
Eastern 9 1.68 9 1.68
Northern 4 1.13 6 1.70
Southern 5 1.90 5 1.90
Western 3 1.32 3 1.32
THE ISLANDS
GUERNSEY 1 1.87 1 1.87
JERSEY 7 10.56 7 10.56
ISLE OF MAN 4 5.37 4 5.37
Note: In addition there were a number of cases that could not be allocated to specific DA(A)T
areas because they were of no fixed abode and/or the jurisdiction in which the inquest was held
covers more than one DA(A)T. Some DA(A)Ts are covered by coroner’s jurisdictions that did not
submit information to the np-SAD; they are marked thus - *.
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Annex AR5: Profile of cases In England and Wales
meeting criteria for monitoring the Government’s drug
strategy, 2007
Introduction
This annex has been compiled at the request
of the Department of Health (England) to
monitor cases against the Government’s drug
strategy definition. Whilst the official target is
being measured by reference to figures
compiled by the Office for National Statistics
(ONS), information generated by cases
notified by coroners to the np-SAD can
complement their data.
Definition of cases
The definition of a drug-related death adopted
for the Government’s drug strategy3 is
somewhat narrower than that for an np-SAD
case (see Section II above). It is possible to
derive information on this narrower basis by
operationalising the np-SAD case definition
using the method described below. The np-
SAD approach is to exclude two specific
categories from its case definition; those
remaining are regarded as meeting the criteria
for the Government’s definition. The two
categories excluded from the np-SAD cases
are; (a) deaths of non-drug abusers where no
Controlled Drugs were found at post mortem
or where a specific compound analgesics was
found at post mortem; and (b) deaths of drug
abusers where no Controlled Drugs were
found at post mortem or where a specific
compound analgesics was found at post
mortem and the mechanism of death was
hanging, drowning, accident, etc.
For the purposes of this annex, the np-SAD
has closely followed the same approach as
the Office for National Statistics and the
General Register Office for Scotland in
respect of the compound analgesics not
treated as Controlled Drugs, the exception
being that of codeine. This cannot be
excluded from our consideration because it is
a by-product of the degeneration of heroin in
the body and thus may represent the
consumption of heroin rather than codeine.
This will not have affected many cases.
3 See ONS (2008) for further details
Profile of cases
The following analysis looks at deaths
occurring in England and Wales during 2007
which meet the above selection criteria
(1,245/1,507 or 82.6% of all cases reported to
the Programme). Demographic details and a
summary of principal drugs implicated in
death are presented below.
1. Demography
The majority of cases were male (80%). The
median age at death was 37 years (semi-inter
quartile range = 7.7), with three-quarters
(76%) being under the age of 45 years.
Where ethnicity was known, the vast majority
(94.1%) were White. Where addict status was
known, the majority (71.8%) had a history of
drug-dependence or abuse. Just over half
(51%) of cases were unemployed and 49% of
cases were living alone or in no fixed abode at
the time of their death (Table AR5.1).
2. Location of death
The majority of cases (68%) died at a defined
residential address (e.g. the deceased’s home
address or other private residential address),
one-fifth (20%) died in hospital and the
remainder (12%) died elsewhere (e.g. in a
public place).
3. Substances implicated in death
Psychoactive substances were implicated in
1,197/1,245 deaths (96.1%). The principal
substances implicated in drug-related deaths
were: heroin/morphine (56%) and alcohol in
combination with other drugs (38%). Other
classes of drugs making a sizeable
contribution (in excess of 10%) to deaths
were: other opiates/opioid analgesics;
methadone; hypnotics/ sedatives; cocaine;
and anti-depressants. Heroin/morphine as the
sole implicated drug accounted for 23% of
deaths. The breakdown of psychoactive
substances implicated in death is presented in
Table AR5.2.
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Table AR5.1: Demographic variables for death reported to np-SAD meeting the criteria for
monitoring the Government’s drug strategy, England & Wales, 2007
Variable Category Number (%)
Total 1,245 (100.0)
Gender Male 998 (80.2)
Female 247 (19.8)
Employment status Unemployed 632 (50.8)
Employed 401 (32.2)








With others 532 (42.7)
No fixed abode 66 (5.3)
Other 45 (3.6)
Not known 58 (4.7)
Table AR5.2: Psychoactive substances implicated in deaths reported to np-SAD meeting
the criteria for monitoring the Government’s drug strategy, England & Wales,
2007
Drug category Number of cases where no
other substance was
implicated
Number of cases where
drug was implicated
No. (%) No. (%)
Total of cases with
psychoactive drug implicated
1,197 (100.0) 1,197 (100.0)
Alcohol-in-combination(1) - 456 (38.1)
Amphetamines 8 (0.7) 51 (4.3)
Anti-depressants 8 (0.7) 184(15.4)
Anti-epileptics 0 (0.0) 15 (1.3)
Anti-psychotics 1 (0.1) 23 (1.9)
Cannabis 3 (0.3) 53 (4.4)
Cocaine 38 (3.2) 232 (19.4)
Ecstasy-type drugs 10 (0.8) 41 (3.4)
GHB 3 (0.3) 6 (0.5)
Heroin/morphine 190 (15.9) 671 (56.1)
Hypnotic/sedatives 15 (1.2) 268 (22.4)
Methadone 61 (5.1) 279 (23.3)
Other opiates/opioid
analgesics
35 (2.9) 294 (24.6)
(1) Alcohol on its own does not meet the criteria for an np-SAD case.
4. Age and drug implicated in death
In cases aged 15-44 years, heroin/morphine
(60.9%) was the most frequently mentioned
drug contributing to fatality. In those aged 45
years and over, heroin/morphine (52.4%)
followed closely by other opiates/opiate
analgesics (48.9%) were the most frequently
mentioned as being implicated (Table AR5.3).
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Table AR5.3: Age and drug implicated in deaths reported to np-SAD meeting the criteria






Drug category (alone or in combination) most
frequently implicated in each age group
All ages 1,197 (100.0) Heroin/morphine (56.1%)
14 & under 1 (0.1) Anti-depressants & hypnotics/sedatives
15–24 141 (11.8) Heroin/morphine (46.8%)
25-34 374 (31.2) Heroin/morphine (65.0%)
35-44 387 (32.3) Heroin/morphine (62.0%)
45-54 189 (15.8) Heroin/morphine (48.7%)
55-64 67 (5.6) Other opiates/opioid analgesics (37.3%)
65 & over 38 (3.2) Other opiates/opioid analgesics (55.3%)
5. Underlying cause(s) of death
The proportions of ICD-10 categories of
underlying cause of death were as follows:
 Accidental poisoning (X40-X47): 69.4%
 Intentional self-poisoning (X60-X67):
10.0%
 Poisonings of undetermined intent (Y10-
Y14): 9.4%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 11.1%
6. Manner of death
The manner of death in these cases was






 Unclassified/not specified: 0.5%
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Annex AR6: Drug-related deaths reported to the Scottish
Crime and Drug Enforcement Agency, 2007
This section describes the pattern of drug-
related deaths in Scotland. The Scottish
Crime and Drug Enforcement Agency
(SCDEA) on behalf of the Association of Chief
Police Officers in Scotland (ACPOS) collate
data on drug-related deaths obtained from
Scottish police forces. These data are used to
populate a national database which is
maintained by the SCDEA. As such the data
supplied to the SCDEA remain the property of
the submitting force that is also responsible
for its accuracy and submission to the
database. Drug-related death cases are those
that meet the definition used by the
Association of Chief Police Officers (Scotland)
– “where there is prima facie evidence of a
fatal overdose of controlled drugs. Such
evidence would be recent drug misuse, for
example controlled drugs and/or a
hypodermic syringe found in close proximity to
the body and/or the person is known to the
police as a drug misuser although not
necessarily a notified addict.” Thus, most
suicides in Scotland are excluded.
1. Demography
Notifications of 357 drug-related deaths
occurring in 2007 were received by the
SCDEA, covering the following police force
areas: Central Scotland (2.5%); Dumfries &
Galloway (1.1%); Fife (6.2%); Grampian
(9.2%); Lothian & Borders (14.0%); Northern
(2.0%); Strathclyde (56.0%); and Tayside
(9.0)%.
The majority (89%) of cases were male (Table
AR6.1). The median age at death was 32.8
years (semi-interquartile range = 6.6) (Figure
AR6.1). The majority (90%) of cases were
under 45 years. Where ethnicity was known,
the majority were White (99%).
Table AR6.1: Demographic variables for drug-related deaths as reported by Scottish
police forces to the SCDEA, 2007
2. Location of death
In line with data protection, the SCDEA
database structure does not record
information on living arrangements and place
of death. This information was available in
only 5% and 5.4% respectively of Scottish
cases. Where data on place of death had
been made available by the Procurator Fiscal,
in Dumbarton; the majority of fatalities (80%)
occurred at a defined residential address (i.e.
the deceased’s home address or other private
residential address), 10% died in hospital and
10% died elsewhere (e.g. in a public place).
3. Cause(s) of death
The majority of fatalities (96%) were
considered to be accidental (i.e. clearly non-
deliberate) poisoning. Deaths due to natural
causes or poisonings of undetermined intent
accounted for the remaining cases.
Variable Category No %
Total 357 100.0








65 & over 1 0.3
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4. Substances implicated in death
4.1 All substances
Psychoactive drugs were not directly
implicated in about 0.8% of cases (n = 3). Of
the remaining 354 cases, the principal
substances implicated were: heroin/morphine
(64%); methadone (27%); alcohol in
combination with other substances (27%);
hypnotics/sedatives (18%); other opiates/
opioid analgesics (15%); and cocaine (11%)
(Table AR6.2).
Figure AR6.2 takes into account data where
one of the following drugs was known to be
implicated: alcohol-in-combination; anti-
depressants; cocaine; ecstasy-type drugs;
heroin/morphine; hypnotics/sedatives;
methadone; or other opiates/opioid
analgesics.
4.2 Single substances
The following substances, as the sole
implicated drug, accounted for 143 (40%)
deaths: heroin/morphine (27%); methadone
(9%); other opiates/opioid analgesics (2%);
cocaine (1%); and amphetamines (1%) (Table
AR6.2).
Table AR6.2: Psychoactive substances implicated in drug-related deaths as reported by
Scottish police forces to the SCDEA, 2007
Drug category Number (%) of cases where
no other substance was
implicated
Number (%) of cases
where drug was
implicated*
Total 354 (100.0) 354 (100.0)
Alcohol-in-combination - 95 (26.8)
Amphetamines 3 (0.8) 6 (1.7)
Anti-depressants 1 (0.3) 16 (4.5)
Anti-epileptics 0 (0.0) 0 (0.0)
Anti-Parkinsons 0 (0.0) 1 (0.3)
Anti-psychotics 0 (0.0) 1 (0.3)
Cannabis 0 (0.0) 0 (0.0)
Cocaine 4 (1.1) 39 (11.0)
Ecstasy-type drugs 2 (0.6) 13 (3.7)
GHB 1 (0.3) 1 (0.3)
Heroin/morphine 94 (26.6) 228(64.4)
Hypnotic/sedatives 0 (0.0) 65 (18.4)
Methadone 31 (8.8) 96 (27.1)
Other opiates/opioid analgesics 7 (2.0) 52 (14.7)
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
Figure AR6.1: Drug-related deaths as reported by Scottish police forces to the SCDEA, by
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Figure AR6.2: Drug-related deaths as reported by Scottish police forces to the SCDEA, by



















































































5. Age and drug implicated in death
In cases aged 15 years and over,
heroin/morphine was the most frequently
mentioned drug contributing to fatality (Table
AR6.3). This was also the case for all of the
individual age-groups, except the sole case
aged 65 or over which involved ant-
depressants alone.
Table AR6.3: Age and psychoactive drug implicated in drug-related deaths as reported by
Scottish police forces to the SCDEA, 2007
Age-group (years) Number (%) Drug category (alone or in combination)
most frequently implicated in each age
group
All ages 354 (100.0) Heroin/morphine (64.4%)
14 & under 0 (0.0) -
15–24 78 (22.0) Heroin/morphine (66.7%)
25-34 132 (37.3) Heroin/morphine (62.1%)
35-44 109 (30.8) Heroin/morphine (67.9%)
45-54 27 (7.6) Heroin/morphine (51.9%)
55-64 7 (2.0) Heroin/morphine (85.7%)
65 and over 1 (0.3) Anti-depressants (1)
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6. Gender and drug implicated in death
In males and females, heroin/morphine was
the most frequently mentioned drug,
accounting for 68% and 89% of fatalities
respectively. However, the pattern of other
drug-specific fatality was somewhat different
in male and female cases.
Among males, the most frequently mentioned
drugs were: heroin/morphine (68%); alcohol-
in-combination (29%); and methadone (24%).
Furthermore, there was a higher proportion of
cases of drug-specific fatality among males
compared to females in respect of alcohol-in-
combination (29% vs. 13%); hypnotics/
sedatives (19% vs. 15%); and cocaine (11%
vs. 8%).
Among female cases, the most frequently
mentioned drugs were: heroin/morphine
(89%); methadone (51%); hypnotics/sedatives
(15%); other opiates/opioid analgesics (15%);
and alcohol in combination (13%). Compared
to male cases, female cases had a higher
proportion of fatality associated with
heroin/morphine (89% vs. 68%); methadone
(51% vs. 24%), and anti-depressants (18%
vs. 3%).
7. Regional patterns
The number of drug-related deaths reported
by police to the SCDEA and meeting the np-
SAD case criteria fell from 312 in 2004 to 254
in 2005, and then rose to 374 in 2006. The
figure for 2007 was 357; this represents a
decrease of 4.5%. Whilst most of this was due
to decreases in the number reported for the
Central Scotland, Grampian and Strathclyde
police force areas, there were increases in the
areas covered by Dumfries & Galloway, Fife
and Tayside forces (Table AR6.4). The rates
in the Strathclyde police force area are on a
par with the higher rates reported in England
and Wales (except Blackpool & the Fylde and
Brighton & Hove).
Table AR6.4: Deaths meeting np-SAD criteria as reported by Scottish police forces to




































































28 8.68 32 8.37
Scotland 264 6.34 374 8.92 357 6.94
(1) The rate per 100,000 population is based on published mid-year population estimates for local
government administrative areas for the years in question.
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Annex AR7: Drug-related deaths recorded by the
Northern Ireland Statistics and Research
Agency (NISRA), 2007
This section describes the pattern of drug-
related deaths in Northern Ireland. The
Northern Ireland Statistics and Research
Agency (NISRA) provided the data analysed
in this section, from registrations recorded by
the General Register Office for Northern
Ireland. Coroners in Northern Ireland routinely
submit returns on drug-related deaths after
conducting an inquiry, similar to that in
England and Wales.
1. Demography
Notifications of 24 drug-related deaths
occurring in 2007 were received from NISRA
and coroners which meet the np-SAD case
criteria. The number of such deaths was 58 in
2004, 65 in 2005, and 54 in 2006. However,
the number of drug-related deaths has varied
greatly from year to year in Northern Ireland.
There is also a backlog of inquests and
related death registrations which means that
further deaths for 2007 may be subsequently
notified to the NISRA by coroners. In 2007
there was a rate of 1.74 drug-related deaths
per 100,000 population aged 16 years and
over, compared with 4.38 in 2004, 4.84 in
2005, and 3.97 in 2006. These rates are low
by comparison with the rest of the UK.
The majority (17/24) of the cases in 2007
were male (Table AR7.1). The median age at
death was 41.3 years (semi-interquartile
range = 9.8) (Figure AR7.1). Nearly three-
fifths (58%) of cases were under 45 years.
Half (50%) were unemployed, nearly three-
fifths (58%) lived with others. Where ethnicity
was known, all decedents were White. Addict
status was known in only 11 cases, four of
which has a history of dependence.
Table AR7.1: Demographic variables for drug-related deaths reported by NISRA and
coroners meeting np-SAD criteria, Northern Ireland, 2007
Figure AR7.1: Drug-related deaths reported by NISRA and coroners meeting np-SAD


























Variable Category Number (n = 24)
Gender Male 17
Female 7
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2. Location of death
Most fatalities (19/24) occurred at a defined
residential address (i.e. the deceased’s home
address or other private residential address).
One occurred in hospital and four elsewhere.
3. Cause(s) of death
Six cases died from accidental poisoning, one
from intentional self-poisoning, and in 15
cases the intent was undetermined. There
was one drowning, and one death involving
an insulin overdose.
4. Substances implicated in death
4.1 All substances
Psychoactive drugs were directly implicated in
all but one case. The principal substances
implicated were: alcohol-in-combination (13);
hypnotics/sedatives (13); anti-depressants
(10); other opiates/opioid analgesics (7); and
anti-epileptics (4) (Table AR7.2). This profile
is different to that seen in England and Wales
and more similar to that seen in Scotland in
terms of the large proportion of hypnotics/
sedatives involved (GROS, 2008).
Figure AR7.2 takes into account data where
one of the following drugs was known to be
implicated: alcohol-in-combination; anti-
depressants; anti-epileptics; anti-psychotics;
cannabis; cocaine; ecstasy-type drugs;
heroin/morphine; hypnotics/sedatives;
methadone; or other opiates/opioid
analgesics.
4.2 Single substances
The following substances, as the sole
implicated drug, accounted for 3/24 deaths:
cocaine; heroin/morphine; and other opiates/
opioid analgesics (Table AR7.2).
Table AR7.2: Psychoactive substances implicated in deaths reported by NISRA and
coroners meeting np-SAD criteria, Northern Ireland, 2007
Drug category Number of cases where no
other substance was implicated
(N = 23)

















Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
5. Age and drug implicated in death
In cases aged 25-34, 45-54, and over 64
years, alcohol-in-combination with other
substances was the most frequently
mentioned substance contributing to fatality
(Table AR7.3).
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Figure AR7.2: Drug-related deaths reported by NISRA and coroners meeting np-SAD








































































































Table AR7.3: Age and psychoactive drug implicated in deaths reported to NISRA meeting
np-SAD criteria, 2007
Age-group (years) Number where
substance
implicated
Drug category (alone or in combination)
most frequently implicated in each age group
All ages 23 Alcohol-in-combination; hypnotics/sedatives (13)
15-24 1 Amphetamines, anti-depressants, ecstasy-type
drugs & hypnotics/sedatives (1)
25-34 5 Alcohol-in-combination (2)
Heroin/morphine (2)
35-44 7 Hypnotics/sedatives (5)
45-54 6 Alcohol-in-combination (4)
55-64 2 Hypnotics/sedatives (2)
65 & over 2 Alcohol-in-combination (2)
Anti-depressants (2)
6. Gender and drug implicated in death
The pattern of other drug-specific fatality was
somewhat different in male and female cases.
Among males, the most frequently mentioned
drugs were: alcohol-in-combination (8/16);
hypnotics/sedatives (8/16); anti-depressants
(6/16); other opiates/opioid analgesics (5/16);
anti-epileptics (2/16); anti-psychotics (2/16);
and heroin/morphine (2/16).
Among female cases, the drugs mentioned
were: alcohol-in-combination (5/7);
hypnotics/sedatives (5/7); anti-depressants
(4/7); other opiates/opioid analgesics (2/7);
and anti-epileptics (2/7). Compared to male
cases, female cases had a higher proportion
of fatality associated with alcohol-in-
combination (5/7 vs. 8/16); hypnotic/sedatives
(5/7 vs. 8/16); and anti-depressants (4/7 vs.
6/18). Furthermore, there were no fatalities
due to amphetamine, cocaine, ecstasy-type
drugs, heroin/morphine, or methadone among
females.
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Key Points
Surveillance Report No. 21: July - December 2007
 A total of 824 inquests into drug-related deaths were reported to the np-SAD for the period
July to December 2007 by the end of June 2008. Information was submitted by 102 out of
115 coroners in England & Wales, as well as Northern Ireland, Guernsey, Jersey, the Isle of
Man, together with one Procurator Fiscal in Scotland. This number of inquests represents
an increase of 12.1% over the same period in 2006 (735 inquests).
 The demographic profile remains consistent with that of previous reports. The majority of
cases were males (76%), under the age of 45 years (73%), and White (94%).
 The proportion of cases receiving prescribed drugs was 52%; the proportion of cases with a
history of drug addiction was 65%. These findings are consistent with previous reports.
 The principal underlying cause(s) of death were: accidental poisoning (60%); poisoning of
undetermined intent (13%); and intentional self-poisoning (13%).
 The following jurisdictions recorded the highest semi-annual drug-related death rate per
100,000 population aged 16 years and over: Boston & Spalding (10.5); Blackpool & the
Fylde (8.9); Brighton & Hove (8.5); Pembrokeshire (6.3); and North Northumberland (5.3).
The rate in Dumbarton was 12.3.
 Compared to the same period in 2006, the following changes were observed:
- An increase in the proportion of cases unemployed from 48% to 50%, and a decrease in
the proportion employed from 31% to 29%.
- An increase in the proportion of cases living with others from 42% to 45%
- An increase in inquests where death was due to heroin/morphine from 304 to 370
- An increase in the involvement of alcohol in inquests concerning drug-related deaths from
230 to 307
- An increase in inquests where hypnotics/sedatives were implicated in death from 96 to
149
- An increase in inquests where death was due to methadone from 108 to 146
- An increase in inquests where death was due to cocaine from 81 to 118
- An increase in inquests where death was due to other opiates/opioid analgesics from 154
to 179
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XI Introduction
A total of 102 out of 115 coroners’ jurisdictions
in England and Wales provided returns for this
surveillance report, which covers returns
made to the np-SAD for the period July to
December 2007, received before the end of
June 2008. Some coroners did not provide ‘nil
returns’ (confirmation from coroners that there
were no inquests involving drug-related
deaths for that period). In addition, coroners
in Northern Ireland, Guernsey, Jersey and the
Isle of Man, together with the Procurator
Fiscal for Dumbarton in Scotland, contributed
data during this period. No information from
the General Register Office for Northern
Ireland or from the Scottish Drugs
Enforcement Agency (SCDEA) is included in
this surveillance report.
Overall, this report covers approximately 88%
of jurisdictions in England and Wales, as well
as Northern Ireland, the Isle of Man and
Channel Islands. There are a number of
possible reasons for not reporting. For
example, the coroners’ workload may prevent
the notification of inquests, or there may be an
assumption that a ‘nil return’ does not have to
be reported. This highlights the importance of
maintaining and resourcing a surveillance
system to which coroners are willing and able
to contribute on a continuous basis. There is
also a need to provide appropriate training
and resources to enable coroners to co-
operate effectively with the requirements of a
surveillance system.
XII Profile of cases
1. Demography
A total of 824 drug-related deaths were
reported to the programme for the period July
to December 2007. The majority of cases
(76%) were male (n = 625). The majority of
cases (73%) were aged less than 45 years.
The median age at death was 37.7 years
(semi-interquartile range 8.2) (Figure 9).
Where ethnicity was known, the vast majority
of cases were White (93.6%); with the rest
being described as Black (2.9%), Asian
(1.4%), and Other (2.1%). Half of cases were
unemployed. Approximately 45% of cases
were living with others at the time of their
death; a similar proportion were living alone
(Table 10).
Table 10: Demographic variables, np-SAD inquests, July-December 2007
Variable Category Number (%)
Total 824 (100.0)
Gender Male 625 (75.8)
Female 199 (24.2)






Not Known 60 (7.3)
Living arrangements Alone 358 (43.4)
With others 369 (44.8)
No fixed abode 34 (4.1)
Other 30 (3.6)
Not known 33 (4.0)
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2. Drug-related death rates
The following jurisdictions recorded the
highest semi-annual drug-related death rate
per 100,000 population aged 16 years and
over: Boston & Spalding (10.5); Blackpool &
the Fylde (8.9); Brighton & Hove (8.5);
Pembrokeshire (6.3); and North
Northumberland (5.3). The rate in Dumbarton
was 12.3 (Annex SR2). The highest
proportions of drug-related cases expressed
as a percentage of the total number of
inquests held were: Boston & Spalding (13.9);
Blackpool & the Fylde (11.1%); Bournemouth,
Poole & Eastern Dorset (10.7%); the Isle of
Man (10.0%); Brighton & Hove (9.0%);
Pembrokeshire (9.0%); Western London
(8.3%); West Lincolnshire (7.8%); and North &
East Cambridgeshire (7.7%).
3. Location of death
Location of death was reported in all but two
cases. Where the location was known, 67% of
cases died in a defined residence (i.e. the
deceased’s home address or other private
residential address), 20% died in hospital and
13% died elsewhere (e.g. in a public place).
4. Underlying cause(s) of death
To enable comparison with various national
and international data-sets all causes of death
have been coded according to the
International Classification of Diseases (ICD-
10). This is an international standard for the
classification of diseases and health related
problems published by the World Health
Organisation (1992). The proportions of ICD-
10 categories of underlying cause(s) of death
were as follows:
 Accidental poisoning (X40-X47): 60.2%
 Intentional self-poisoning (X60-X67):
12.9%
 Poisonings of undetermined intent (Y10-
Y14): 12.9%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 14.0%
5. Manner of death
The manner of death in these cases was






 Unclassified/not specified: 0.7%
6. Substances implicated in death (Table
11)
6.1 All substances
Psychoactive substances were implicated in
93.9% of cases (n = 774). The principal
substances implicated in fatalities were:
heroin/morphine (48%); alcohol in
combination with other substances (40%);
other opiates/opioid analgesics (23%); anti-
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depressants (20%); hypnotic/sedatives (19%);
methadone (19%); and cocaine (15%).
6.2 Single substances
The following substances, as the sole
implicated drug, accounted for 263 (34%)
deaths: heroin/morphine (15%); other
opiates/opioid analgesics (5%); anti-
depressants (4%); methadone (4%), and
cocaine (4%) (Table 11).
7. Prescribed psychoactive medication
(Table 12)
Four hundred and thirty cases were known to
be receiving prescribed psychoactive
medication at the time of their death.
Prescribed medications were reported in the
following proportions for these therapeutic
drug classes: anti-depressants 47%;
hypnotic/sedatives 42%; anti-psychotics 22%,
other opiates/opioid analgesics 21%;
methadone 16%; and anti-epileptics 9%.
’Polypharmacy’ i.e. multiple prescriptions of
psychoactive drugs, occurred in 71% of these
cases.
Table 11: Psychoactive substances implicated in death, np-SAD inquests, July-December
2007
Drug category Number (%) of cases where
no other substance
implicated
Number (%) of cases
where drug implicated
Total 774 (100.0) 774 (100.0)
Alcohol - 307 (39.7)
Amphetamines 4 (0.5) 25 (3.2)
Anti-depressants 30 (3.9) 156 (20.2)
Anti-epileptics 1 (0.1) 14 (1.8)
Anti-psychotics 4 (0.5) 30 (3.9)
Cannabis 3 (0.4) 25 (3.2)
Cocaine 27 (3.5) 118 (15.2)
Ecstasy-type drugs 7 (0.9) 26 (3.4)
GHB 1 (0.1) 3 (0.4)
Heroin/morphine 116 (15.0) 370 (47.8)
Hypnotic/sedatives 7 (0.9) 149 (19.3)
Methadone 27 (3.5) 146 (18.9)
Other opiate/opioid
analgesics
36 (4.7) 179 (23.1)
Note: Column totals may sum to more than 100% since more than one substance may be implicated in a death.
Table 12: Prescribed psychoactive medication, np-SAD inquests, July-December 2007
Drug category Number (%) of cases on
prescribed
psychoactive medication




Amphetamines 0 (0.0) 0 (0.0)
Anti-depressants 201 (46.7) 104 (51.7)
Anti-epileptics 40 (9.3) 8 (20.0)
Anti-psychotics 94 (21.9) 24 (25.5)
Heroin/morphine 16 (3.7) 13 (81.3)
Hypnotic/sedatives 181 (42.1) 73 (40.3)
Methadone 68 (15.8) 50 (73.5)
Other opiates/opioid
analgesics
91 (21.2) 64 (70.3)
Note: Column totals may sum to more than 100% since more than one substance may be prescribed to an individual
and more than one substance may be implicated in a death.
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XIII Associated risks
1. Prescribed psychoactive drugs
Of the 430 cases prescribed psychoactive
medication (52% of cases) at the time of their
death, 78% had those same drugs implicated
in their death (Table 12).
1.1 Methadone
Methadone, alone and in combination with
other drugs, was implicated in 146 cases. Of
these, 66% may have obtained methadone
illicitly, compared to the 34% who were known
to be receiving prescribed methadone prior to
their death (Percentage Ratio (PR): = 1.9,
95% Confidence Interval (CI) = 1.5 - 2.5).
Methadone alone was implicated in 27 cases.
Of these, 67% may have obtained methadone
illicitly, whilst 33% were prescribed the drug
(Percentage Ratio (PR): = 2.0, 95%
Confidence Interval (CI) = 1.1 - 3.6).
More methadone deaths seem to have arisen
from illicit sources than from prescription
sources. Altogether, methadone-related
deaths still appear to more likely to arise from
illicit than prescribed methadone.
1.2 Anti-depressants
Anti-depressants, alone and in combination
with other drugs, were implicated in 156
cases. Of these, 67% were known to be
receiving prescribed antidepressants at the
time of their death, compared to 33% who
used drugs that may have been prescribed for
others (PR = 2.0, 95% CI = 1.6 - 2.6).
Anti-depressants alone were implicated in 30
cases. Of these, 75% were known to be
receiving prescribed medication, compared to
25% who had used drugs that may have been
prescribed for others (PR = 4.0, 95% CI = 1.9
- 8.4).
This indicates that those receiving prescribed
anti-depressants were significantly more likely
to have that class of drug implicated in their
death, either in combination or as the sole
drug.
1.3 Other opiates/opioid analgesics
Other opiates/opioid analgesics (e.g.
dihydrocodeine, dextropropoxyphene) alone
and in combination with other drugs, were
implicated in 179 cases. Of these, 64% may
have obtained the drug by other means,
compared to the 36% who were known to be
receiving prescribed opiates/opioid analgesics
prior to their death (PR = 1.8, 95% CI = 1.4 -
2.2).
Other opiates/opioid analgesics alone were
implicated in 36 cases. Of these, the drugs
were known to be prescribed in 47% of cases
and could have been obtained by other
means in 53% of cases.
The risk of fatality from other opiate/opioid
analgesics was equally likely to occur in those
prescribed these drugs and in those who
obtained them from other sources, where it
was the sole substance.
1.4 Hypnotics/sedatives
Hypnotic/sedatives, alone and in combination
with other drugs, were implicated in 149
cases. Of these, 49% were known to be
receiving a prescription for this class of drug,
compared to 51% who could have obtained
them illicitly (PR = 1.1, 95% CI = 0.7 - 1.8).
Seven cases had hypnotic/sedatives alone
implicated in their death, five of whom had
received this drug category via prescription.
2. Gender and underlying cause(s) of
death
Males were more likely than females to die of
accidental poisoning (64% vs. 49%) (PR =
1.3, 95% CI = 1.1 - 1.5). Females, by contrast,
were more likely than males to die of
intentional self-poisoning (22% vs. 10%) (PR
= 2.1, 95% CI = 1.5 - 3.0), and poisoning of
undetermined intent (19% vs. 11%) (PR = 1.7,
95% CI = 1.2 - 2.4).
3. Gender and manner of death
A similar pattern is exhibited with regard to
manner of death. Males were more likely than
females to die an accidental death (73% vs.
59%) (PR = 1.2, 95% CI = 1.1 - 1.4).
Conversely, females were more likely than
males to die a suicidal death (24% vs. 14%)
(PR = 1.7, 95% CI = 1.3 - 2.3), or a death
where the manner was undetermined (14%
vs. 10%) (PR = 1.4, 95% CI = 0.9 - 2.2).
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4. Age and underlying cause(s) of death
Those aged less than 45 years were more
likely than older individuals to die of accidental
poisoning (68% vs. 41%) (PR = 1.7, 95% CI =
1.4 - 2.0). Those aged 45 years or over, by
contrast, were more likely than younger
individuals to die of intentional self-poisoning
(29% vs. 7%) (PR = 4.2, 95% CI = 2.9 - 6.0),
and poisoning of undetermined intent (16%
vs. 12%) (PR = 1.4, 95% CI = 0.9 - 2.0).
5. Age and manner of death
A similar pattern is exhibited with regard to
manner of death. Those aged less than 45
years were more likely than older individuals
to die an accidental death (77% vs. 51%) (PR
= 1.5, 95% CI = 1.3 - 1.7). Conversely, those
aged 45 years or over were more likely than
younger individuals to die a suicidal death
(31% vs. 11%) (PR = 2.1, 95% CI = 2.1 - 3.9),
or a death where the manner was
undetermined (15% vs. 9%) (PR = 1.5, 95%
CI = 1.0 - 2.3).
Table 13: Age and psychoactive drug implicated in death, np-SAD inquests, July–
December 2007
Age group (years) Number (%) Drug category (alone or in combination)
most frequently implicated with age group
Total 774 (100.0) Heroin/morphine (47.8%)
Under 15 0 (0.0) -
15 – 24 80 (10.3) Heroin/morphine (43.8%)
25 – 34 226 (29.2) Heroin/morphine (60.2%)
35 – 44 254 (32.8) Heroin/morphine (52.4%)
45 – 54 125 (16.1) Alcohol-in-combination (46.4%)
55 – 64 60 (7.8) Anti-depressants (45.0%)
65 and over 29 (3.7) Other opiates/opioid analgesics (41.4%)
6. Age and drug implicated in death
The most frequently implicated drugs among
cases aged 44 years and under were opiates,
notably heroin/morphine (46%), methadone
(18%), and other opiates/opioid analgesics
(16%). Alcohol-in-combination (34%) also
featured prominently. Alcohol-in-combination
(39%), anti-depressants (35%), other opiates/
opioid analgesics (35%), heroin/morphine
(31%), and hypnotics/sedatives (21%) were
most frequently implicated in cases aged over
45 years (Table 13).
7. Gender and drug implicated in death
The following substances, alone or in
combination with substances, were implicated
in deaths as below.
Male: heroin/morphine 55%; alcohol-in-
combination 41%; other opiates/opioid
analgesics 21%; methadone 19%; hypnotics/
sedatives 17%; cocaine 16%; and anti-
depressants 13% of cases.
Female: anti-depressants 42%; alcohol-in-
combination 35%; other opiates/opioid
analgesics 30%; heroin/morphine 27%;
hypnotic/sedatives 26%; methadone 20; and
cocaine 12% of cases.
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XIV Drug abuse/dependence
Cases with a history of drug
abuse/dependence (n = 414) were compared
to those without such a history (n = 222) on
the following variables: demography, location
of death, underlying cause(s) and manner of
death. One hundred and eighty-eight cases
(23%) were reported as ’not known’ with
respect to history of drug abuse/dependence.
They were excluded from further analysis.
1. Demography
In comparison with non-drug abusers (NDAs:
62%), drug abusers/dependents (DAs: 81%)
were more likely to be male (PR = 1.3, 95% CI
= 1.2 - 1.5) and more likely to be less than 45
years of age, 82% vs. 52% (PR = 1.6, 95% CI
= 1.4 - 1.8). The median age at death for DAs
was 36.5 years (semi-interquartile range 6.4),
while that for NDAs was 45.7 years (semi-
interquartile range 11.0) (Mann-Whitney U =
30,035.5, p< 0.0005). Similar proportions of
both Das and NDAs lived alone (DAs =
43.5%, NDAs = 42.3%. A higher proportion of
NDAs (53%) than DAs (41%) lived with others
(PR = 1.3, 95% CI = 1.0 – 1.5). DAs (59%)
were more likely than NDAs (38%) to be
unemployed (PR = 1.5, 95% CI = 1.3 – 1.9).
2. Location of death
The majority of both DAs and NDAs died at a
defined residential address, although this
proportion was higher amongst the first group:
DAs = 69%; NDAs = 67% (PR = 1.0, 95% CI
= 0.9 - 1.2). Non drug addicts were more likely
to die in hospital (28%), than drug addicts
(20%) (PR = 1.4, 95% CI = 1.0 - 1.9).
Figure 10: Principal underlying cause(s) of death by drug abuse/dependence history, np-




















Accidental poisoning Intentional self poisoning Undetermined poisoning
3. Underlying cause(s) of death (Figure 10)
DAs were more likely than NDAs to die of
accidental poisoning (74% vs. 40%) (PR =
1.9, 95% CI = 1.6 - 2.0) - Figure 10. NDAs, by
contrast, were more likely than DAs to die of
intentional self-poisoning (30% vs. 4%) (PR =
7.7, 95% CI = 4.6 – 13.0, and poisoning of
undetermined intent (19% vs. 8%) (PR = 2.3,
95% CI = 1.5 - 3.6).
4. Manner of death
A similar pattern is exhibited with regard to
manner of death. DAs were more likely than
DAs to die an accidental death (82% vs. 49%)
(PR = 1.7, 95% CI = 1.5 - 1.9). Conversely,
NDAs were more likely than DAs to die a
suicidal death (34% vs. 7%) (PR = 4.8, 95%
CI = 3.2 - 7.2), or a death where the manner
was undetermined (15% vs. 6%) (PR = 2.5,
95% CI = 1.6 - 4.1).
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XV Commentary
The increase of 12.1% in the number of
inquests notified during this surveillance
period compared to the corresponding one in
2006 probably reflects an actual increase in
inquests into drug-related deaths. The rate of
compliance is similar to that in the previous
year. The average number of inquests and the
overall total for jurisdictions that reported in
both periods increased; this is in line with
reported deaths in 2007 (see the Annual
Report above).
The demographic profile of inquests reported
remains consistent with previous reports. For
the period of this report, the majority of
subjects of these inquests were males (76%),
under the age of 45 years (73%), and White
(94%). Where the information was available,
65% of cases were drug abusers/dependents,
as defined by the Programme.
One aim of the Programme is to provide early
warning through surveillance of high-risk
populations. For the period July to December
2007, Boston & Spalding recorded the highest
semi-annual death rate (10.5/100,000) in
England & Wales, followed by Blackpool & the
Fylde (8.9), and Brighton & Hove (8.5).
Dumbarton had a rate of 12.3.
Previous reports have highlighted areas with
marked changes in semi-annual death rates,
and noted that the validity of those changes
can only be commented on through continued
monitoring. These areas are revisited in this
report as well as newly identified areas where
death rates have fluctuated (Annex SR3).
Jurisdictions that stood out from others in this
report as a result of an increase in the number
of reported cases since the previous
comparable reporting period (July-December
2006) (which led to increased semi-annual
death rates since the previous reporting
period) were: Dumbarton (from 3.1 to 12.3/
100,000 population); Pembrokeshire (1.1 to
6.3); Blackpool & the Fylde (5.5 to 8.9);
Cornwall (1.2 to 4.3); Spilsby & Louth (0.0 to
2.3); Greater Norfolk (0.8 to 3.4);
Northamptonshire (0.8 to 2.8); and Wirral (2.4
to 4.4).
Conversely, the jurisdictions which reported a
marked decline in the number of cases
reported since the previous comparable 6-
month period (which resulted in a decline in
their semi-annual death rates) were:
Hartlepool (from 6.9 to 1.4/100,000
population); Teesside (5.6 to 0.5); Swansea
(5.4 to 1.1); Brighton & Hove (10.8 to 8.5);
Sunderland (3.0 to 0.4); Mid & North
Shropshire (3.2 to 0.6); Isle of Wight (4.3 to
1.7); Southampton & New Forest (5.5 to 3.3);
and East Lancashire 4.2 to 2.1).
Looking at the trends over a longer period, it
can be seen that the mortality rates in Greater
Norfolk have varied from 5.0 to 0.8/100,000
population and now the semi-annual death
rate is 3.4/100,000. In Peterborough rates had
varied between 1.6 and 4.8 and now the rate
is 3.1. In Neath – Port Talbot the rate varied
from 4.5 to 0.9, but is now 1.8. Other areas
demonstrating large variations over the last
six surveillance periods include: South & East
Cumbria; Southend-on-Sea & South East
Essex; the Isle of Wight; East Lancashire;
Teesside; and Wolverhampton; as well as
Dumbarton, Guernsey, Jersey and the Isle of
Man (Annex SR3).
The semi-annual death rate in the East Riding
& Hull fell over the period January-June 2005
to July-December 2007 from 6.0 to 2.1/
100,000 population. Similar declines were
observed in Isle of Man (11.3 to 3.0); South
Manchester (3.5 to 0.5); Southampton & New
Forest (5.6 to 3.3); Hertfordshire (2.5 to 0.4);
East Lancashire (4.7 to 2.1); North
Lincolnshire & Grimsby (3.2 to 1.2); Liverpool
(7.7 to 3.4); North Northumberland (7.4 to
5.3); Western Somerset (3.4 to 1.4); and
Teesside (3.0 to 0.5).
Areas showing increases in semi-annual
death rates over the last six surveillance
periods are: Boston & Spalding (1.8 to 10.5/
100,000 population); Wirral (0.4 to 4.4);
Blackburn, Hyndburn & Ribble Valley (0.0 to
3.7); Bournemouth, Poole & Eastern Dorset
(2.0 to 4.3); North West Wales (0.7 to 3.3);
North & East Cambridgeshire (0.8 to 2.9);
Cornwall (1.9 to 4.3); Derby & South
Derbyshire (1.1 to 3.5); and Dumbarton (9.5 to
12.3).
It should be noted that changes in these rates
might be an artefact of other factors that affect
the way in which inquests are processed, e.g.
prolonged investigations, increased workload,
better identification of relevant cases, etc.
While the pattern of other drug-specific
mortality remains stable, comparisons
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between July to December 2007 and the
same period in 2006 revealed the following
noticeable changes:
- An increase in the proportion of cases
unemployed from 48% to 50%, and a
decrease in the proportion employed from
31% to 29%.
- An increase in the proportion of cases living
with others from 42% to 45%
- An increase in inquests where death was
due to heroin/morphine from 304 to 370
- An increase in the involvement of alcohol in
inquests concerning drug-related deaths
from 230 to 307
- An increase in inquests where
hypnotics/sedatives were implicated in
death from 96 to 149
- An increase in inquests where death was
due to methadone from 108 to 146
- An increase in inquests where death was
due to cocaine from 81 to 118
- An increase in inquests where death was
due to other opiates/opioid analgesics from
154 to 179
As noted in the Annual Report, there has
been evidence of the continuing trend to
polydrug fatalities, and the increasing
involvement of alcohol in such cases.
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Annex SR1: np-SAD cases reported in July-December























and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified





















and psychotropic drugs, not elsewhere classified
Narcotics and psychodysleptics (hallucinogens), not
elsewhere classified
Other drugs acting on the autonomic nervous
system



































Mental & behavioural disorders due to psychoactive
substance use
Chronic alcoholism
Harmful use - cocaine
Intoxication – volatile substances

























Cardiovascular system – diseases, defects or
conditions affecting
Essential (primary) hypertension

























Diseases of the respiratory system
Bronchopneumonia
Adult respiratory distress syndrome













Diseases of the liver
Other & unspecified intestinal obstruction
Alcoholic liver disease
Fatty (change of) liver, not elsewhere specified
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Fracture of skull & facial bones, part unspecified
Head injuries unspecified
Decapitation/traumatic amputation at neck level
Injury of thoracic aorta
Pedestrian injured in collision with 2/3 wheeled
motor vehicle
Driver injured in collision with fixed/stationary object
Car driver injured in non-collision accident












Other accidental hanging and strangulation
Intentional hanging















Aspiration of gastric contents/foreign body in
respiratory tract
Asphyxiation from effects of carbon monoxide
Asphyxiation









































Brain damage, anoxic or hypoxic
Poisoning, other non-steroidal anti-inflammatory
Poisoning, heroin
Poisoning, synthetic opioid analgesic
Hypothermia
Misadventures to patients during surgical & medical
procedures
R99 8 1.0 Unascertained
Where possible, causes of death have been grouped together in terms of the mechanisms of death. At present, although all
causes of death on the death certificate (together with other information if available) are taken into consideration in classifying
underlying cause of death, the principal cause of death is used here by np-SAD to allocate the ICD-10 code. In order to achieve
a greater level of consistency, a hierarchical system was introduced for classifying the underlying cause of death using ICD-10
criteria for deaths involving multiple substances. Deaths that involve a combination of narcotics and other psychoactive drugs are
coded as narcotic deaths. Where possible a code which specifies intentionality is used.
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Annex SR2: np-SAD cases reported in July-December
2007 by coroner’s jurisdiction (No. of cases,
rate per 100,000 population (16 years old
and over) and as a percentage of all
inquests)









Annual % of all
inquests held
in 2007 (2)
Queen's Household 0 0.00 0.00
ENGLAND
AVON 6 0.69 1.03
BEDFORDSHIRE 9 1.90 4.50
BERKSHIRE - - -
BUCKINGHAMSHIRE
Buckinghamshire 10 2.56 6.45
Milton Keynes 5 2.79 3.82
CAMBRIDGESHIRE
North & East Cambridgeshire 4 2.86 7.69
Peterborough 4 3.10 3.92
South & West Cambridgeshire 5 1.44 2.28
CHESHIRE 15 1.84 2.50
CORNWALL
Cornwall 19 4.34 5.03
Isles of Scilly 0 0.00 0.00
CUMBRIA
North & West Cumbria 9 4.06 6.43
South & East Cumbria 1 0.53 0.57
DERBYSHIRE
Derby & South Derbyshire 17 3.52 6.77
North Derbyshire 7 2.13 2.48
DEVON
Exeter & Greater Devon 16 3.29 4.62
Plymouth & South West Devon 6 2.49 2.30
Torbay & South Devon 1 0.50 1.02
DORSET
Bournemouth, Poole & Eastern
Dorset
17 4.25 10.69
Western Dorset 1 0.53 1.22
DURHAM
Darlington & South Durham 1 0.45 1.04
North Durham 2 0.74 1.03
EAST SUSSEX
Brighton & Hove 18 8.48 9.00
East Sussex 4 0.96 1.43
ESSEX
Essex & Thurrock 9 0.82 1.92
Southend & South East Essex 7 2.59 6.25
GLOUCESTERSHIRE - - -
GREATER MANCHESTER
Manchester 12 3.21 2.67
North Manchester 8 1.67 2.41
South Manchester 3 0.53 0.67
West Manchester 7 1.11 1.32
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Central Hampshire 2 0.72 1.08
North East Hampshire 6 1.90 5.41
Portsmouth & South East Hampshire 15 3.28 5.47
Southampton & New Forest 11 3.25 6.15
HEREFORDSHIRE 1 0.68 1.19
HERTFORDSHIRE 3 0.35 0.82
HUMBERSIDE
East Riding & Hull 10 2.07 4.69
ISLE OF WIGHT 2 1.72 2.04
KENT
Central & South East Kent 9 3.39 6.08
Mid Kent & Medway 2 0.48 0.93
North East Kent - - -
North West Kent - - -
LANCASHIRE
Blackburn, Hyndburn & Ribble Valley 8 3.66 3.45
Blackpool & the Fylde 16 8.85 11.11
East Lancashire 4 2.06 2.58
Preston & West Lancashire 12 2.07 2.78
LEICESTERSHIRE
Leicester City & South Leicestershire 2 0.48 0.37
Rutland & North Leicestershire 1 0.27 0.91
LINCOLNSHIRE
Boston & Spalding 9 10.46 13.85
North Lincolnshire & Grimsby 3 1.17 2.65
Spilsby & Louth 3 2.31 6.12
Stamford 1 0.94 3.23
West Lincolnshire 8 3.66 7.84
LONDON
City of London 0 0.00 0.00
Eastern London 11 1.25 3.21
Inner North London 28 4.08 5.22
Inner South London 30 3.60 5.99
Inner West London 6 0.80 1.46
Northern London 17 1.60 4.30
Southern London 9 1.08 3.09
Western London 33 3.17 8.29
MERSEYSIDE
Knowsley, St Helens & Sefton 3 0.61 1.33
Liverpool 12 3.35 2.49
Wirral 11 4.38 3.83
NORFOLK
Greater Norfolk 21 3.39 5.74
Great Yarmouth - - -
NORTHAMPTONSHIRE 15 2.76 6.41
NORTHUMBERLAND
North Northumberland 6 5.25 3.70
South Northumberland - - -
NORTH YORKSHIRE
North Yorkshire Eastern 3 1.48 2.26
North Yorkshire Western 1 0.70 0.88
York - - -
NOTTINGHAMSHIRE - - -
OXFORDSHIRE 6 1.16 1.66
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Mid & North Shropshire 1 0.62 1.01
South Shropshire 0 0.00 0.00
The Wrekin 3 2.34 4.41
SOMERSET
Eastern Somerset 2 0.92 1.87
Western Somerset 3 1.43 2.21
SOUTH YORKSHIRE
South Yorkshire East 6 1.37 1.91
South Yorkshire West 14 2.27 3.13
STAFFORDSHIRE
South Staffordshire 10 2.03 3.40
Stoke-on-Trent & North Staffordshire 10 2.66 2.28
SUFFOLK 14 2.43 5.07
SURREY 14 1.58 3.95
TEESSIDE
Hartlepool 1 1.37 1.75
Teesside 2 0.53 0.65
TYNE & WEAR
Gateshead & South Tyneside - - -
Newcastle-upon-Tyne - - -
North Tyneside - - -
Sunderland 1 0.44 0.35
WARWICKSHIRE 4 0.93 1.87
WEST MIDLANDS
Birmingham 10 1.05 1.04
Black Country 4 0.59 1.32
Coventry 3 1.22 1.47
Wolverhampton 0 0.00 0.00
WEST SUSSEX 18 2.84 6.14
West YORKSHIRE
West Yorkshire Eastern 25 2.82 5.02
West Yorkshire Western 21 2.43 5.20
WILTSHIRE 3 0.58 1.08
WORCESTERSHIRE 4 0.88 1.52
WALES
Bridgend & Glamorgan Valleys 8 2.34 2.42
Cardiff & the Vale of Glamorgan 4 1.11 0.74
Carmarthenshire 2 1.37 2.63
Central North Wales - - -
Ceredigion 0 0.00 0.00
Gwent 7 1.55 5.15
Neath & Port Talbot 2 1.78 3.45
North East Wales - - -
North West Wales 5 3.26 3.79
Pembrokeshire 6 6.28 8.96
Powys 0 0.00 0.00
Swansea 2 1.07 1.28
NORTHERN IRELAND
Northern Ireland 39 2.83 -
THE ISLANDS
GUERNSEY 0 0.00 0.00
JERSEY 2 2.68 4.76
ISLE OF MAN 2 3.02 10.00
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Dumbarton 12 12.33 -
Please note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no
reports were submitted for the specific period from that jurisdiction. In subsequent reports these rates may increase as
more inquests on deaths in 2007 are held and/or notified to the np-SAD. These rates should therefore be regarded as
minimum rates.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 23 of the coroners' jurisdictions
in England and Wales, as well as the area covered by the Procurators Fiscal region in Dumbarton, are not co-
terminous with these boundaries and cover parts of such areas (see Appendix 1). Where administrative areas
are split between jurisdictions, the estimated population has been divided into two or three as applicable.
However, this means that the population of some coroners' jurisdictions may be either over- or under-
estimated. It is necessary to make such assumptions until more accurate figures can be obtained or
calculated.
(2) Inquests held on all ages.
(3) The following amalgamations of coroner’s jurisdictions took place during the period covered by this report: In
Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in Cumbria, the
three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to form two
new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Annex SR3: Changes in semi-annual death rate per
100,000 population for np-SAD cases,
2005-2007 (16 years old and over)




















Queen's Household 0.00 0.00 0.00 0.00 0.00 0.00
ENGLAND
AVON 1.33 0.85 0.60 1.09 0.92 0.69
BEDFORDSHIRE 2.20 2.64 3.04 1.96 2.56 1.90
BERKSHIRE - 0.00 0.15 - - -
BUCKINGHAMSHIRE
Buckinghamshire 2.90 1.85 0.79 1.57 2.05 2.56
Milton Keynes 1.17 3.54 1.13 2.92 1.11 2.79
CAMBRIDGESHIRE
North & East Cambridgeshire 0.76 5.31 1.49 1.49 2.86 2.86
Peterborough 1.60 2.39 0.79 4.77 4.64 3.10
South & West Cambridgeshire 1.19 0.00 0.58 0.29 0.86 1.44
CHESHIRE 1.50 2.38 2.62 1.87 1.72 1.84
CORNWALL
Cornwall 1.88 0.94 0.00 1.17 4.11 4.34
Isles of Scilly 0.00 0.00 0.00 0.00 0.00 0.00
CUMBRIA
North & West Cumbria 1.34 2.68 3.18 4.54 3.61 4.06
South & East Cumbria 0.54 1.62 2.12 1.59 1.59 0.53
DERBYSHIRE
Derby & South Derbyshire 1.07 2.78 1.28 1.28 2.28 3.52
North Derbyshire 2.80 2.49 3.71 2.78 1.22 2.13
DEVON
Exeter & Greater Devon 3.97 5.01 3.72 3.10 2.58 3.29
Plymouth & South West Devon - - 2.52 3.36 4.56 2.49
Torbay & South Devon 1.03 2.57 1.02 1.54 1.51 0.50
DORSET
Bournemouth, Poole & Eastern
Dorset
2.02 1.52 3.28 3.78 3.50 4.25
Western Dorset - 1.08 3.74 0.54 2.64 0.53
DURHAM
Darlington & South Durham 1.36 1.81 0.90 0.45 0.45 0.45
North Durham 0.38 0.76 1.50 2.23 1.47 0.74
EAST SUSSEX
Brighton & Hove 9.37 10.78 7.97 10.78 9.89 8.48
East Sussex 2.72 0.74 2.46 1.97 3.36 0.96
ESSEX
Essex & Thurrock 1.05 0.48 0.38 0.57 0.91 0.82
Southend & South East Essex 0.76 3.05 2.66 1.90 2.95 2.59
GLOUCESTERSHIRE 0.21 1.07 1.70 1.50 - -
GREATER MANCHESTER
Manchester - 0.28 3.08 1.40 2.68 3.21
North Manchester 1.26 1.47 0.84 1.26 1.25 1.67
South Manchester 3.51 2.98 1.40 2.28 1.40 0.53
West Manchester 0.95 0.48 0.16 3.01 0.16 1.11
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Central Hampshire 1.47 2.58 1.09 1.45 0.72 0.72
North East Hampshire 1.95 1.95 0.97 2.26 0.32 1.90
Portsmouth & South East
Hampshire
1.80 3.15 3.38 1.80 2.20 3.28
Southampton & New Forest 5.56 2.78 3.69 5.53 0.30 3.25
HEREFORDSHIRE 2.05 1.38 0.68 0.00 0.00 0.68
HERTFORDSHIRE 2.53 1.57 1.20 1.44 1.17 0.35
HUMBERSIDE
East Riding & Hull 6.02 2.80 2.77 1.71 0.83 2.07
ISLE OF WIGHT 0.00 2.63 2.59 4.31 3.45 1.72
KENT
Central & South East Kent 1.55 0.78 3.06 2.30 3.39 3.39
Mid Kent & Medway 2.40 2.40 0.49 2.20 1.93 0.48
North East Kent - - - - - -
North West Kent - - - - - -
LANCASHIRE
Blackburn, Hyndburn & Ribble
Valley
0.00 4.19 2.79 2.79 3.66 3.66
Blackpool & the Fylde 7.76 5.01 9.42 5.54 8.30 8.85
East Lancashire 4.71 5.24 6.19 4.18 4.62 2.06
Preston & West Lancashire 0.36 0.36 1.06 1.06 1.21 2.07
LEICESTERSHIRE
Leicester City & South
Leicestershire
- - 1.22 1.20 0.95 0.48
Rutland & North Leicestershire 1.14 0.28 0.28 1.40 0.82 0.27
LINCOLNSHIRE
Boston & Spalding 1.75 1.75 - - 1.16 10.46
North Lincolnshire & Grimsby 3.17 1.99 0.79 0.00 0.00 1.17
Spilsby & Louth 0.79 0.00 0.79 0.00 2.31 2.31
Stamford 0.00 0.00 0.00 0.00 0.00 0.94
West Lincolnshire 3.35 3.35 1.42 2.83 4.12 3.66
LONDON
City of London - 0.00 0.00 0.00 0.00 0.00
Eastern London 0.69 1.27 2.40 1.60 0.57 1.25
Inner North London 4.18 3.88 2.66 3.13 3.49 4.08
Inner South London 2.13 4.34 5.58 1.98 2.76 3.60
Inner West London 0.94 0.67 0.13 - 0.66 0.80
Northern London 2.19 2.48 2.08 1.04 2.17 1.60
Southern London 0.97 1.45 0.48 1.44 0.48 1.08
Western London 5.08 4.70 3.08 3.17 4.51 3.17
MERSEYSIDE
Knowsley, St Helens & Sefton 2.47 2.46 2.05 1.64 1.02 0.61
Liverpool 7.74 4.70 3.82 4.10 2.79 3.35
Wirral 0.40 3.18 2.38 2.38 1.59 4.38
NORFOLK
Greater Norfolk 4.96 2.15 2.12 0.82 0.97 3.39
Great Yarmouth - - - - - -
NORTHAMPTONSHIRE 2.89 1.56 2.12 0.77 2.21 2.76
NORTHUMBERLAND
North Northumberland 7.38 4.22 5.29 4.22 6.30 5.25
South Northumberland 0.62 - - - - -
NORTH YORKSHIRE
North Yorkshire Eastern 1.50 1.00 1.00 0.00 0.49 1.48
North Yorkshire Western 0.37 2.58 0.74 1.47 0.00 0.88
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York 4.49 2.60 1.28 - - -
NOTTINGHAMSHIRE 0.83 0.83 0.47 0.24 0.34 -
OXFORDSHIRE 1.18 1.77 1.18 0.20 0.97 1.16
SHROPSHIRE
Mid & North Shropshire 2.54 2.54 1.27 3.17 0.62 0.62
South Shropshire 1.28 0.00 0.00 0.00 - 0.00
The Wrekin 0.79 1.58 2.36 1.57 0.00 2.34
SOMERSET
Eastern Somerset 0.95 1.42 0.47 0.00 1.84 0.92
Western Somerset 3.43 1.47 2.43 1.46 1.43 1.43
SOUTH YORKSHIRE
South Yorkshire East 1.61 1.16 2.76 2.07 2.28 1.37
South Yorkshire West 2.98 3.18 3.97 3.31 2.43 2.27
STAFFORDSHIRE
South Staffordshire 1.24 0.83 1.24 0.62 0.81 2.03
Stoke-on-Trent & North
Staffordshire
2.16 2.16 2.15 1.40 3.19 2.66
SUFFOLK 2.86 2.50 0.54 1.07 2.77 2.43
SURREY 0.35 1.16 0.81 1.27 1.35 1.58
TEESSIDE
Hartlepool - 2.81 5.52 6.91 5.47 1.37
Teesside 2.98 5.41 3.79 5.60 3.72 0.53
TYNE & WEAR
Gateshead & South Tyneside 2.86 1.43 1.07 3.22 0.71 -
Newcastle-upon-Tyne 7.01 3.50 3.13 5.25 4.00 -
North Tyneside 0.64 - - - 0.62 -
Sunderland 1.73 0.87 3.49 3.03 1.74 0.44
WARWICKSHIRE 0.92 - 1.61 0.46 2.10 0.93
WEST MIDLANDS
Birmingham 2.03 1.29 0.11 2.77 2.31 1.05
Black Country 0.59 0.90 0.59 1.04 0.89 0.59
Coventry 0.41 0.41 2.03 2.05 0.81 1.22
Wolverhampton 1.04 4.16 1.56 1.56 3.16 0.00
WEST SUSSEX 2.57 2.43 1.91 2.55 2.21 2.84
WEST YORKSHIRE
West Yorkshire Eastern 2.98 3.19 3.19 2.95 3.27 2.82
West Yorkshire Western 2.27 2.39 0.95 1.66 2.66 2.43
WILTSHIRE 1.20 1.00 0.59 0.20 0.19 0.58




1.50 2.69 1.79 2.69 1.75 2.34
Cardiff & the Vale of
Glamorgan
- - 0.84 0.28 0.28 1.11
Carmarthenshire 2.08 0.69 3.45 0.69 0.00 1.37
Central North Wales - - - - - -
Ceredigion - 3.07 6.18 1.52 0.00 0.00
Gwent 1.36 0.90 0.23 1.35 0.22 1.55
Neath & Port Talbot 4.54 3.63 0.91 3.64 2.68 1.78
North East Wales - - - - - -
North West Wales 0.66 3.30 3.93 3.94 2.61 3.26
Pembrokeshire - 1.06 2.11 1.06 1.05 6.28
Powys - 1.88 0.93 0.00 0.92 0.00
Swansea - - - 5.40 2.66 1.07
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Northern Ireland - - 0.00 2.47 2.83
THE ISLANDS
GUERNSEY 0.00 6.13 0.00 0.00 0.00 0.00
JERSEY 0.00 4.17 1.39 4.10 10.74 2.68
ISLE OF MAN 11.32 0.00 0.00 1.53 3.02 3.02
SCOTLAND
ARGYLL & CLYDE
Dumbarton 9.49 0.00 4.12 3.09 5.14 12.33
* Constituent areas have not reported consistently for every period
Please note that (0) refers to either no drug-related deaths or death rates of less than 0.01, whilst (–) indicates that no
reports were submitted for the specific period from that jurisdiction. In subsequent reports these rates may increase if
more inquests on deaths are notified to the np-SAD after the preparation of the reports. These rates should be regarded
as minimum rates.
(1) The rate per 100,000 population is based on published mid-year population estimates for local government
administrative areas for the years in question. However, the areas covered by 20 of the coroners' jurisdictions
in England and Wales, as well as the area covered by the Procurators Fiscal region in Dumbarton, are not co-
terminous with these boundaries and cover parts of such areas (see Appendix 1). Where administrative areas
are split between jurisdictions, the estimated population has been divided into two or three as applicable.
However, this means that the population of some coroners' jurisdictions may be either over- or under-
estimated. It is necessary to make such assumptions until more accurate figures can be obtained or
calculated.
(2) These rates are based on the number of inquests reported to the np-SAD during the relevant 6-month period.
They do not, therefore, reflect the workload of the coroners in terms of the number of drug-related death
inquests held in these periods. Furthermore, details of additional inquests held in these periods may be
subsequently notified to the np-SAD.
(3) The following amalgamations of coroner’s jurisdictions took place during the period covered by this report: In
Norfolk, King’s Lynn and Norwich & Central Norfolk to form Greater Norfolk (6 April 2007); in Cumbria, the
three jurisdictions of North East Cumbria, Southern Cumbria & Furness, and Western Cumbria to form two
new areas - North & West Cumbria and South & East Cumbria (1 May 2007).
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Annex SR4: np-SAD cases in July-December 2007 by
Drug and (Alcohol) Action Team area (16
years and over)
Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
ENGLAND
NORTH EAST
County Durham 3 0.72 3 0.72
Darlington 0 0.00 0 0.00
Gateshead - - - -
Hartlepool 1 1.37 1 1.37
Middlesbrough 0 0.00 0 0.00
Newcastle-upon-Tyne* 1 0.44 1 0.44
North Tyneside - - - -
Northumberland 4 1.56 5 1.95
Redcar and Cleveland 2 1.77 2 1.77
South Tyneside - - - -
Stockton on Tees 0 0.00 0 0.00
Sunderland 1 0.44 1 0.44
NORTH WEST
Blackburn with Darwen 6 5.63 6 5.63
Blackpool 13 11.17 13 11.17
Bolton 3 1.45 2 0.96
Bury 2 1.37 2 1.37
Cheshire 6 1.07 8 1.42
Cumbria 10 2.44 10 2.44
Halton 4 4.21 4 4.21
Knowsley 1 0.83 1 0.83
Lancashire 20 2.11 21 2.21
Liverpool 11 3.07 12 3.35
Manchester 11 2.94 13 3.48
Oldham 1 0.58 2 1.17
Rochdale 5 3.08 4 2.46
Salford 1 0.56 0 0.00
Sefton 2 0.88 1 0.44
St Helens 1 0.70 1 0.70
Stockport 0 0.00 0 0.00
Tameside 2 1.16 2 1.16
Trafford 1 0.59 3 1.76
Warrington 3 1.91 3 1.91
Wigan 4 1.62 5 2.02
Wirral 11 4.38 11 4.38
YORKSHIRE AND HUMBER
Barnsley 4 2.20 4 2.20
Bradford 8 2.08 12 3.11
Calderdale 2 1.25 0 0.00
Doncaster 5 2.13 6 2.56
East Riding of Yorkshire 2 0.73 2 0.73
Kingston-upon-Hull 6 2.88 8 3.83
Kirklees 10 3.14 10 3.14
Leeds 15 2.39 11 1.76
North East Lincolnshire 0 0.00 0 0.00
North Lincolnshire 3 2.32 3 2.32
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
North Yorkshire* 4 0.82 3 0.61
Rotherham 1 0.49 1 0.49
Sheffield 10 2.29 10 2.29
Wakefield 10 3.83 13 4.98
York - - - -
EAST MIDLANDS
Derby 9 4.70 10 5.23
Derbyshire 15 2.42 13 2.10
Leicester* 2 0.86 2 0.86
Leicestershire 2 0.38 1 0.19
Lincolnshire 22 3.86 20 3.51
Northamptonshire 14 2.57 15 2.76
Nottingham - - - -
Nottinghamshire - - - -
Rutland 0 0.00 0 0.00
WEST MIDLANDS
Birmingham 11 1.40 11 1.40
Coventry 3 1.22 3 1.22
Dudley 2 0.81 2 0.81
Herefordshire 1 0.68 1 0.68
Sandwell 1 0.44 1 0.44
Shropshire 1 0.42 1 0.42
Solihull 0 0.00 0 0.00
Staffordshire 14 2.07 13 1.92
Stoke-on-Trent 8 4.13 7 3.62
Telford and Wrekin 3 2.34 3 2.34
Walsall 1 0.50 1 0.50
Warwickshire 5 1.17 4 0.93
Wolverhampton 0 0.00 0 0.00
Worcestershire 3 0.66 2 0.44
EAST
Bedfordshire 5 1.53 4 1.23
Cambridgeshire 9 1.85 9 1.85
Essex 12 1.08 9 0.81
Hertfordshire 4 0.47 3 0.35
Luton 3 2.04 5 3.40
Norfolk* 23 3.30 21 3.01
Peterborough 2 1.55 4 3.10
Southend-on-Sea 3 2.29 5 3.82
Suffolk 12 2.08 14 2.43
Thurrock 1 0.85 1 0.85
LONDON
Inner London
Camden 9 4.60 9 4.60
City of London 0 0.00 0 0.00
Hackney 4 2.45 4 2.45
Hammersmith and Fulham 7 4.84 7 4.84
Haringey 8 4.42 4 2.21
Islington 8 5.09 11 7.00
Kensington and Chelsea 2 1.33 1 0.66
Lambeth 8 3.56 11 4.90
Lewisham 5 2.41 4 1.93
Newham* 2 1.05 3 1.58
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Drug and Alcohol Action Team Number and annual
death rate per 100,000
population – usual area
of residence
Number and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Southwark 3 1.33 6 2.67
Tower Hamlets 5 2.92 6 3.51
Wandsworth 0 0.00 1 0.42
Westminster 4 1.97 5 2.46
Outer London
Barking and Dagenham* 2 1.58 1 0.79
Barnet 6 2.29 6 2.29
Bexley 2 1.13 1 0.56
Brent 1 0.46 7 3.20
Bromley 3 1.24 3 1.24
Croydon 4 1.49 5 1.86
Ealing 2 0.81 2 0.81
Enfield 4 1.78 6 2.67
Greenwich 4 2.27 7 3.97
Harrow 1 0.58 2 1.16
Havering* 2 1.08 1 0.54
Hillingdon 7 3.51 8 4.02
Hounslow 8 4.51 9 5.08
Kingston-upon-Thames 3 2.32 4 3.10
Merton 0 0.00 0 0.00
Redbridge 2 1.00 2 1.00
Richmond-upon-Thames 4 2.76 3 2.07
Sutton 0 0.00 0 0.00
Waltham Forest* 2 1.14 4 2.29
SOUTH EAST
Bracknell Forest* - - - -
Brighton and Hove 18 8.48 17 8.01
Buckinghamshire 9 2.31 10 2.56
East Sussex 4 0.96 4 0.96
Hampshire 22 2.13 17 1.64
Isle of Wight 2 1.72 2 1.72
Kent* 10 0.89 10 0.89
Medway towns 2 1.00 1 0.50
Milton Keynes 5 2.79 5 2.79
Oxfordshire 5 0.97 6 1.16
Portsmouth 4 2.44 7 4.28
Reading* - - - -
Slough* - - - -
Southampton 8 4.15 10 5.18
Surrey 13 1.47 14 1.58
West Berkshire* 1 0.84 - -
West Sussex 22 3.48 18 2.84
Windsor and Maidenhead* - - - -
Wokingham* 1 0.80 - -
SOUTH WEST
Bath and North East Somerset 1 0.68 3 2.03
Bournemouth 10 7.27 13 9.46
Bristol 3 0.87 2 0.58
Cornwall & Isles of Scilly 18 4.09 18 4.09
Devon 14 2.25 14 2.25
Dorset 5 1.48 1 0.30
Gloucestershire* - - - -
North Somerset 1 0.60 1 0.60
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Drug and Alcohol Action Team National and annual
death rate per 100,000
population – usual area
of residence
National and annual
death rate per 100,000
population – place of
death
No Rate No Rate
Plymouth 7 3.39 7 3.39
Poole 2 1.76 3 2.64
Somerset 6 8.00 5 1.17
South Gloucestershire 0 0.00 1 0.48
Swindon 1 0.66 1 0.66
Torbay 1 0.90 1 0.90
Wiltshire 2 0.55 2 0.55
WALES
Bro Taf 9 1.52 7 1.18
Dyfed Powys 5 1.20 0.5 0.12
Gwent 7 1.55 7 1.55
Iechyd Morgannwg 5 1.22 5 1.22
North Wales 6 1.08 5 0.90
NORTHERN IRELAND
Eastern 15 2.80 15 2.80
Northern 9 2.55 11 3.11
Southern 7 2.66 7 2.66
Western 6 2.64 6 2.64
THE ISLANDS
GUERNSEY 0 0.00 0 0.00
JERSEY 2 3.02 2 3.02
ISLE OF MAN 2 2.68 2 2.68
Note: In addition there were a number of cases that could not be allocated to specific DA(A)T
areas because they were of no fixed abode and/or the jurisdiction in which the inquest was held
covers more than one DA(A)T. Some DA(A)Ts are covered by coroner’s jurisdictions that did not
submit information to the np-SAD; they are marked thus - *.
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Annex SR5: Profile of cases meeting criteria for
monitoring the UK Drug Strategy, July -
December 2007
Introduction
This annex has been compiled at the request
of the Department of Health to enable them to
monitor progress against the UK Drug
Strategy target for reducing drug-related
deaths. Whilst the official target is being
measured by reference to figures compiled by
the Office for National Statistics (ONS),
information generated by cases notified by
coroners to the np-SAD can complement their
data.
Definition of cases
The definition of a drug-related death adopted
for the UK Drug Strategy is somewhat
narrower than that for an np-SAD case (see
Section II above). It is possible to derive
information on this narrower basis by
operationalising the np-SAD case definition
using the method described below. The np-
SAD approach is to exclude two specific
categories from its case definition; those
remaining are regarded as meeting the criteria
for the UK government definition. The two
categories excluded from the np-SAD cases
are; (a) deaths of non-drug abusers where no
Controlled Drugs were found at post mortem
or where a specific compound analgesics was
found at post mortem; and (b) deaths of drug
abusers where no Controlled Drugs were
found at post mortem or where a specific
compound analgesics was found at post
mortem and the mechanism of death was
hanging, drowning, accident, etc.
For the purposes of this annex, the np-SAD
has closely followed the same approach as
the Office for National Statistics and the
General Register Office for Scotland in
respect of the compound analgesics not
treated as Controlled Drugs, the exception
being that of codeine. This cannot be
excluded from our consideration because it is
a by-product of the degeneration of heroin in
the body and thus may represent the
consumption of heroin rather than codeine.
This will not have affected many cases.
Profile of cases
The following analysis looks at inquests held
in the second half of 2007 for deaths in
England and Wales which meet the above
selection criteria (652/824 or 79.1% of all np-
SAD cases reported on here). Demographic
details and a summary of principal drugs
implicated in death are presented below.
1. Demography
The majority of cases were male (80%). The
median age at death was 36.5 years (semi-
inter quartile range = 7.4), with about three-
quarters (78%) being under the age of 45
years. Where ethnicity was known, the vast
majority (92.6%) were White. Where addict
status was known, the majority (71.6%) had a
history of drug-dependence or abuse. Just
over half (51%) of cases were unemployed
and 43% of cases were living alone and a
similar proportion living with others at the time
of their death (Table SR5.1).
3. Location of death
The majority of cases (65%) died at a defined
residential address (e.g. the deceased’s home
address or other private residential address),
just under one-fifth (21%) died in hospital and
the remainder (14%) died elsewhere (e.g. in a
public place).
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Table SR5.1: Demographic variables for inquests reported to np-SAD meeting the criteria
for monitoring the UK Drug Strategy, England & Wales, July – December 2007
Variable Category Number (%)
Total 652 (100.0)
Gender Male 522 (80.1)
Female 130 (19.9)
Employment status Unemployed 335 (51.4)
Employed 197 (30.2)




Not known 48 (7.4)
Living arrangements Alone 282 (43.3)
With others 283 (43.4)
No fixed abode 33 (5.1)
Other 27 (4.1)
Not known 27 (4.1)
3. Substances implicated in death
Psychoactive substances were implicated in
623/652 deaths (95.6%). The principal
substances implicated in drug-related deaths
were: heroin/morphine (54%) and alcohol in
combination with other drugs (37%). Other
classes of drugs making a sizeable
contribution to deaths were: other methadone
(22%); opiates/opioid analgesics (20%);
hypnotics/sedatives (18%); cocaine (17%);
and anti-depressants (12%). Heroin/ morphine
as the sole implicated drug accounted for 17%
of deaths. The breakdown of psychoactive
substances implicated in death is presented in
Table SR5.2.
Table SR5.2: Psychoactive substances implicated in death for inquests reported to np-
SAD meeting the criteria for monitoring the UK Drug Strategy, England & Wales,
July – December 2007
Drug category Number of cases where no
other substance was
implicated
Number of cases where
drug was implicated
No. (%) No. (%)
Total of cases with
psychoactive drug implicated
623 (100.0) 623 (100.0)
Alcohol-in-combination(1) - 241 (37.0)
Amphetamines 4 (0.6) 23 (3.5)
Anti-depressants 4 (0.6) 81 (12.4)
Anti-epileptics 0 (0.0) 6 (0.9)
Anti-psychotics 0 (0.0) 10 (1.5)
Cannabis 3 (0.5) 24 (3.7)
Cocaine 25 (3.8) 111 (17.0)
Ecstasy-type drugs 6 (0.9) 20 (3.1)
GHB 1 (0.2) 3 (0.5)
Heroin/morphine 112 (17.2) 350 (53.7)
Hypnotic/sedatives 6 (0.9) 114 (17.5)
Methadone 27 (4.1) 145 (22.2)
Other opiates/opioid
analgesics
22 (3.4) 129 (19.8)
(1) Alcohol on its own does not meet the criteria for an np-SAD case.
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4. Age and drug implicated in death
In cases aged 15-44 years, heroin/morphine
(56.8%) was the most frequently mentioned
drug contributing to fatality. In those aged 45
years and over, heroin/morphine (42.9%),
alcohol-in-combination (38.1%), and other
opiates/opioid analgesics (35.4%) were the
most frequently mentioned as being
implicated (Table SR5.3).
Table SR5.3: Age and drug implicated in deaths for inquests reported to np-SAD meeting






Drug category (alone or in combination) most
frequently implicated in each age group
All ages 623 (100.0) Heroin/morphine (53.7%)
14 & under 0 (0.0) -
15–24 68 (10.8) Heroin/morphine (45.6%)
25-34 200 (32.1) Heroin/morphine (66.0%)
35-44 210 (33.4) Heroin/morphine (59.0%)
45-54 95 (15.2) Heroin/morphine (53.7%)
55-64 33 (5.3) Other opiates/opioid analgesics (35.3%)
Alcohol-in-combination (35.3%)
65 & over 17 (2.7) Other opiates/opioid analgesics (52.9%)
5. Underlying cause(s) of death
The proportions of ICD-10 categories of
underlying cause of death were as follows:
 Accidental poisoning (X40-X47): 68.1%
 Intentional self-poisoning (X60-X67):
9.4%
 Poisonings of undetermined intent (Y10-
Y14): 9.5%
 Other (e.g. natural causes, drowning,
hanging, unascertained): 13.0%
6. Manner of death
The manner of death in these cases was






 Unclassified/not specified: 0.5%
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np-SAD
International Centre for Drug Policy97
Appendix 1: The national programme on Substance
Abuse Deaths (np-SAD)
Aims and objectives
The Programme’s principal aim is to reduce
and prevent drug-related deaths in the UK
due to the misuse of drugs, both licit and
illicit, by collecting, analysing and
disseminating information on the extent and
nature of death. The Programme offers a
comprehensive prevention package to Drug
(and Alcohol) Action Teams (D(A)ATs),
Primary Care Trusts (PCTs) and Strategic
Health Authorities (SHAs) with a mission to
tackle the problem of drug-related deaths.
The Programme’s objectives are to:
 Collect and collate drug-related mortality
data
 Develop and maintain a computerised
surveillance system
 Identify substances implicated in drug-
related deaths – including new drugs and
new combinations
 Monitor and examine patterns and
trends, e.g. geographic, demographic,
substances implicated in death, method
of death
 Act as an early warning system for new
trends in mortality and drug misuse
 Use data as an indicator to estimate the
prevalence of substance-related
problems and assess the hazards
associated with substance abuse
 Collaborate with relevant agencies in
research on substance-related mortality
locally, nationally and internationally
 Inform and facilitate discussion on the
prevention of drug-related deaths,
whether accidental or intentional
 Provide data for local and national drug
abuse policy formulation and programme
planning
 Disseminate information on drug-related
mortality to the scientific community,
clinicians, policy makers and other
interested parties
np-SAD database
The Coroners Drug-Related Deaths
Database was established in conjunction
with the Home Office, who lead on the UK
Government’s drug strategy, following the
closure of the national UK Addicts Index.
The purpose of the database is to provide
information for the management of a national
surveillance system to monitor drug-related
deaths reported by coroners and procurators
fiscal. Data are sent to the np-SAD on a
standard reporting form (see below).
Surveillance data management
Data collection
All coroners in the UK (see Appendix 1) are
issued with copies of the standard data
collection form (see Appendix 2). They are
invited to complete the forms on all deaths
that meet the criteria described in this report
and return them to the np-SAD at the ICDP
office at St. George’s, University of London for
coding and entry onto the database.
Data submission is mostly directly on paper
by coroners or their staff. There is also
manual completion of the np-SAD data
collection form or print-out of completed
computer-generated forms using bespoke
software. Forms are submitted when inquests
are complete – either singly or in batches.
Some data are received electronically. Manual
extraction of data by team members is
undertaken at some coroners’ courts – mostly
in London.
Data entry and coding
A great deal of consideration was given to the
area of data coding to ensure that comparison
with other databases was possible and that
the final analyses would be useful to readers.
For example, all cases were coded for area of
residence of the deceased. Causes of death
(immediate and underlying) are re-coded
according to ICD-10. All drugs (i.e. those
implicated in the death) are coded separately




Due to the nature of the information collected
by the programme, i.e. drug-related deaths as
reported by the coroners, this is an
observational study. Hence, statistical
methods employed are based on proportions
and ratios. Where the data include proportions
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of incidence for particular groups of interest,
the ratio of the proportions forms a measure
of the relative risk in one group compared
with that of another. These scales of
measurement are generally known as point
estimates. Although point estimates can be
calculated they do not represent the ‘true’
values. Each point estimate is subject to
random variation. Confidence intervals (CI)
provide an indication of the range in the true
values for the population as a whole, which
would be expected in future investigations.
The methods used for quantitative data relied
mainly on complex assumptions of
distributional form. It may be the case that
the assumptions are not always satisfied. In
such cases, methods known as distribution-
free methods can be applied, also known as
non-parametric tests (e.g. Mann-Whitney).
The data were analysed using SPSS™ for
Windows version 15.
Data storage
The anonymised data-set for coroners is held
on a SPSS database for analysis. All data
held, whether electronic or paper, is stored
securely and treated as confidential. Access
is restricted to Programme staff; only
aggregated and anonymised data are
released to third parties.
What is an np-SAD case?
An np-SAD case is defined as a relevant
death where any of the following criteria are
met at a completed inquest, fatal accident
inquiry or similar investigation:
 One or more psychoactive substances*
directly** implicated in death;
 History of dependence or abuse of
psychoactive drugs;
 Presence of Controlled Drugs*** at post
mortem; or
 Cases of deaths directly due to drugs
but with no inquest.
Deaths where solvents and other volatile
substances are implicated alone are NOT
included. Information on this is collected by
the Department of Community Health
Sciences at St. George’s, University of
London; further information can be seen at
http://www.vsareport.org. Alcohol is included
only when implicated in combination with
other qualifying drugs.
* ‘Psychoactive’ substances are those having
a direct effect on perception, mood,
cognition, behaviour or motor function.
Typically these include opiates and opioid
analgesics, hypnotics, sedatives, anti-
depressants, anti-epileptics, anti-psychotics,
hallucinogens and stimulants such as
amphetamines and cocaine.
** ‘Directly implicated’ means that drugs were
considered by the coroner or other person
investigating the death to have been
instrumental in the coming about of the
deceased’s death (e.g. through poisoning or
intoxication), or causing their powers of
reasoning and/or perception to be so affected
as to induce them to take risks which they
would not have done had they been sober
(e.g. thinking they could fly).
*** ‘Controlled Drugs’ are those drugs
specifically classified by the Misuse of Drugs
Act 1971 as amended by subsequent
legislation. Controlled drugs include opioids,
cocaine, amphetamines, cannabis, GHB,
hallucinogens and most benzodiazepines.
Who is a drug abuser/dependent?
A drug abuser/dependent case is defined as
one with a history of substance abuse where
one or more of the following criteria are met:
 Reported as a known illicit drug user by
the coroner, based on evidence obtained
at inquest;
 Prescribed substitute medication for drug
dependence;
 Presence of an illicit drug at post mortem,
where not prescribed; or
 Presence of any additional information on
the coroner’s report suggestive of a
history of drug abuse, and where such a
history fulfils ICD-10 criteria: (F11-F16
and F19, using the 4-code subdivisions
of .0 (acute intoxication), .1 (harmful
use), and .2 (dependence syndrome).
Other activities and resources
The np-SAD team also conduct in-depth
psychological autopsies on individual cases
and carry out confidential inquiry exercises on
request. The team also provides analysis of
data for specific Drug and Alcohol Action
Teams (DAATs), Primary Care Trusts (PCTs)
and (Special Health Authorities) SHAs on
request.
As a consequence of the work to date,
information on the trends and patterns of
death among UK drug misusers, including the
impact of illicit and prescribed drugs, has
been made available.
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In addition to the above activities, the
Programme
 Is the official custodian of the national
UK Addicts Index Access database and
paper files covering the period 1968-
1997
 Holds a copy of the official Dead Addicts
datafile
 Is located in an academic centre with
input from relevant disciplines
 Brings to a broad range of expertise
from different professional backgrounds
– psychiatry, psychology, social
science, pharmacology, epidemiology,
addictive behavioural science,
database, project management, etc.
 Has national and international
experience, collaborating in research
and training with bodies such as the
World Health Organisation, European
Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), and the European
Collaborating Centres for Addiction
Studies.
National Steering Group
The np-SAD has a National Steering Group to
provide additional expertise to the Programme
through involvement and participation. Its
principal role is in giving advice on the full
range of its activities, including the national
surveillance of coroners and production of 6-
monthly and annual reports.
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Appendix 2: Coroner’s jurisdictions/ police force areas





(The) Queen's Household "The Coroner of the Queen's Household has
exclusive jurisdiction in respect of inquests and,
semble, inquiries which do not lead to inquests, on
persons whose bodies are lying within the limits of
any of the Queen's palaces or within the limits of
any other house where Her Majesty is then
demurrant and abiding in her own royal person,
notwithstanding the subsequent removal of Her
Majesty from such palace or house. The limits of
the palace or house are deemed to extend to any
courts, gardens or other places within the curtilage
of the palace or house but not further. Where a
body is lying dead beyond these limits, the coroner
of the Queen's Household has no jurisdiction."
ENGLAND
Avon Avon The city of Bristol and the districts of Bath &
North East Somerset, North West Somerset &
South Gloucestershire
Bedfordshire Bedfordshire & Luton The whole county of Bedfordshire and the
county of Luton
Berkshire Berkshire The whole county of Berkshire
Buckinghamshire Buckinghamshire The whole county of Buckinghamshire (excl.
Milton Keynes)
Milton Keynes The whole county of Milton Keynes
Cambridgeshire North & East Cambridgeshire The districts of Fenland & East Cambridgeshire
Peterborough The district of Peterborough
South & West Cambridgeshire The City of Cambridge, the districts of Huntingdon
and South Cambridgeshire
Cheshire Cheshire The whole county of Cheshire
Cornwall Cornwall The whole county of Cornwall (exc. Isles of
Scilly)
Isles of Scilly The Isles of Scilly
Cumbria North and West Cumbria The districts of Allerdale, Carlisle and Copeland.
South and East Cumbria The districts of Barrow-in-Furness, Eden, and
South Lakeland.
Derbyshire Derby & South Derbyshire The county of Derby and the districts of Erewash
& South Derbyshire. The district of Amber Valley
(except the parts in the Coroner’s Jurisdictions
of North Derbyshire). In the district of West
Derbyshire, the parishes of Alkmonton,
Ashbourne, Atlow, Biggin, Boylestone,
Bradbourne, Bradley, Brailsford, Clifton &
Compton, Cubley, Doveridge, Edlaston &
Wyaston, Fenny Bentley, Hognaston, Hollington,
Hulland, Hulland Ward, Hungry Bentley, Kirk
Ireton, Kniveton, Lea Hall, Longford, Mapleton,
Marston Montgomery, Mercaston, Norbury &
Roston, Offcote & Underwood, Osmaston,
Rodsley, Shirley, Snelston, Somersal Herbert,
Sudbury, Thorpe, Tissington, Yeaveley and
Yeldersley
North Derbyshire The District of Bolsover and North East
Derbyshire. The Boroughs of Chesterfield and
High Peak. In the Borough of Amber Valley the
parishes of Denthick, Lea and Holloway, South
Wingfield and Alfreton. The District of Derbyshire
Dales except the parishes in the Derby and
South Derbyshire Coroner’s District.
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Devon Exeter & Greater Devon The districts of East Devon, Exeter, Mid Devon,
North Devon, Torridge, West Devon. That part of
the district of Teignbridge comprising the
parishes of Alphington, Ashton, Bovey Tracey,
Bridford, Christow, Chudleigh,
Doddiscombsleigh, Dunchideock, Dunsford,
Exminster, Hennock, Holcombe Burnell, Ide,
Kenn, Lustleigh, Manaton, Moretonhampstead,
North Bovey, Shillingford St George, Tedburn St
Mary, Trusham & Whitestone.
Plymouth & South West Devon The district of Plymouth. The district of South
Hams except the parishes in the Torbay and
South Devon coroner's district.
Torbay & South Devon The district of Torbay. The district of Teignbridge
except the parishes in the Coroner’s Jurisdiction of
Exeter and Greater Devon. That part of the district
of South Hams comprising the parishes of
Ashprington, Berry Pomeroy, Blackawton,
Cornworthy, Dartington, Dartmouth, Dean Prior,
Dittisham, Halwell, Harberton, Holne, Kingswear,
Littlehampton, Marldon, Rattery, Slapton,
Staverton, Stoke Fleming, Stoke Gabriel, Strete,
Totnes and West Buckfastleigh
Dorset Bournemouth, Poole &
Eastern Dorset
The counties of Bournemouth & Poole,
Christchurch, Purbeck and Wimbourne
Western Dorset The districts of West Dorset, North Dorset and
Weymouth & Portland
Durham Darlington & South Durham The county of Darlington and the districts of
Sedgefield and Teesdale {Wear Valley also
included]
North Durham The districts of Chester-Le-Street, Derwentside,
Durham and Easington
East Sussex Brighton & Hove The county of Brighton & Hove
East Sussex The whole county of East Sussex
Essex Essex & Thurrock (Essex No
1)
The districts of Basildon, Braintree, Brentwood,
Chelmsford, Colchester, Epping Forest, Harlow,
Maldon, Tendring, Thurrock and Uttlesford
Southend & South East Essex
(Essex No 2)
The districts of Southend, Rochford and Castle
Point
Gloucestershire Gloucestershire The county of Gloucestershire
Greater Manchester Manchester The district of Manchester
North Manchester The districts of Bury, Rochdale & Oldham
South Manchester The districts of Stockport, Tameside and
Trafford
West Manchester The districts of Wigan, Bolton and Salford
Hampshire Central Hampshire The districts of Winchester, Test Valley and
Eastleigh
North East Hampshire The districts of Basingstoke, Hart & Rushmoor
and that part of the district of East Hampshire
not contained in the Portsmouth & South East
Hampshire coroner's district
Portsmouth & South East
Hants
The county of Portsmouth and the districts of
Fareham, Gosport and Havant and, in the district
of East Hampshire, the parishes of Buriton,
Clanfield, Colemore and Priors Dean, East Meon,
Froxfield, Hawkley, Horndean, Langrish, Liss,
Petersfield, Rowlands Castle and Steep
Southampton & New Forest The county of Southampton and the district of
New Forest
Herefordshire Herefordshire The whole county of Herefordshire
Hertfordshire Hertfordshire The whole county of Hertfordshire
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Humberside East Riding & Hull The counties of the East Riding of Yorkshire and
the city of Kingston-upon-Hull
Isle of Wight Isle of Wight The whole county of the Isle of Wight
Kent Central & South East Kent The district of Shepway. The borough of
Ashford. The district of Dover except those
parishes with the North East Kent coroner's
district. In the district of Swale, the parishes of
Boughton under Bleab, Doddington, Dunkirk,
Eastling, Faversham, Graveney & Goodnestone,
Hernhill, Luddenham, Lynsted, Newnham,
Norton & Buckland, Oare, Ospringe, Selling,
Sheldwich Badlesmere & Leaveland, Stalisfield,
Stone, Teynham, Throwley
Mid Kent & Medway The City of Rochester upon Medway, the districts
of Gillingham and Maidstone. The district of
Swale, with the exception of Faversham and the
parishes in the Coroner’s Jurisdiction of East Kent.
In the district of Tonbridge and Malling, the
parishes of Addington, Aylesford, Birling, Burham,
Ditton, East Malling & Larkfield, King's Hill,
Leybourne, Mereworth, Offham, Ryarsh,
Snodland, Trottiscliffe, Wateringbury & East
Peckham, Wouldham.
North East Kent The district of Thanet. The City of Canterbury. In
the district of Dover, the parishes of Ash,
Aylesham, Deal, Eastry, Eythorpe,
Goodnestone, Great Mongeham, Nonington,
Northbourne, Preston, Ringwould & Kingsdown,
Ripple, Sandwich, Sholden, Staple, Stourmouth,
Sutton by Dover, Tilmanstone, Walmer,
Wingham, Woodnesborough, Worth.
North West Kent The districts of Dartford, Gravesham, Sevenoaks
and Tunbridge Wells. The district of Tonbridge and
Malling, except the parishes in the Mid-Kent and
Medway Coroner's district.
Lancashire Blackburn, Hyndburn & Ribble
Valley
The districts of Blackburn, Hyndburn & Ribble
Valley
Blackpool & the Fylde The districts of Blackpool and Fylde
East Lancashire The districts of Burnley, Pendle and Rossendale
Preston & West Lancashire The districts of Lancaster, Wyre, Chorley, Preston,
South Ribble and West Lancashire
Leicestershire Leicester City & South
Leicestershire
The county of Leicester and the districts of
Blaby, Harborough, Oadby, Wigston
Rutland & North Leicestershire The county of Rutland and the districts of
Charnwood, Hinckley & Bosworth, Melton and
North West Leicestershire
Lincolnshire Boston & Spalding The districts of Boston and South Holland
North Lincolnshire & Grimsby The counties of North Lincolnshire and North
East Lincolnshire
Spilsby & Louth The district of East Lindsey, except the parishes
in the West Lincolnshire coroners' district. In the
district of West Lindsey, the parishes of Bigby,
Brocklesbury, Cabourne, Caistor, Claxby,
Grasby, Great Limber, Holton Le Moor, Keelby,
Kirmond le Mire, Legsby Linwood, Market
Rasen, Middle Rasen, Nettleton, Normanby le
Wold, North Kelsey, North Willingham, Osgodby,
Owersby, Riby, Rothwell, Searby cum Owmby,
Sixhills, Somerby, South Kelsey, Stainton le
Vale, Swallow, Swinhope, Tealby, Thoresway,
Thorganby and Walesby.
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Stamford In the district of South Kesteven, the parishes of
Aslackby & Laughton, Barholm & Stowe, Baston,
Billingborough, Bourne, Braceborough &
Wilsthorpe, Careby Aunby & Holywell, Carlby,
Castle Bytham, Corby Glen, Counthorpe &
Creeton, Deeping St James, Dowsby, Dunsby,
Edenham, Folkingham, Greatford, Haconby,
Horbling, Irnham, Kirkby Underwood, Langtoft,
Little Bytham, Market Deeping, Morton, Pointon &
Sempringham, Rippingale, Stamford, Swayfield,
Swinstead, Tallington, Thurlby, Toft with Lound &
Manthorpe, Uffington, West Deeping and Witham
on the Hill
West Lincolnshire The district of Lincoln. The district of North
Kesteven. The district of South Kestevan, except
the parishes in the Coroner’s Jurisdiction of
Stamford. The district of West Lindsey, except
the parishes in the Coroner’s jurisdiction of
Spilsby & Louth. In the district of East Lindsey,
the parishes of East & West Barkwith, Hatton,
Langton by Wragby, Panton, West Torrington,
Wragby.
London City of London City of London
Eastern London The London boroughs of Barking, Havering,
Newham, Redbridge & Waltham Forest
Inner North London The London boroughs of Camden, Hackney,
Islington & Tower Hamlets
Inner South London The London boroughs of Greenwich, Lambeth,
Lewisham & Southwark
Inner West London The London boroughs of Wandsworth & Merton,
the Royal Borough of Kensington & Chelsea,
and the City of Westminster
Northern London The London boroughs of Barnet, Brent, Enfield,
Haringey & Harrow
Southern London The London boroughs of Bexley, Bromley,
Croydon and Sutton
Western London The London boroughs of Ealing, Hammersmith,
Hillingdon, Hounslow and Richmond-upon-
Thames, and the Royal Borough of Kingston-
upon-Thames
Merseyside Knowsley, St Helens & Sefton The districts of Knowsley, St Helens and Sefton
Liverpool The district of Liverpool
Wirral The district of Wirral
Norfolk Greater Norfolk The city of Norwich, the districts of Breckland,
Broadland, King’s Lynn, North Norfolk, South
Norfolk, and West Norfolk
Great Yarmouth The borough of Great Yarmouth
Northamptonshire Northamptonshire The whole county of Northamptonshire
Northumberland North Northumberland The districts of Alnwick and Berwick-upon-Tweed
and so much of the districts of Castle Morpeth and
Wansbeck as lies north of the line for the time
being of the centre of the River Wansbeck
South Northumberland The districts of Blyth Valley & Tynedale, and so
much of the districts of Castle Morpeth &
Wansbeck as lie south of the line for the time
being of the centre of the River Wansbeck
North Yorkshire North Yorkshire Eastern The districts of Hambleton, Ryedale and
Scarborough
North Yorkshire Western The districts of Richmondshire, Craven,
Harrogate and Selby
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York The county of York. In the district of Harrogate,
the parishes of Nether and Upper Poppleton. In
the district of Ryedale, the parishes of Clifton
(without), Earswick, Haxby, Heworth (without),
Holtby, Huntington, Murton, New Earswick,
Osbaldwick, Rawcliffe, Skelton, Stockton-on-the-
Forest, Strensall, Towthorpe, Wigginton. In the
district of Selby, the parishes of Dunnington,
Elvington, Fulford, Heslington, Kexby, Naburn &
Deighton, Wheldrake.
Nottinghamshire Nottinghamshire The whole county of Nottinghamshire and the
City of Nottingham
Oxfordshire Oxfordshire The whole of the county of Oxfordshire
Shropshire Mid & North Shropshire The districts of Oswestry, North Shropshire,
Shrewsbury & Atcham
South Shropshire The districts of South Shropshire and Bridgnorth
The Wrekin The whole county of the Wrekin
Somerset Eastern Somerset The districts of Mendip and South Somerset
Western Somerset The districts of Sedgemoor, Taunton Deane and
West Somerset
South Yorkshire South Yorkshire East The district of Doncaster and Rotherham
South Yorkshire West The districts of Barnsley and Sheffield
Staffordshire South Staffordshire The districts of Cannock Chase, East




The county of Stoke-on-Trent, and the districts
of Newcastle-under-Lyme and Staffordshire
Moorlands.
Suffolk Suffolk The county of Suffolk.
Surrey Surrey The whole county of Surrey
Teesside Hartlepool The county of Hartlepool
Teesside The counties of Middlesbrough, Redcar &
Cleveland and Stockton-on-Tees.
Tyne & Wear Gateshead & South Tyneside The districts of Gateshead and South Tyneside
Newcastle-upon-Tyne The City of Newcastle-upon-Tyne
North Tyneside The district of North Tyneside
Sunderland The district of Sunderland
Warwickshire Warwickshire The whole county of Warwickshire
West Midlands Birmingham The districts of Birmingham & Solihull
Black Country The districts of Dudley, Sandwell, and Walsall
Coventry The district of Coventry
Wolverhampton The district of Wolverhampton
West Sussex West Sussex The whole county of West Sussex
West Yorkshire West Yorkshire Eastern The metropolitan district of Leeds and Wakefield
West Yorkshire Western The metropolitan districts of Bradford,
Calderdale and Kirklees
Wiltshire Wiltshire & Swindon The counties of Wiltshire and Swindon
Worcestershire Worcestershire The whole county of Worcestershire
WALES
Bridgend & Glamorgan Valleys The county boroughs of Bridgend, Merthyr Tydfil &
Rhondda, Cynon & Taff
Cardiff & the Vale of
Glamorgan
The county of Cardiff and the county borough of
the Vale of Glamorgan
Carmarthenshire The districts of Carmarthen, Llanelli and Dinefwr
Central North Wales The county of Denbighshire, the county borough
of Aberconwy & Colwyn.
Ceredigion The district of Ceredigion
Gwent The county of Monmouthshire, the county borough
of Blaenau Gwent, Caerphilly, Newport and
Torfaen
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Neath & Port Talbot The districts of Neath & Port Talbot. In the
borough of Lliw Valley, the communties of
Cilybebyll, Clydach, Cwmllnfell, Gwam-Cae-
Gurwen, Mawr, Pontardawe & Ystalyfera
North East Wales The boroughs of Flintshire and Wrexham. In the
district of Glyndwr, the communities of Ceiriog
Ucha, Chirk, Glyntraian, Llangedwyn, Llangollen,
Llangollen Rural, Llanrhaeadr-ym-Mochnant,
Llansantffraid Glyn Ceiriog, Llansilin &
Llantysilio.
North West Wales The counties of Anglesey, Caernarfonshire,
Merionethshire
Pembrokeshire The district of Preseli and South Pembrokeshire
(including Caldey Island and St Margaret's Island)
Powys The whole county of Powys
Swansea The district of Swansea. In the borough of Lliw
Valley, the communities of Gorseinon,






Whole of Northern Ireland
THE ISLANDS
Guernsey Alderney, Brecqhou, Guernsey, Herm, Jethou,
Lihou, Little Sark, Sark
Jersey Jersey
Isle of Man Isle of Man
SCOTLAND









Dumfries & Galloway Council area
Fife Constabulary Fife Council area




East Lothian, City of Edinburgh, Midlothian,
West Lothian, and the Borders Council areas
Northern
Constabulary
Highland, Orkney Islands, Shetlands Islands,
and Western Isles Council areas, and parts of
Argyllshire (Ardnamuchan and Glencoe) and
Morayshire (Grantown-on-Spey and Cromdale)
Strathclyde Police Argyll and Bute, East Dumbartonshire,
Dumbarton and Clydebank, South Lanarkshire,
North Lanarkshire, East Ayrshire, North
Ayrshire, East Renfrewshire, City of Glasgow,
Inverclyde, South Ayrshire, and
Renfrewshire Council areas
Tayside Police Angus, City of Dundee, and
Perthshire and Kinross Council areas
Since the start of 2004, the following amalgamations of coroners' jurisdictions in England have occurred: East Berkshire,
Reading and West Berkshire to form one for the whole county of Berkshire (1 April 2004); East and West Cornwall to
form one for the whole county of Cornwall, but excluding the Isles of Scilly (1 February 2004); in Cumbria, Furness and
Southern Cumbria to form South Cumbria & Furness (1 April 2004); Hertford and West & North Hertfordshire to form one
for the whole county of Hertfordshire (1 October 2004); in Lincolnshire, Louth and Spilsby to form Spilsby & Louth (1
December 2003); in the West Midlands, Dudley, Sandwell, and Walsall to form Black Country (1 August 2004); in
Derbyshire, High Peak and Scarsdale to form North Derbyshire (1 February 2006); in Gloucestershire, Gloucester and
Cheltenham to form Gloucestershire (1 April 2006); in Suffolk, Greater Suffolk and Lowestoft to form Suffolk (1 August
2006). Further amalgamations have taken place in 2007, these changes will be reflected in future reports.
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The retirement of several coroners has resulted in some coroners taking on responsibility for additional jurisdictions. The
Isles of Scilly (regarded as part of Cornwall) are currently being looked after by the coroner for Plymouth & South West
Devon. Data for Herefordshire are also submitted now together with those for Worcestershire. The two jurisdictions in
Durham are now being looked after by the same coroner, but have not been formally amalgamated. The coroner for
Suffolk is also coroner for Southend & South East Essex.
In Northern Ireland, a process of amalgamation has been completed and since 1 April 2006 there has been a single
coroner’s area covering the whole of the Province. It is centred on the Greater Belfast office and served by three full-
time coroners, overseen by a High Court judge.
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Appendix 3: np-SAD data collection form
The National Programme on Substance Abuse Deaths (np-SAD)
NOTIFICATION OF DRUG-RELATED DEATHS
Section I Demographic information
Deceased forename(s): _____________________________ Gender:  Male  Female
Family name: ____________________Other names known by: _______________________
Date of birth: ______/______/______ Place of birth: ________________________________
Usual address:______________________________________________________________
_____________________________________________Postcode: __________________________
Ethnicity (tick one only)
White  Pakistani  Black African  Other, specify_________
 Chinese  Bangladeshi  Black Caribbean  Not known
 Indian  Black other, specify ______________
Occupational status (tick one only)
 Employed (manual)  Unemployed  Retired
 Employed (non-manual)  Childcare/houseperson  Student/pupil
 Self employed  Invalidity/sickness  Other, specify_________
 Not known
Living arrangements (tick one only)
 Alone  Self and children  No fixed abode
 With partner With parent(s)  Other, specify_______________
 With partner & children  With friend(s)  Not known
Section II Details of death
Date of death: _______/_______/_________
Place of death: (tick one only)
 Home  Residential premises (.e. hotel)  In custody
 Place of work  Street or highway  Place of recreation/sport
 Treatment centre  Educational establishment  Hospital
 Other place, specify________________________________________________________
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The National Programme on Substance Abuse Deaths (np-SAD)
Toxicology
Please list drugs and alcohol present at post mortem (in order of importance, if known)
Drug/alcohol Level Drug/alcohol Level




B = Blood; T = Tissues; U = Urine
Section III Coroner’s verdict
Section IV Background information
Recent history of drug use and other relevant information: e.g. evidence of injecting drug
use; evidence of ‘crack’ use; recently released from prison or discharged from treatment
programme; psychiatric history; known to alcohol/drug services; length of use; poly-substance
user; known health problems associated with substance misuse; last 24 hours of life (if
known), time police summoned, any drugs paraphernalia, etc.:
Was the deceased on prescribed psychoactive medication?  Yes  No  Not known
If yes, please list drugs:
1 _______________________________ 2 ___________________________
3 _______________________________ 4 ___________________________
5 _______________________________ 6 ___________________________
Was the deceased a drug addict or known drug abuser?  Yes  No  Not known
Section V Coroner’s details
Coroner’s name: __________________________Date inquest completed: ____/_____/_____
Jurisdiction: __________________________________ Office: _______________________
Signature: ___________________________________ Date: _______/________/________
Please send completed form to:
National Programme on Substance Abuse Deaths (np-SAD)
International Centre for Drug Policy
St George’s, University of London
FREEPOST LON 10141,
London SW17 0BR
For general enquiries: Tel 020 8725 2623 or Fax 020 8266 6494
This form is available electronically
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Copies available from
National Programme on Substance Abuse Deaths (np-SAD)
International Centre for Drug Policy (ICDP)
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